NONE0000057725--06-302023Q3falsehttp://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherAssetsNoncurrent11.5111.5P36M0.330.250000057725us-gaap:TreasuryStockCommonMember2023-01-012023-03-310000057725us-gaap:TreasuryStockCommonMember2022-07-012023-03-310000057725us-gaap:TreasuryStockCommonMember2022-01-012022-03-310000057725us-gaap:TreasuryStockCommonMember2021-07-012022-03-310000057725us-gaap:CommonStockMember2023-01-012023-03-310000057725us-gaap:CommonStockMember2022-07-012023-03-310000057725us-gaap:CommonStockMember2022-01-012022-03-310000057725us-gaap:CommonStockMember2021-07-012022-03-310000057725us-gaap:EmployeeStockMember2021-07-012022-03-3100000577252023-02-062023-02-060000057725us-gaap:TreasuryStockCommonMember2023-03-310000057725us-gaap:RetainedEarningsMember2023-03-310000057725us-gaap:AdditionalPaidInCapitalMember2023-03-310000057725us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000057725us-gaap:TreasuryStockCommonMember2022-12-310000057725us-gaap:RetainedEarningsMember2022-12-310000057725us-gaap:AdditionalPaidInCapitalMember2022-12-310000057725us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-3100000577252022-12-310000057725us-gaap:TreasuryStockCommonMember2022-06-300000057725us-gaap:RetainedEarningsMember2022-06-300000057725us-gaap:AdditionalPaidInCapitalMember2022-06-300000057725us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000057725us-gaap:TreasuryStockCommonMember2022-03-310000057725us-gaap:RetainedEarningsMember2022-03-310000057725us-gaap:AdditionalPaidInCapitalMember2022-03-310000057725us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310000057725us-gaap:TreasuryStockCommonMember2021-12-310000057725us-gaap:RetainedEarningsMember2021-12-310000057725us-gaap:AdditionalPaidInCapitalMember2021-12-310000057725us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-3100000577252021-12-310000057725us-gaap:TreasuryStockCommonMember2021-06-300000057725us-gaap:RetainedEarningsMember2021-06-300000057725us-gaap:AdditionalPaidInCapitalMember2021-06-300000057725us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000057725us-gaap:CommonStockMember2023-03-310000057725us-gaap:CommonStockMember2022-12-310000057725us-gaap:CommonStockMember2022-06-300000057725us-gaap:CommonStockMember2022-03-310000057725us-gaap:CommonStockMember2021-12-310000057725us-gaap:CommonStockMember2021-06-300000057725us-gaap:EmployeeStockOptionMember2021-07-012022-06-300000057725us-gaap:EmployeeStockOptionMember2022-06-300000057725us-gaap:EmployeeStockOptionMember2021-07-012022-03-310000057725us-gaap:EmployeeStockOptionMember2023-03-310000057725us-gaap:EmployeeStockMember2003-02-280000057725us-gaap:EmployeeStockMember2022-01-012022-01-310000057725us-gaap:EmployeeStockMember2023-03-310000057725us-gaap:EmployeeStockOptionMember2022-07-012023-03-310000057725us-gaap:RestrictedStockMember2023-03-310000057725us-gaap:RestrictedStockMember2022-06-300000057725us-gaap:PerformanceSharesMember2022-06-300000057725lci:NamedExecutiveOfficersMemberlci:CashBasedIncentiveMember2022-07-012022-09-300000057725us-gaap:PerformanceSharesMember2022-07-012023-03-310000057725lci:AuburnMember2023-01-012023-03-310000057725lci:AuburnMember2022-07-012023-03-310000057725lci:AuburnMember2022-01-012022-03-310000057725lci:AuburnMember2021-07-012022-03-310000057725lci:RespiratoryAllergyCoughColdMember2023-01-012023-03-310000057725lci:OtherMedicalIndicationsMember2023-01-012023-03-310000057725lci:MigraineHeadacheMember2023-01-012023-03-310000057725lci:InfectiousDiseaseMember2023-01-012023-03-310000057725lci:GastrointestinalMember2023-01-012023-03-310000057725lci:EndocrinologyMember2023-01-012023-03-310000057725lci:ContractManufacturingRevenueMember2023-01-012023-03-310000057725lci:CentralNervousSystemMember2023-01-012023-03-310000057725lci:CardiovascularMember2023-01-012023-03-310000057725lci:AntiPsychosisMember2023-01-012023-03-310000057725lci:AnalgesicMember2023-01-012023-03-310000057725lci:RespiratoryAllergyCoughColdMember2022-07-012023-03-310000057725lci:OtherMedicalIndicationsMember2022-07-012023-03-310000057725lci:MigraineHeadacheMember2022-07-012023-03-310000057725lci:InfectiousDiseaseMember2022-07-012023-03-310000057725lci:GastrointestinalMember2022-07-012023-03-310000057725lci:EndocrinologyMember2022-07-012023-03-310000057725lci:ContractManufacturingRevenueMember2022-07-012023-03-310000057725lci:CentralNervousSystemMember2022-07-012023-03-310000057725lci:CardiovascularMember2022-07-012023-03-310000057725lci:AntiPsychosisMember2022-07-012023-03-310000057725lci:AnalgesicMember2022-07-012023-03-310000057725lci:RespiratoryAllergyCoughColdMember2022-01-012022-03-310000057725lci:OtherMedicalIndicationsMember2022-01-012022-03-310000057725lci:MigraineHeadacheMember2022-01-012022-03-310000057725lci:InfectiousDiseaseMember2022-01-012022-03-310000057725lci:GastrointestinalMember2022-01-012022-03-310000057725lci:EndocrinologyMember2022-01-012022-03-310000057725lci:ContractManufacturingRevenueMember2022-01-012022-03-310000057725lci:CentralNervousSystemMember2022-01-012022-03-310000057725lci:CardiovascularMember2022-01-012022-03-310000057725lci:AntiPsychosisMember2022-01-012022-03-310000057725lci:AnalgesicMember2022-01-012022-03-310000057725lci:RespiratoryAllergyCoughColdMember2021-07-012022-03-310000057725lci:OtherMedicalIndicationsMember2021-07-012022-03-310000057725lci:MigraineHeadacheMember2021-07-012022-03-310000057725lci:InfectiousDiseaseMember2021-07-012022-03-310000057725lci:GastrointestinalMember2021-07-012022-03-310000057725lci:EndocrinologyMember2021-07-012022-03-310000057725lci:ContractManufacturingRevenueMember2021-07-012022-03-310000057725lci:CentralNervousSystemMember2021-07-012022-03-310000057725lci:CardiovascularMember2021-07-012022-03-310000057725lci:AntiPsychosisMember2021-07-012022-03-310000057725lci:AnalgesicMember2021-07-012022-03-310000057725lci:RestructuringPlan2022Member2023-03-310000057725lci:RestructuringPlan2022Member2022-12-152022-12-150000057725lci:RestructuringPlan2022Member2022-12-150000057725lci:LicenseAndCollaborationAgreementWithSunshineMember2022-07-012023-03-310000057725lci:LicenseAndCollaborationAgreementWithHecMember2022-07-012023-03-310000057725srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2022-07-012023-03-310000057725srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2022-07-012023-03-310000057725srt:MinimumMemberus-gaap:BuildingAndBuildingImprovementsMember2022-07-012023-03-310000057725srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2022-07-012023-03-310000057725srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2022-07-012023-03-310000057725srt:MaximumMemberus-gaap:BuildingAndBuildingImprovementsMember2022-07-012023-03-310000057725us-gaap:GeographicDistributionForeignMember2023-03-310000057725us-gaap:ConstructionInProgressMember2023-03-310000057725us-gaap:GeographicDistributionForeignMember2022-06-300000057725us-gaap:ConstructionInProgressMember2022-06-300000057725us-gaap:MachineryAndEquipmentMember2023-03-310000057725us-gaap:FurnitureAndFixturesMember2023-03-310000057725us-gaap:BuildingAndBuildingImprovementsMember2023-03-310000057725us-gaap:MachineryAndEquipmentMember2022-06-300000057725us-gaap:LandMember2022-06-300000057725us-gaap:FurnitureAndFixturesMember2022-06-300000057725us-gaap:BuildingAndBuildingImprovementsMember2022-06-300000057725lci:RestructuringPlan2022Member2022-07-012023-03-310000057725us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000057725us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012023-03-310000057725us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310000057725us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012022-03-310000057725lci:YpsomedAgreementMember2023-03-310000057725lci:LicenseAndCollaborationAgreementWithSunshineMember2023-03-310000057725lci:LicenseAndCollaborationAgreementWithHecMember2023-03-310000057725lci:YpsomedAgreementMember2022-04-300000057725lci:LicenseAndCollaborationAgreementWithSunshineMember2021-02-080000057725srt:MaximumMemberlci:LicenseAndCollaborationAgreementWithHecMember2020-06-300000057725lci:LicenseAndCollaborationAgreementWithHecMember2020-06-300000057725us-gaap:RetainedEarningsMember2023-01-012023-03-310000057725us-gaap:RetainedEarningsMember2022-07-012023-03-310000057725us-gaap:RetainedEarningsMember2022-01-012022-03-310000057725us-gaap:RetainedEarningsMember2021-07-012022-03-310000057725lci:GovernmentPricingMember2019-05-222019-05-220000057725lci:GovernmentPricingMember2019-08-312019-08-310000057725lci:SandozIncMember2022-04-012022-06-300000057725lci:AblCreditFacilityMember2023-03-310000057725lci:AblCreditFacilityMember2019-12-070000057725lci:AblCreditFacilityMember2019-12-060000057725lci:TorresdaleFacilityMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2023-01-012023-03-310000057725lci:StateRoadFacilityMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2022-09-012022-09-300000057725lci:SeymourIndianaFacilityMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2022-07-012023-03-310000057725lci:StateRoadFacilityMember2022-07-012022-09-300000057725lci:SilarxMemberus-gaap:DistributionRightsMember2023-03-310000057725lci:KremersUrbanPharmaceuticalsIncMemberus-gaap:TradeNamesMember2023-03-310000057725lci:OtherProductRightsMember2023-03-310000057725lci:SilarxMemberus-gaap:DistributionRightsMember2022-06-300000057725lci:KremersUrbanPharmaceuticalsIncMemberus-gaap:TradeNamesMember2022-06-300000057725lci:KremersUrbanPharmaceuticalsIncMemberus-gaap:OtherIntangibleAssetsMember2022-06-300000057725lci:OtherProductRightsMember2022-06-3000000577252022-10-012022-12-3100000577252020-12-312020-12-310000057725lci:AblCreditFacilityMemberus-gaap:SubsequentEventMember2023-05-012023-05-010000057725us-gaap:SubsequentEventMember2023-05-020000057725lci:SeniorSecuredNotesDue2026Member2022-03-310000057725lci:SeniorSecuredNotesDue2026Member2021-04-220000057725lci:SecondLienFacilityMember2021-04-050000057725lci:ConvertibleSeniorNotesDue2026Member2019-09-270000057725lci:SeniorSecuredNotesDue2026Member2022-06-300000057725lci:SecondLienFacilityMember2022-06-300000057725lci:ConvertibleSeniorNotesDue2026Member2022-06-300000057725lci:AblCreditFacilityMemberus-gaap:BaseRateMember2021-04-222021-04-220000057725lci:CustomerCMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310000057725lci:CustomerBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310000057725lci:CustomerAMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310000057725lci:CustomerCMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012023-03-310000057725lci:CustomerBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012023-03-310000057725lci:CustomerAMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012023-03-310000057725lci:CustomerCMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310000057725lci:CustomerBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310000057725lci:CustomerAMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310000057725lci:CustomerCMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-07-012022-03-310000057725lci:CustomerBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-07-012022-03-310000057725lci:CustomerAMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-07-012022-03-3100000577252023-05-022023-05-020000057725lci:TorresdaleFacilityMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2023-03-310000057725lci:StateRoadFacilityMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2023-03-310000057725lci:SeymourIndianaFacilityMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2023-03-310000057725lci:StateRoadFacilityMember2022-09-300000057725lci:TorresdaleFacilityMember2022-10-012022-12-310000057725lci:SeymourIndianaFacilityMember2022-07-012023-03-310000057725us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310000057725us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310000057725us-gaap:CostOfSalesMember2023-01-012023-03-310000057725us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012023-03-310000057725us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012023-03-310000057725us-gaap:CostOfSalesMember2022-07-012023-03-310000057725us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-310000057725us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310000057725us-gaap:CostOfSalesMember2022-01-012022-03-310000057725us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012022-03-310000057725us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012022-03-310000057725us-gaap:CostOfSalesMember2021-07-012022-03-310000057725lci:SecondLienFacilityMember2021-04-222021-04-220000057725us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100000577252023-01-012023-03-310000057725us-gaap:AdditionalPaidInCapitalMember2022-07-012023-03-310000057725us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100000577252022-01-012022-03-310000057725us-gaap:AdditionalPaidInCapitalMember2021-07-012022-03-310000057725lci:SilarxMemberus-gaap:DistributionRightsMember2022-07-012023-03-310000057725lci:KremersUrbanPharmaceuticalsIncMemberus-gaap:TradeNamesMember2022-07-012023-03-310000057725lci:KremersUrbanPharmaceuticalsIncMemberus-gaap:OtherIntangibleAssetsMember2022-07-012023-03-310000057725lci:OtherProductRightsMember2022-07-012023-03-310000057725lci:AuburnMember2023-03-310000057725lci:AuburnMember2022-06-300000057725lci:AblCreditFacilityMember2021-04-220000057725us-gaap:EmployeeStockMember2022-07-012023-03-310000057725lci:SeniorSecuredNotesDue2026Member2023-03-310000057725lci:SecondLienFacilityMember2023-03-310000057725lci:NamedExecutiveOfficersMember2022-07-012023-03-310000057725lci:NamedExecutiveOfficersMemberus-gaap:RestrictedStockMember2022-07-012023-03-310000057725lci:NamedExecutiveOfficersMemberus-gaap:PerformanceSharesMember2022-07-012023-03-310000057725lci:NamedExecutiveOfficersMemberlci:CashBasedIncentiveMember2022-07-012023-03-310000057725us-gaap:RestrictedStockMember2022-07-012023-03-310000057725us-gaap:RestrictedStockMember2021-07-012022-03-310000057725lci:RebateProvisionMember2023-03-310000057725lci:RebateProvisionMember2022-06-300000057725lci:ReserveForReturnsMember2022-03-310000057725lci:ReserveForChargebacksMember2022-03-310000057725lci:RebateProvisionMember2022-03-310000057725lci:OtherAdjustmentsMember2022-03-3100000577252022-03-310000057725lci:ReserveForReturnsMember2021-06-300000057725lci:ReserveForChargebacksMember2021-06-300000057725lci:RebateProvisionMember2021-06-300000057725lci:OtherAdjustmentsMember2021-06-3000000577252021-06-300000057725us-gaap:OtherNoncurrentAssetsMember2023-03-310000057725us-gaap:OtherCurrentAssetsMember2023-03-310000057725lci:ConvertibleSeniorNotesDue2026Member2023-03-310000057725lci:ConvertibleSeniorNotesDue2026Member2022-07-012023-03-310000057725lci:SecondLienFacilityMember2021-04-2200000577252016-07-012017-06-300000057725lci:AblCreditFacilityMember2021-04-222021-04-220000057725lci:LicenseAndCollaborationAgreementFiveYearsAfterFirstTenYearsMemberlci:LicenseAndCollaborationAgreementWithSunshineMember2021-02-082021-02-080000057725lci:LicenseAndCollaborationAgreementCommercializationFirstTenYearsMemberlci:LicenseAndCollaborationAgreementWithSunshineMember2021-02-082021-02-080000057725lci:LicenseAndCollaborationAgreementFiveYearsAfterFirstTenYearsMemberlci:LicenseAndCollaborationAgreementWithHecMember2019-07-012020-06-300000057725lci:LicenseAndCollaborationAgreementCommercializationFirstTenYearsMemberlci:LicenseAndCollaborationAgreementWithHecMember2019-07-012020-06-300000057725lci:LicenseAndCollaborationAgreementWithHecMember2019-07-012020-06-300000057725lci:InterestRateFirstYearOfAnniversaryMemberlci:SecondLienFacilityMember2021-04-050000057725lci:InterestRateAfterFirstYearOfAnniversaryMemberlci:SecondLienFacilityMember2021-04-050000057725lci:AblCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2021-04-222021-04-220000057725lci:ReserveForReturnsMember2023-01-012023-03-310000057725lci:ReserveForChargebacksMember2023-01-012023-03-310000057725lci:RebateProvisionMember2023-01-012023-03-310000057725lci:OtherAdjustmentsMember2023-01-012023-03-310000057725lci:ReserveForReturnsMember2022-01-012022-03-310000057725lci:ReserveForChargebacksMember2022-01-012022-03-310000057725lci:RebateProvisionMember2022-01-012022-03-310000057725lci:OtherAdjustmentsMember2022-01-012022-03-310000057725lci:ReserveForReturnsMember2022-07-012023-03-310000057725lci:ReserveForChargebacksMember2022-07-012023-03-310000057725lci:RebateProvisionMember2022-07-012023-03-310000057725lci:OtherAdjustmentsMember2022-07-012023-03-310000057725lci:ReserveForReturnsMember2021-07-012022-03-310000057725lci:ReserveForChargebacksMember2021-07-012022-03-310000057725lci:RebateProvisionMember2021-07-012022-03-310000057725lci:OtherAdjustmentsMember2021-07-012022-03-3100000577252021-07-012022-03-3100000577252023-03-3100000577252022-06-300000057725lci:ReserveForReturnsMember2023-03-310000057725lci:ReserveForRebatesMember2023-03-310000057725lci:ReserveForChargebacksMember2023-03-310000057725lci:OtherAdjustmentsMember2023-03-310000057725lci:ReserveForReturnsMember2022-06-300000057725lci:ReserveForRebatesMember2022-06-300000057725lci:ReserveForChargebacksMember2022-06-300000057725lci:OtherAdjustmentsMember2022-06-3000000577252023-04-2800000577252022-07-012023-03-31xbrli:sharesiso4217:USDxbrli:pureiso4217:USDxbrli:shareslci:segmentiso4217:CHFlci:employee

​

​

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED March 31, 2023

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

Commission File No. 001-31298

LANNETT COMPANY, INC.

(Exact Name of Registrant as Specified in its Charter)

State of Delaware

​

23-0787699

(State of Incorporation)

​

(I.R.S. Employer I.D. No.)

​

1150 Northbrook Drive, Suite 155

Trevose, PA 19053

(215) 333-9000

(Address of principal executive offices and telephone number)

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class

​

Trading Symbol(s)

​

Name of each exchange on which registered

Common Stock, $0.001 par value

​

LCINQ (1)

​

(1)

​

(1) On April 19, 2023, our common stock was suspended from trading on the New York Stock Exchange (the “NYSE”). On April 20, 2023, our common stock began trading over-the-counter under the symbol “LCIN” and on May 3, 2023, it began trading under the symbol “LCINQ.” On May 4, 2023, the NYSE filed a Form 25 with the Securities and Exchange Commission (the “SEC”) to delist our common stock from trading on the NYSE and to remove it from registration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The delisting became effective 10 days after the filing of the Form 25. In accordance with Rule 12d2-2 of the Exchange Act, the de-registration of our common stock under Section 12(b) of the Exchange Act will become effective 90 days, or such shorter period as the SEC may determine, after the date of the Form 25 filing.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐

​

Accelerated filer ☐

Non-accelerated filer ☒

​

Smaller reporting company ☐

Emerging growth company ☐

​

​

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12B-12 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each class of the registrant’s common stock, as of the latest practical date.

​

Class

​

Outstanding as of April 28, 2023

Common stock, par value $0.001 per share

​

10,780,187

​

​

​

Table of Contents

​

​

​

​

Page No.

PART I. FINANCIAL INFORMATION

​

​

​

​

​

ITEM 1.

FINANCIAL STATEMENTS (UNAUDITED)

​

​

​

​

​

​

​

Consolidated Balance Sheets as of March 31, 2023 and June 30, 2022

3

​

​

​

​

​

​

Consolidated Statements of Operations for the three and nine months ended March 31, 2023 and 2022

4

​

​

​

​

​

​

Consolidated Statements of Comprehensive Loss for the three and nine months ended March 31, 2023 and 2022

5

​

​

​

​

​

​

Consolidated Statements of Changes in Stockholders’ Deficit for the three and nine months ended March 31, 2023 and 2022

6

​

​

​

​

​

​

Consolidated Statements of Cash Flows for the nine months ended March 31, 2023 and 2022

7

​

​

​

​

​

​

Notes to Consolidated Financial Statements

8

​

​

​

​

​

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

44

​

​

​

​

​

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

63

​

​

​

​

​

ITEM 4.

CONTROLS AND PROCEDURES

63

​

​

PART II. OTHER INFORMATION

​

​

​

​

​

ITEM 1.

LEGAL PROCEEDINGS

64

​

​

​

​

​

ITEM 1A.

RISK FACTORS

64

​

​

​

​

​

ITEM 6.

EXHIBITS

70

​

​

2

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

LANNETT COMPANY, INC.

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(In thousands, except share and per share data)

​

​

​

​

​

​

​

​

​

    

March 31, 2023

    

June 30, 2022

ASSETS

​

​

​

​

​

​

Current assets:

​

​

​

​

​

​

Cash and cash equivalents

​

$

46,540

​

$

87,854

Accounts receivable, net

​

 

68,153

​

 

56,241

Inventories

​

 

90,805

​

 

95,158

Current income taxes receivable

​

​

—

​

​

36,793

Assets held for sale

​

 

38,200

​

 

—

Other current assets

​

 

18,018

​

 

14,070

Total current assets

​

 

261,716

​

 

290,116

Property, plant and equipment, net

​

 

12,363

​

 

133,178

Intangible assets, net

​

 

18,907

​

 

32,179

Operating lease right-of-use assets

​

​

9,131

​

​

9,646

Income taxes receivable

​

 

17,981

​

 

—

Other assets

​

 

14,526

​

 

19,316

TOTAL ASSETS

​

$

334,624

​

$

484,435

​

​

​

​

​

​

​

LIABILITIES

​

​

​

​

​

​

Current liabilities:

​

​

​

​

​

​

Accounts payable

​

$

21,073

​

$

29,737

Accrued expenses

​

 

34,888

​

 

23,667

Accrued payroll and payroll-related expenses

​

 

11,918

​

 

8,342

Rebates payable

​

 

13,425

​

 

21,568

Royalties payable

​

​

8,218

​

​

5,677

Restructuring liability

​

​

748

​

​

490

Current operating lease liabilities

​

​

2,079

​

​

2,064

Debt, net, due within one year

​

 

628,391

​

 

—

Other current liabilities

​

​

12,339

​

​

13,395

Total current liabilities

​

 

733,079

​

 

104,940

Long-term debt, net

​

 

—

​

 

614,948

Long-term operating lease liabilities

​

​

9,158

​

​

9,994

Other liabilities

​

​

4,646

​

​

5,616

TOTAL LIABILITIES

​

 

746,883

​

 

735,498

Commitments and contingencies (Notes 11 and 12)

​

​

​

​

​

​

​

​

​

​

​

​

​

STOCKHOLDERS’ DEFICIT

​

​

​

​

​

​

Common stock ($0.001 par value, 25,000,000 shares authorized; 11,218,213 and 11,168,069 shares issued; 10,780,272 and 10,776,603 shares outstanding at March 31, 2023 and June 30, 2022, respectively)

​

 

11

​

 

11

Additional paid-in capital

​

 

368,669

​

 

363,988

Accumulated deficit

​

 

(762,183)

​

 

(596,386)

Accumulated other comprehensive loss

​

 

(384)

​

 

(411)

Treasury stock (437,941 and 391,466 shares at March 31, 2023 and June 30, 2022, respectively)

​

 

(18,372)

​

 

(18,265)

Total stockholders’ deficit

​

 

(412,259)

​

 

(251,063)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT

​

$

334,624

​

$

484,435

​

The accompanying notes are an integral part of the Consolidated Financial Statements.

​

3

LANNETT COMPANY, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

(In thousands, except share and per share data)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

​

March 31, 

​

March 31, 

​

​

    

2023

    

2022

    

2023

    

2022

​

Net sales

​

$

80,507

​

$

78,357

​

$

236,480

​

$

266,390

​

Cost of sales

​

 

64,289

​

 

72,658

​

 

190,832

​

 

230,656

​

Amortization of intangibles

​

​

1,043

​

​

2,621

​

​

3,596

​

​

10,425

​

Gross profit

​

 

15,175

​

 

3,078

​

 

42,052

​

 

25,309

​

Operating expenses (income):

​

​

​

​

​

​

​

​

​

​

​

​

​

Research and development expenses

​

 

7,105

​

 

5,807

​

 

19,212

​

 

16,318

​

Selling, general and administrative expenses

​

 

20,446

​

 

17,572

​

 

55,460

​

 

55,268

​

Restructuring expenses

​

​

1,795

​

​

1,782

​

​

2,276

​

​

2,673

​

Asset impairment charges

​

​

72,510

​

​

—

​

​

83,147

​

​

49,361

​

Gain on sale of intangible assets

​

​

—

​

​

—

​

​

(3,563)

​

​

—

​

Total operating expenses

​

 

101,856

​

 

25,161

​

 

156,532

​

 

123,620

​

Operating loss

​

 

(86,681)

​

 

(22,083)

​

 

(114,480)

​

 

(98,311)

​

Other income (expense), net:

​

​

​

​

​

​

​

​

​

​

​

​

​

Investment income

​

​

83

​

​

34

​

​

574

​

​

114

​

Interest expense

​

 

(15,179)

​

 

(14,517)

​

 

(45,393)

​

 

(43,171)

​

Loss on loan receivable

​

​

—

​

​

—

​

​

(6,826)

​

​

—

​

Other income (expense)

​

​

336

​

​

303

​

​

423

​

​

252

​

Total other expense, net

​

 

(14,760)

​

 

(14,180)

​

 

(51,222)

​

 

(42,805)

​

Loss before income tax

​

 

(101,441)

​

 

(36,263)

​

 

(165,702)

​

 

(141,116)

​

Income tax expense (benefit)

​

 

29

​

 

(1,365)

​

 

95

​

 

(2,791)

​

Net loss

​

$

(101,470)

​

$

(34,898)

​

$

(165,797)

​

$

(138,325)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Loss per common share (1):

​

​

​

​

​

​

​

​

​

​

​

​

​

Basic

​

$

(9.84)

​

$

(3.45)

​

$

(16.13)

​

$

(13.74)

​

Diluted

​

$

(9.84)

​

$

(3.45)

​

$

(16.13)

​

$

(13.74)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Weighted average common shares outstanding (1):

​

​

​

​

​

​

​

​

​

​

​

​

​

Basic

​

 

10,311,428

​

 

10,125,825

​

 

10,279,085

​

 

10,065,333

​

Diluted

​

 

10,311,428

​

 

10,125,825

​

 

10,279,085

​

 

10,065,333

​

(1)See Note 14 “Loss Per Common Share” for details on calculation.

​

The accompanying notes are an integral part of the Consolidated Financial Statements.

​

4

LANNETT COMPANY, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(UNAUDITED)

(In thousands)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

​

March 31, 

​

March 31, 

​

​

    

2023

    

2022

​

2023

    

2022

​

Net loss

​

$

(101,470)

​

$

(34,898)

​

$

(165,797)

​

$

(138,325)

​

Other comprehensive income:

​

​

​

​

​

​

​

​

​

​

​

​

​

Foreign currency translation gain

​

 

(17)

​

 

(7)

​

 

27

​

 

22

​

Total other comprehensive income

​

 

(17)

​

 

(7)

​

 

27

​

 

22

​

Comprehensive loss

​

$

(101,487)

​

$

(34,905)

​

$

(165,770)

​

$

(138,303)

​

​

The accompanying notes are an integral part of the Consolidated Financial Statements.

​

5

LANNETT COMPANY, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

(UNAUDITED)

(In thousands)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Three Months Ended March 31, 2023

​

​

​

​

​

​

​

​

​

​

​

​

​

Accumulated

​

​

​

​

​

​

​

​

Common Stock

​

Additional

​

​

​

​

Other

​

​

​

​

Total

​

​

Shares

​

​

​

​

Paid-In

​

Accumulated

​

Comprehensive

​

Treasury

​

Stockholders’

​

    

Issued

    

Amount

    

Capital

    

Deficit

    

Loss

    

Stock

    

Deficit

Balance, December 31, 2022

 

10,749

​

$

11

​

$

367,166

​

$

(660,713)

​

$

(367)

​

$

(18,371)

​

$

(312,274)

Shares issued in connection with share-based compensation plans

 

19

​

 

—

​

 

28

​

 

—

​

 

—

​

 

—

​

 

28

Share-based compensation

 

—

​

 

—

​

 

1,475

​

 

—

​

 

—

​

 

—

​

 

1,475

Purchase of treasury stock

 

—

​

 

—

​

 

—

​

 

—

​

 

—

​

 

(1)

​

 

(1)

Other comprehensive income

 

—

​

 

—

​

 

—

​

 

—

​

 

(17)

​

 

—

​

 

(17)

Net loss

 

—

​

 

—

​

 

—

​

 

(101,470)

​

 

—

​

 

—

​

 

(101,470)

Balance, March 31, 2023

 

10,768

​

$

11

​

$

368,669

​

$

(762,183)

​

$

(384)

​

$

(18,372)

​

$

(412,259)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Three Months Ended March 31, 2022

​

​

​

​

​

​

​

​

​

​

​

​

​

Accumulated

​

​

​

​

​

​

​

​

Common Stock

​

Additional

​

​

​

​

Other

​

​

​

​

Total

​

​

Shares

​

​

​

​

Paid-In

​

Accumulated

​

Comprehensive

​

Treasury

​

Stockholders’

​

    

Issued

    

Amount

    

Capital

    

Deficit

    

Loss

    

Stock

    

Deficit

Balance, December 31, 2021

 

10,513

​

$

11

​

$

360,796

​

$

(468,193)

​

$

(519)

​

$

(18,255)

​

$

(126,160)

Shares issued in connection with share-based compensation plans

 

32

​

 

—

​

 

67

​

 

—

​

 

—

​

 

—

​

 

67

Share-based compensation

 

—

​

 

—

​

 

1,699

​

 

—

​

 

—

​

 

—

​

 

1,699

Purchase of treasury stock

 

—

​

 

—

​

 

—

​

 

—

​

 

—

​

 

(9)

​

 

(9)

Other comprehensive income

 

—

​

 

—

​

 

—

​

 

—

​

 

(7)

​

 

—

​

 

(7)

Net loss

 

—

​

 

—

​

 

—

​

 

(34,898)

​

 

—

​

 

—

​

 

(34,898)

Balance, March 31, 2022

 

10,545

​

$

11

​

$

362,562

​

$

(503,091)

​

$

(526)

​

$

(18,264)

​

$

(159,308)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Nine Months Ended March 31, 2023

​

​

​

​

​

​

​

​

​

​

​

​

​

Accumulated

​

​

​

​

​

​

​

​

Common Stock

​

Additional

​

​

​

​

Other

​

​

​

​

Total

​

​

Shares

​

​

​

​

Paid-In

​

Accumulated

​

Comprehensive

​

Treasury

​

Stockholders’

​

    

Issued

    

Amount

    

Capital

    

Deficit

    

Loss

    

Stock

    

Deficit

Balance, June 30, 2022

 

10,567

​

$

11

​

$

363,988

​

$

(596,386)

​

$

(411)

​

$

(18,265)

​

$

(251,063)

Shares issued in connection with share-based compensation plans

 

201

​

 

—

​

 

95

​

 

—

​

 

—

​

 

—

​

 

95

Share-based compensation

 

—

​

 

—

​

 

4,586

​

 

—

​

 

—

​

 

—

​

 

4,586

Purchase of treasury stock

 

—

​

 

—

​

 

—

​

 

—

​

 

—

​

 

(107)

​

 

(107)

Other comprehensive income

 

—

​

 

—

​

 

—

​

 

—

​

 

27

​

 

—

​

 

27

Net loss

 

—

​

 

—

​

 

—

​

 

(165,797)

​

 

—

​

 

—

​

 

(165,797)

Balance, March 31, 2023

 

10,768

​

$

11

​

$

368,669

​

$

(762,183)

​

$

(384)

​

$

(18,372)

​

$

(412,259)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Nine Months Ended March 31, 2022

​

​

​

​

​

​

​

​

​

​

​

​

​

Accumulated

​

​

​

​

​

​

​

​

Common Stock

​

Additional

​

​

​

​

Other

​

​

​

​

Total

​

​

Shares

​

​

​

​

Paid-In

​

Retained

​

Comprehensive

​

Treasury

​

Stockholders’

​

    

Issued

    

Amount

    

Capital

    

Earnings

    

Loss

    

Stock

    

Equity

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Balance, June 30, 2021

 

10,228

​

$

11

​

$

355,269

​

$

(364,766)

​

$

(548)

​

$

(17,437)

​

$

(27,471)

Shares issued in connection with share-based compensation plans

 

317

​

 

—

​

 

267

​

 

—

​

 

—

​

 

—

​

 

267

Share-based compensation

 

—

​

 

—

​

 

7,026

​

 

—

​

 

—

​

 

—

​

 

7,026

Purchase of treasury stock

 

—

​

 

—

​

 

—

​

 

—

​

 

—

​

 

(827)

​

 

(827)

Other comprehensive income

 

—

​

 

—

​

 

—

​

 

—

​

 

22

​

 

—

​

 

22

Net loss

 

—

​

 

—

​

 

—

​

 

(138,325)

​

 

—

​

 

—

​

 

(138,325)

Balance, March 31, 2022

 

10,545

​

$

11

​

$

362,562

​

$

(503,091)

​

$

(526)

​

$

(18,264)

​

$

(159,308)

​

The accompanying notes are an integral part of the Consolidated Financial Statements.

​

6

LANNETT COMPANY, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(In thousands)

​

​

​

​

​

​

​

​

​

​

Nine Months Ended

​

​

March 31, 

​

    

2023

    

2022

OPERATING ACTIVITIES:

​

​

​

​

​

​

Net loss

​

$

(165,797)

​

$

(138,325)

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

​

​

​

​

​

​

Depreciation and amortization

​

 

19,333

​

 

26,659

Share-based compensation

​

 

4,586

​

 

7,026

Asset impairment charges

​

​

83,147

​

​

49,361

Loss on loan receivable

​

​

6,826

​

​

—

(Gain) loss on sale/disposal of assets

​

 

(3,563)

​

 

(279)

Accrual of payment-in-kind interest on Second Lien Credit Facility

​

​

8,171

​

​

15,115

Amortization of debt discount and other debt issuance costs

​

​

5,542

​

​

4,553

Provision for inventory write-downs

​

​

4,068

​

​

11,427

Other noncash expenses

​

 

673

​

 

628

Changes in assets and liabilities which provided (used) cash:

​

​

​

​

​

​

Accounts receivable, net

​

 

(11,912)

​

 

34,860

Inventories

​

 

285

​

 

2,684

Income taxes receivable/payable

​

 

18,894

​

 

(2,194)

Other assets

​

 

(6,244)

​

 

(561)

Rebates payable

​

 

(8,143)

​

 

5,307

Royalties payable

​

​

2,541

​

​

(7,634)

Restructuring liability

​

​

258

​

​

891

Operating lease assets/liabilities

​

​

(989)

​

​

(835)

Accounts payable

​

 

(8,664)

​

 

(1,014)

Accrued expenses

​

 

11,071

​

 

2,795

Accrued payroll and payroll-related expenses

​

​

3,576

​

​

137

Other liabilities

​

​

(2,108)

​

​

1,284

Net cash (used in) provided by operating activities

​

 

(38,449)

​

 

11,885

INVESTING ACTIVITIES:

​

​

​

​

​

​

Purchases of property, plant and equipment

​

 

(6,580)

​

 

(9,260)

Proceeds from sale of assets

​

 

4,700

​

 

12,235

Purchases of intangible assets

​

​

(1,000)

​

​

(1,500)

Net cash (used in) provided by investing activities

​

 

(2,880)

​

 

1,475

FINANCING ACTIVITIES:

​

​

​

​

​

​

Proceeds from issuance of stock

​

 

95

​

 

267

Purchase of treasury stock

​

 

(107)

​

 

(827)

Net cash used in financing activities

​

 

(12)

​

 

(560)

Effect on cash and cash equivalents of changes in foreign exchange rates

​

 

27

​

 

22

NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

​

 

(41,314)

​

 

12,822

CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD

​

 

92,854

​

 

98,286

CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD

​

$

51,540

​

$

111,108

​

​

​

​

​

​

​

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

​

​

​

​

​

​

Interest paid

​

$

23,993

​

$

17,155

Income taxes refunded

​

$

(18,798)

​

$

(596)

Purchases of property, plant and equipment included in accounts payable

​

$

53

​

$

1,096

​

The accompanying notes are an integral part of the Consolidated Financial Statements.

​

7

LANNETT COMPANY, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Interim Financial Information

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for the presentation of interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited financial statements do not include all the information and footnotes necessary for a comprehensive presentation of the financial position, results of operations and cash flows for the periods presented. In the opinion of management, the unaudited financial statements include all the normal recurring adjustments that are necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented. Operating results for the three and nine months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2023. These unaudited financial statements should be read in combination with the other Notes in this section; “Management’s Discussion and Analysis of Financial Condition and Results of Operations” appearing in Item 2; and the Consolidated Financial Statements, including the Notes to the Consolidated Financial Statements, included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022. The Consolidated Balance Sheet as of June 30, 2022 was derived from audited financial statements.

Note 2. The Business and Nature of Operations

Lannett Company, Inc., a Delaware corporation, (“LCI,” and as it may be reorganized pursuant to the Prepackaged Plan (as defined below), “Reorganized LCI”) and its subsidiaries (collectively, the “Company,” “Lannett, ” “we” or “us” and as it may be reorganized pursuant to the Prepackaged Plan, the “Reorganized Company” ) primarily develop, manufacture, package, market and distribute solid oral and extended release (tablets and capsules), topical, nasal and oral solution finished dosage forms of drugs that address a wide range of therapeutic areas. Certain of these products are manufactured by others and distributed by the Company.

The Company operates a pharmaceutical manufacturing plant in Seymour, Indiana. During Fiscal 2022, the Company completed the sale of its Silarx Pharmaceuticals, Inc. (“Silarx”) facility in Carmel, New York. In connection with the sale, the buyer will continue to produce certain products on behalf of the Company at the Carmel facility while the Company completes the transfer of such products to its Seymour, Indiana plant.

The Company’s customers include generic pharmaceutical distributors, drug wholesalers, chain drug stores, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities and health maintenance organizations.

Going Concern

Our interim unaudited consolidated financial statements included herein have been prepared using the going concern basis of accounting, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the normal course of business. In accordance with ASC 205, Going Concern, the Company evaluated whether there are any conditions or events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q. As a result of our evaluation, we concluded that substantial doubt exists regarding our ability to continue as a going concern primarily as a result of the risks and uncertainties related to the Prepackaged Plan and Chapter 11 Cases, which are both defined and discussed further in this Quarterly Report on Form 10-Q.

8

On April 4, 2023 and April 17, 2023, the Company elected to defer interest payments on the Company’s 4.50% Convertible Senior Notes (the “Convertible Notes”) and the Company’s 7.750% Senior Secured Notes due 2026 (the “Secured Notes” and, together with the Convertible Notes, the “Notes”), respectively, and, in each case, enter a 30-day grace period. Failure to make an interest payment within the 30-day grace period constitutes an event of default under the Indenture, dated as of September 27, 2019 (the “Convertible Notes Indenture”), between the Company and Wilmington Trust, National Association, as trustee, and the Indenture, dated April 22, 2021, as supplemented by the first supplemental indenture, dated April 22, 2021(the “Secured Notes Indenture”), among the Company, the subsidiary guarantors party thereto and Wilmington Trust, National Association, as trustee and note collateral agent. Because the 30-day grace period has elapsed, an event of default occurred with respect to the Convertible Notes. As such, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding Convertible Notes may declare 100% of the principal of, and accrued and unpaid interest on, all the Convertible Notes to be due and payable immediately. With respect to the Secured Notes, as a result of the event of default, the trustee or the holders of not less than 30% in aggregate principal amount of the outstanding Secured Notes may declare 100% of the principal of, and accrued and unpaid interest on, the Secured Notes to be due and payable immediately.

Additionally, on April 24, 2023, the Company elected to defer an interest payment (together with the missed interest payments on the Notes, the “Missed Interest Payments”) in respect of its second lien credit and guaranty agreement, dated April 22, 2021 (the “Second Lien Credit Agreement”), by and among the Company, the other credit parties party thereto, the lenders party thereto and Alter Domus (US) LLC, as administrative agent and collateral agent, pursuant to which lenders party thereto made available to the Company a second lien term loan credit facility (the “Second Lien Credit Facility”). The Company did not make the interest payment within the ten-business day grace period (such grace period having been extended pursuant to the Restructuring Support Agreement, as defined below), which constituted an event of default under the Second Lien Credit Facility. Upon an event of default, the administrative agent, itself or at the request of requisite lenders, may declare the Second Lien Credit Facility and interest thereon due and payable and exercise all rights and remedies under the Second Lien Credit Facility and related agreements. The Company’s failure to pay the interest on the Second Lien Credit Facility by the end of the grace period also constituted an event of default under the Convertible Notes Indenture, the Secured Notes Indenture and the Company’s Credit and Guaranty Agreement, dated as of December 7, 2020 (as amended, the “Amended ABL Credit Agreement”), among the Company, certain of its wholly-owned domestic subsidiaries party thereto, as borrowers or as guarantors, Wells Fargo Bank, National Association, as administrative agent and as collateral agent and the other lenders party thereto.

On April 19, 2023, the Company received written notice from the New York Stock Exchange (the “NYSE”) notifying the Company that the NYSE had commenced proceedings to delist the Company’s common stock. The NYSE reached this determination pursuant to Section 802.01(B) of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an average global market capitalization of at least $15.0 million over a consecutive 30 trading-day period. The NYSE suspended trading in the Company’s common stock immediately after market close on April 19, 2023, and on April 20, 2023, the Company’s common stock began trading in the over-the-counter markets under the symbol “LCIN.” After the filing of the Chapter 11 Cases (as defined below), on May 3, 2023, our common stock began trading in the over-the-counter markets under the symbol “LCINQ.” On May 4, 2023, the NYSE filed a Form 25 with the Securities and Exchange Commission (the “SEC”) to delist our common stock from trading on the NYSE and to remove it from registration under Section 12(b) of the Exchange Act. The delisting of the Company’s common stock (the “Delisting”) became effective 10 days after the filing of the Form 25. In accordance with Rule 12d2-2 of the Exchange Act, the de-registration of our common stock under Section 12(b) of the Exchange Act will become effective 90 days, or such shorter period as the SEC may determine, after the date of the Form 25 filing.

Pursuant to the Convertible Notes Indenture, the Delisting constituted a Fundamental Change (as defined therein). Upon the occurrence of a Fundamental Change, the Company must provide all holders of Convertible Notes and the trustee a notice (the “Fundamental Change Company Notice”) of the occurrence of the Fundamental Change and of the holder’s option to require the Company to repurchase for cash all of such holder’s notes at 100% of the principal amount, plus accrued and unpaid interest. Failure by the Company to issue a Fundamental Change Company Notice within 20 days following the fundamental change constitutes an event of default and, if the trustee or holders of at least 25% in aggregate principal amount of the Convertible Notes declared 100% of the principal of, and accrued and unpaid interest on, all the Notes to be due and payable immediately, the Convertible Notes would become immediately due and payable.

9

If holders were to exercise their option to accelerate the maturity of either series of the Notes, it would also constitute an event of default under the other series of Notes, as well as the Second Lien Credit Facility and the Amended ABL Credit Agreement. Similarly, if the Second Lien Credit Facility administrative agent, itself or at the request of requisite lenders, exercises its option to accelerate the maturity of the Second Lien Credit Facility, it would also constitute an event of default under the Notes and the Amended ABL Credit Agreement.

On April 30, 2023, Lannett Company, Inc., Kremers Urban Pharmaceuticals, Inc., Cody Laboratories, Inc. and Silarx Pharmaceuticals, Inc. (collectively, the “Company Parties”) and certain of the Company’s debtholders (the “Consenting Stakeholders”) entered into the restructuring support agreement (the “Restructuring Support Agreement”) to facilitate the financial restructuring (the “Restructuring”) of the existing debt of, existing equity interests in and certain other obligations of the Company Parties. In connection therewith, on May 2, 2023 (the “Petition Date”), the Company Parties commenced cases (the “Chapter 11 Cases”) under chapter 11 (“Chapter 11”) of title 11 of the United States Code (the “Bankruptcy Code”) in the Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”). On May 2, 2023, the Company Parties filed the Joint Prepackaged Chapter 11 Plan of Reorganization of Lannett Company, Inc. and Its Debtor Affiliates (the “Prepackaged Plan”). Each Company Party will continue to operate its business as a “debtor in possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and the orders of the Bankruptcy Court. The Chapter 11 Cases are being jointly administered under the caption In re Lannett Company, Inc., et al., Case No. 23-10559 (JKS).

The filing of the Chapter 11 Cases constituted an event of default that accelerated all of our debt obligations under the Convertible Notes Indenture, the Secured Notes Indenture, the Second Lien Credit Agreement and the Amended ABL Credit Agreement. As such, we have reclassified all debt obligations to debt due within a year on our Consolidated Balance Sheet as of March 31, 2023. Our consolidated interim unaudited financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. For additional discussion related to the impact of the Chapter 11 Cases on our debt obligations, see Note 10 “Debt.” For additional information related to the effect of the automatic stay on actions to collect indebtedness incurred prior to the Petition Date or to exercise control over the Company Parties’ property, see Note 11 “Legal, Regulatory Matters and Contingencies” and Note 20 “Subsequent Events.”

Our ability to continue as a going concern is contingent upon, among other things, our ability to, subject to the Bankruptcy Court’s approval, implement the Prepackaged Plan, successfully emerge from the Chapter 11 Cases and establish a sustainable capital structure through the Restructuring. As a result of risks and uncertainties related to the Missed Interest Payments, the Delisting and the effects of disruption from the Chapter 11 Cases making it more difficult to maintain business, financing and operational relationships, together with the Company’s recurring losses from operations and accumulated deficit, substantial doubt exists regarding our ability to continue as a going concern. For detailed discussion about the Restructuring Support Agreement and the Prepackaged Plan, see Note 20 “Subsequent Events.”

Note 3. Summary of Significant Accounting Policies

Basis of presentation

The Consolidated Financial Statements have been prepared in conformity with U.S. GAAP.

Principles of consolidation

The Consolidated Financial Statements include the accounts of Lannett Company, Inc. and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.

10

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year financial statement presentation.

Reverse stock split

On January 25, 2023, the stockholders of the Company and the Board of Directors approved a 1-for-4 reverse stock split (the “Reverse Stock Split”), and the Company filed an amendment to our Certificate of Incorporation to effectuate the Reverse Stock Split on February 6, 2023. The Company’s common stock began trading on a split-adjusted basis on February 7, 2023. The Company's authorized shares of common stock, outstanding warrants, equity-based awards and Convertible Notes were also proportionately adjusted. No fractional shares were issued in connection with the Reverse Stock Split. Following the completion of the Reverse Stock Split, Lannett’s transfer agent aggregated all fractional shares that otherwise would have been issued as a result of the Reverse Stock Split and those shares were sold into the market. Stockholders who would have otherwise held a fractional share of Lannett common stock received a cash payment from the proceeds of that sale in lieu of such fractional share. There was no change to the par value of the Company’s common stock. Beginning in the third quarter of Fiscal 2023, common stock, outstanding warrants, equity-based awards, Convertible Notes and earnings (loss) per share figures have been retroactively restated for all periods presented.

Use of estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition and sales deductions for estimated chargebacks, rebates, returns and other adjustments including a provision for the Company’s liability under the Medicare Part D program. Additionally, significant estimates and assumptions are required when determining the value of inventories and long-lived assets, including intangible assets, income taxes, and contingencies.

Because of the inherent subjectivity and complexity involved in these estimates and assumptions, actual results could differ from those estimates.

Foreign currency translation

The Consolidated Financial Statements are presented in U.S. dollars, the reporting currency of the Company. The financial statements of the Company’s foreign subsidiary are maintained in local currency and translated into U.S. dollars at the end of each reporting period. Assets and liabilities are translated at period-end exchange rates, while revenues and expenses are translated at average exchange rates during the period. The adjustments resulting from the use of differing exchange rates are recorded as part of stockholders’ equity (deficit) in accumulated other comprehensive income (loss). Gains and losses resulting from transactions denominated in foreign currencies are recognized in the Consolidated Statements of Operations under other income (loss). Amounts recorded due to foreign currency fluctuations are immaterial to the Consolidated Financial Statements.

Cash, cash equivalents and restricted cash

The Company considers all highly liquid investments with original maturities less than or equal to three months at the date of purchase to be cash and cash equivalents. Cash and cash equivalents are stated at cost, which approximates fair value, and consist of bank deposits and money market funds. The Company maintains its cash deposits and cash equivalents at well-known, stable financial institutions. Such amounts frequently exceed insured limits. In connection with the Second Lien Credit Facility, the Company is required to maintain at least $5.0 million in a deposit account at all times, subject to control by the Second Lien Collateral Agent. At March 31, 2023, the Company classified this balance as restricted cash, which is included in other assets on the Consolidated Balance Sheets.

11

Presented in the table below is a reconciliation of the cash, cash equivalents and restricted cash amounts presented on the Consolidated Balance Sheets to the sum of such amounts presented on the Consolidated Statements of Cash Flows for the periods ended March 31, 2023 and 2022.

​

​

​

​

​

​

​

​

​

    

March 31, 2023

​

March 31, 2022

Cash and cash equivalents

​

$

46,540

​

$

106,108

Restricted cash, included in other assets

​

​

5,000

​

​

5,000

Cash, cash equivalents and restricted cash as presented on the Consolidated Statements of Cash Flows

​

$

51,540

​

$

111,108

​

Allowance for expected credit losses

The Company complies with ASU 2016-13, Measurement of Credit Losses on Financial Instruments, which requires the Company to recognize an allowance that reflects a current estimate of credit losses expected to be incurred over the life of the financial asset, including trade receivables. The Company continuously monitors collections and payments from its customers and maintains a provision for estimated credit losses. The Company determines its allowance for expected credit losses by considering a number of factors, including the length of time balances are past due, the Company’s previous loss history, the customer’s current ability to pay its obligations to the Company and the expected condition of the general economy and the industry as a whole. The Company writes off accounts receivable when they are determined to be uncollectible.

Inventories

Inventories are stated at the lower of cost or net realizable value by the first-in, first-out method. Inventories are regularly reviewed and write-downs for excess and obsolete inventory are recorded based primarily on current inventory levels, expiration date and estimated sales forecasts.

Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation is computed on a straight-line basis over the assets’ estimated useful lives. Repairs and maintenance costs that do not extend the useful life of the asset are expensed as incurred.

Intangible assets

Definite-lived intangible assets are stated at cost less accumulated amortization. Amortization of definite-lived intangible assets is computed on a straight-line basis over the assets’ estimated useful lives, which commence upon first shipment of the product associated with the intangible asset. The Company continually evaluates the reasonableness of the useful lives of these assets. Costs to renew or extend the term of a recognized intangible asset are expensed as incurred.

Valuation of long-lived assets, including intangible assets

The Company’s long-lived assets primarily consist of property, plant and equipment and definite-lived intangible assets. Property, plant and equipment and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances (“triggering events”) indicate that the carrying amount of the asset may not be recoverable. If a triggering event is determined to have occurred, the asset’s carrying value is compared to the future undiscounted cash flows expected to be generated by the asset. If the carrying value exceeds the undiscounted cash flows of the asset, then impairment exists.

An impairment loss is measured as the excess of the asset’s carrying value over its fair value, which in most cases is calculated using a discounted cash flow model. Discounted cash flow models are highly reliant on various assumptions which are considered Level 3 inputs, including estimates of future cash flows (including long-term growth rates), discount rates and the probability of achieving the estimated cash flows.

12

Revenue disaggregation

The Company operates in one reportable segment, generic pharmaceuticals. As such, the Company aggregates its financial information for all products. The following table identifies the Company’s net sales by medical indication for the three and nine months ended March 31, 2023 and 2022.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

(In thousands)

​

March 31, 

​

March 31, 

​

Medical Indication

    

2023

    

2022

    

2023

    

2022

​

Analgesic

​

$

2,741

​

$

3,292

​

$

8,757

​

$

12,525

​

Anti-Psychosis

​

​

2,082

​

​

3,346

​

​

7,277

​

​

9,156

​

Cardiovascular

​

 

13,059

​

 

9,468

​

 

37,030

​

 

33,321

​

Central Nervous System

​

​

19,311

​

​

15,177

​

​

61,887

​

​

60,302

​

Endocrinology

​

​

8,066

​

​

6,792

​

​

21,209

​

​

22,934

​

Gastrointestinal

​

​

9,932

​

​

11,709

​

​

26,590

​

​

40,972

​

Infectious Disease

​

​

2,826

​

​

5,438

​

​

12,884

​

​

24,473

​

Migraine

​

 

2,768

​

 

3,507

​

 

9,666

​

 

12,638

​

Respiratory/Allergy/Cough/Cold

​

​

981

​

​

2,309

​

​

3,651

​

​

7,291

​

Other

​

 

13,342

​

 

14,700

​

 

33,056

​

 

35,327

​

Contract manufacturing revenue

​

​

5,399

​

​

2,619

​

​

14,473

​

​

7,451

​

Total net sales

​

$

80,507

​

$

78,357

​

$

236,480

​

$

266,390

​

​

Product and customer concentration

For the three and nine months ended March 31, 2023 and 2022, the Company did not have any products, defined as containing the same active ingredient or combination of ingredients, that accounted for at least 10% of total net sales.

The following table presents the percentage of total net sales, for the three and nine months ended March 31, 2023 and 2022, for certain of the Company’s customers which accounted for at least 10% of total net sales in any of those periods:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

​

Nine Months Ended

​

​

​

    

March 31, 

    

    

March 31, 

    

    

​

    

2023

    

2022

    

    

2023

    

2022

    

​

Customer A

 

26

%

17

%

 

23

%

25

%

 

Customer B

 

17

%

19

%

 

19

%

18

%

 

Customer C

​

14

%

12

%

​

15

%

14

%

​

​

Revenue recognition

Under Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers, the Company recognizes revenue when (or as) we satisfy our performance obligations by transferring a promised good or service to a customer at an amount that reflects the consideration the Company is expected to be entitled. Our revenue consists almost entirely of sales of our pharmaceutical products to customers, whereby we ship product to a customer pursuant to a purchase order. Revenue contracts such as these do not generally give rise to contract assets or contract liabilities because: (i) the underlying contracts generally have only a single performance obligation and (ii) we do not generally receive consideration until the performance obligation is fully satisfied. Under ASC 606, Revenue from Contracts with Customers, the Company recognizes certain contract manufacturing arrangements “over time.”

When revenue is recognized, a simultaneous adjustment to gross sales is made for estimated chargebacks, rebates, returns, promotional adjustments and other potential adjustments. These provisions are primarily estimated based on historical experience, future expectations, contractual arrangements with wholesalers and indirect customers and other factors known to management at the time of accrual. Accruals for provisions are presented in the Consolidated Financial Statements as a reduction to gross sales with the corresponding reserve presented as a reduction of accounts receivable or included as rebates payable, depending on the nature of the reserve.

13

Provisions for chargebacks, rebates, returns and other adjustments require varying degrees of subjectivity. While rebates generally are based on contractual terms, chargebacks and returns require management to make more subjective assumptions. Each major category is discussed in detail below:

Chargebacks

The provision for chargebacks is the most significant and complex estimate used in the recognition of revenue. The Company sells its products directly to wholesale distributors, generic distributors, retail pharmacy chains and mail-order pharmacies. The Company also sells its products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes and group purchasing organizations, collectively referred to as “indirect customers.” The Company enters into agreements with its indirect customers to establish pricing for certain products. The indirect customers then independently select a wholesaler from which to purchase the products. If the price paid by the indirect customers is lower than the price paid by the wholesaler, the Company will provide a credit, called a chargeback, to the wholesaler for the difference between the contractual price with the indirect customers and the wholesaler purchase price. The provision for chargebacks is based on expected sell-through levels by the Company’s wholesale customers to the indirect customers and estimated wholesaler inventory levels. As sales to the large wholesale customers, such as Cardinal Health, AmerisourceBergen and McKesson increase (decrease), the reserve for chargebacks will also generally increase (decrease). However, the size of the increase (decrease) depends on product mix and the amount of sales made to indirect customers with which the Company has specific chargeback agreements. The Company continually monitors the reserve for chargebacks and makes adjustments when management believes that expected chargebacks may differ from the actual chargeback reserve.

Rebates

Rebates are offered to the Company’s key chain drug store, distributor and wholesaler customers to promote customer loyalty and increase product sales. These rebate programs provide customers with credits upon attainment of pre-established volumes or attainment of net sales milestones for a specified period. Other promotional programs are incentive programs offered to the customers. Additionally, as a result of the Patient Protection and Affordable Care Act (“PPACA”) enacted in the U.S. in March 2010, the Company participates in a cost-sharing program for certain Medicare Part D beneficiaries designed primarily for the sale of brand drugs and certain generic drugs if their Food and Drug Administration (“FDA”) approval was granted under a New Drug Application (“NDA”) or 505(b) NDA versus an Abbreviated New Drug application ("ANDA”). Drugs purchased within the Medicare Part D coverage gap (commonly referred to as the “donut hole”) result in additional rebates. The Company estimates the reserve for rebates and other promotional credit programs based on the specific terms in each agreement when revenue is recognized. The reserve for rebates increases (decreases) as sales to certain wholesale and retail customers increase (decrease). However, since these rebate programs are not identical for all customers, the size of the reserve will depend on the mix of sales to customers that are eligible to receive rebates.

Returns

Consistent with industry practice, the Company has a product returns policy that allows customers to return product within a specified time period prior to and subsequent to the product’s expiration date in exchange for a credit to be applied to future purchases. The Company’s policy requires that the customer obtain pre-approval from the Company for any qualifying return. The Company estimates its provision for returns based on historical experience, changes to business practices, credit terms and any extenuating circumstances known to management. While historical experience has allowed for reasonable estimations in the past, future returns may or may not follow historical trends. The Company continually monitors the reserve for returns and makes adjustments when management believes that actual product returns may differ from the established reserve. Generally, the reserve for returns increases as net sales increase.

14

Other adjustments

Other adjustments consist primarily of “price adjustments,” also known as “shelf-stock adjustments” and “price protections,” which are both credits issued to reflect increases or decreases in the invoice or contract prices of the Company’s products. In the case of a price decrease, a credit is given for product remaining in customer’s inventories at the time of the price reduction. Contractual price protection results in a similar credit when the invoice or contract prices of the Company’s products increase, effectively allowing customers to purchase products at previous prices for a specified period of time. Amounts recorded for estimated shelf-stock adjustments and price protections are based upon specified terms with direct customers, estimated changes in market prices and estimates of inventory held by customers. The Company regularly monitors these and other factors and evaluates the reserve as additional information becomes available. Other adjustments also include prompt payment discounts and “failure-to-supply” adjustments. If the Company is unable to fulfill certain customer orders, the customer can purchase products from our competitors at their prices and charge the Company for any difference in our contractually agreed upon prices.

Leases

Under ASC Topic 842, Leases, when the Company enters into a new arrangement, it must determine, at the inception date, whether the arrangement is or contains a lease. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. Once a lease has been identified, the Company must determine the lease term, the present value of lease payments and the classification of the lease as either operating or financing.

The lease term is determined to be the non-cancelable period including any lessee renewal options which are considered to be reasonably certain of exercise. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.

The present value of lease payments includes fixed and certain variable payments, less lease incentives, together with amounts probable of being owed by the Company under residual value guarantees and, if reasonably certain of being paid, the cost of certain renewal options and early termination penalties set forth in the lease arrangement. To calculate the present value of lease payments, we use our incremental borrowing rate based on the information available at commencement date, as the rate implicit in the lease is generally not readily available.

In making the determination of whether a lease is an operating lease or a finance lease, the Company considers the lease term in relation to the economic life of the leased asset, the present value of lease payments in relation to the fair value of the leased asset and certain other factors.

Upon the commencement of the lease, the Company will record a lease liability and right-of-use (“ROU”) asset based on the present value of the future minimum lease payments over the lease term at commencement date. The ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred.

For operating leases, a single lease cost is generally recognized in the Consolidated Statements of Operations on a straight-line basis over the lease term unless an impairment has been recorded with respect to a leased asset. For finance leases, amortization expense and interest expense are recognized separately in the Consolidated Statements of Operations, with amortization expense generally recorded on a straight-line basis and interest expense recorded using the effective interest method. Variable lease costs not initially included in the lease liability and ROU asset impairment charges are expensed as incurred. The Company does not recognize short-term leases of 12 months or less on its Consolidated Balance Sheets.

15

Cost of sales, including amortization of intangibles

Cost of sales includes all costs related to bringing products to their final selling destination, which includes direct and indirect costs, such as direct material, labor and overhead expenses. Additionally, cost of sales includes product royalties, depreciation, amortization and costs to renew or extend recognized intangible assets, freight charges and other shipping and handling expenses.

Research and development

Research and development costs are expensed as incurred, including all production costs until a drug candidate is approved by the FDA. Research and development expenses include costs associated with internal projects as well as costs associated with third-party research and development contracts.

Contingencies

Loss contingencies, including litigation-related contingencies, are included in the Consolidated Statements of Operations when the Company concludes that a loss is both probable and reasonably estimable. Legal fees for litigation-related matters are expensed as incurred and included in the Consolidated Statements of Operations under the Selling, general and administrative expenses line item.

Restructuring costs

The Company records charges associated with approved restructuring plans to remove duplicative headcount and infrastructure associated with business acquisitions or to simplify business processes. Restructuring charges can include severance costs to eliminate a specified number of employees, infrastructure charges to vacate facilities and consolidate operations and contract cancellation costs. The Company records restructuring charges based on estimated employee terminations, site closure and consolidation plans. The Company accrues severance and other employee separation costs under these actions when it is probable that a liability exists, and the amount is reasonably estimable.

Share-based compensation

Share-based compensation costs are recognized over the requisite service period, typically the vesting period, using a straight-line method, based on the fair value of the instrument on the date of grant less an estimate for expected forfeitures. The Company uses the stock price on the grant date to value restricted stock and performance-based shares with vesting based on the satisfaction of a performance condition. The Company uses the Black-Scholes valuation model to determine the fair value of stock options and the Monte-Carlo simulation model to determine the fair value of performance-based shares with a market condition. The Black-Scholes valuation and Monte-Carlo simulation models include various assumptions, including the expected volatility, the expected life of the award, dividend yield and the risk-free interest rate as well as performance assumptions of peer companies. These assumptions involve inherent uncertainties based on market conditions which are generally outside the Company’s control. Changes in these assumptions could have a material impact on share-based compensation costs recognized in the Consolidated Financial Statements.

Self-insurance

The Company self-insures for certain employee medical and prescription benefits. The Company also maintains stop loss coverage with third party insurers to limit its total liability exposure. The liability for self-insured risks is primarily calculated using independent third-party actuarial valuations which take into account actual claims, claims growth and claims incurred but not yet reported. Actual experience, including claim frequency and severity as well as health-care inflation, could result in different liabilities than the amounts currently recorded. The liability for self-insured risks under this plan was $1.2 million and $0.5 million as of March 31, 2023 and June 30, 2022, respectively, and is recorded in the accrued payroll and payroll-related expenses caption in the Consolidated Balance Sheets.

16

Income taxes

The Company uses the liability method to account for income taxes as prescribed by ASC 740, Income Taxes. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. Deferred tax expense (benefit) is the result of changes in deferred tax assets and liabilities. Deferred income tax assets and liabilities are adjusted to recognize the effects of changes in tax laws or enacted tax rates in the period during which they are signed into law. The Company evaluates the need for a valuation allowance each reporting period weighing all positive and negative evidence. The factors used to assess the likelihood of realization include, but are not limited to, the Company’s forecast of future taxable income, historical results of operations, statutory expirations and available tax planning strategies and actions that could be implemented to realize the net deferred tax assets. Under ASC 740, Income Taxes, a valuation allowance is required when it is more likely than not that all or some portion of the deferred tax assets will not be realized.

The Company may recognize the tax benefit from an uncertain tax position claimed on a tax return only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The authoritative accounting standards also provide guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures.

Earnings (loss) per common share

The presentation of basic and diluted earnings (loss) per common share is required on the face of the Company's Consolidated Statements of Operations as well as a reconciliation of the computation of basic earnings (loss) per common share to diluted earnings (loss) per common share. In accordance with ASC 260, Earnings per share, the Company computes earnings (loss) per share using the two-class method, which requires an allocation of earnings between the holders of common stock and the Company’s participating security holders. The warrants issued in connection with the Second Lien Secured Loan Facility (the “Warrants”) are considered participating securities, as discussed further in Note 13 “Warrants.” Basic earnings (loss) per share is calculated by dividing net income (loss) available to common stockholders, which excludes the income allocated to participating security holders, by the basic weighted average common shares outstanding.

For purposes of determining diluted earnings per share, the Company further adjusts the basic earnings per share to include the effect of potentially dilutive shares outstanding, including options and restricted stock awards, the Convertible Notes, and the Warrants. In this calculation, the Company reallocates net income based on the rights of each potentially dilutive share and will report the most dilutive earnings (loss) per share. The weighted average number of diluted shares is adjusted for the potential dilutive effect of the exercise of stock options, treats unvested restricted stock as if it were vested, includes performance-based shares that would be issued if the performance criteria were met as of the end of the reporting period, and assumes the conversion of the Convertible Notes. The Company uses the “if-converted" method to compute earnings (loss) per share when assuming the conversion of the Convertible Notes, which is calculated by dividing the adjusted "if-converted" net income by the adjusted weighted average number of shares of common stock outstanding during the period. The adjusted "if-converted" net income is adjusted for interest expense and amortization of debt issuance costs, both net of tax, associated with the Convertible Notes. Because the Warrants do not participate in losses, the Company will allocate undistributed earnings when calculating basic and diluted earnings per share in periods of net income only. Anti-dilutive securities are excluded from the calculation. Dilutive shares are also excluded in the calculation in periods of net loss because the effect of including such securities would be anti-dilutive.

Comprehensive income (loss)

Comprehensive income (loss) reflects all changes in equity during a period except those that resulted from investments by or distributions to the Company’s stockholders. This includes, but is not limited to, foreign currency translation gain (loss). Other comprehensive income (loss) refers to gains and losses that are included in comprehensive income (loss) but excluded from income (loss) for all amounts are recorded directly as an adjustment to stockholders’ equity.

17

​

Note 4. Restructuring Charges

On December 15, 2022, the Company authorized a restructuring and cost savings plan (the “2022 Restructuring Plan”) to streamline and realign our operations to ensure the continued progression of our existing pipeline and future growth. The 2022 Restructuring Plan includes operational improvements and cost efficiencies as well as engagement with more external partners and technology providers, globally, to execute on our R&D plans and operations.

The total reduction in headcount, and the basis of the estimated severance costs, for the 2022 Restructuring Plan is expected to be approximately 60 positions. The Company expects the reduction in force to be completed by the end of Fiscal 2023. The Company estimates that it will incur approximately $3 million in severance-related costs in connection with the 2022 Restructuring Plan. A reconciliation of the changes in restructuring liabilities associated with the 2022 Restructuring Plan from June 30, 2022 through March 31, 2023 is set forth in the following table:

​

​

​

​

​

​

    

Employee

(In thousands)

    

Separation Costs

Balance at June 30, 2022

​

$

—

Restructuring charges

​

 

1,968

Payments

​

 

(1,220)

Balance at March 31, 2023

​

$

748

​

In connection with the shift in our R&D operations, the Company also anticipates exiting our State Road and Torresdale facilities in Philadelphia, Pennsylvania by the end of our current fiscal year. In the first quarter of Fiscal 2023, the Company recorded an impairment charge of $4.7 million to adjust the State Road facility and certain equipment to fair value less costs to sell and the remaining assets of $1.3 million were recorded in the assets held for sale caption in the Consolidated Balance Sheet. In the second quarter of Fiscal 2023, the Company recorded an impairment charge of $6.0 million to adjust the Torresdale facility to its approximate fair value.

Note 5. Accounts Receivable, net

Accounts receivable, net consisted of the following components at March 31, 2023 and June 30, 2022:

​

​

​

​

​

​

​

​

​

​

March 31, 

    

June 30, 

(In thousands)

    

2023

    

2022

Gross accounts receivable

​

$

180,873

​

$

199,242

Less: Chargebacks reserve

​

 

(48,532)

​

 

(54,501)

Less: Rebates reserve

​

 

(14,969)

​

 

(26,921)

Less: Returns reserve

​

 

(35,690)

​

 

(46,478)

Less: Other deductions

​

 

(12,580)

​

 

(14,117)

Less: Allowance for expected credit losses

​

 

(949)

​

 

(984)

Accounts receivable, net

​

$

68,153

​

$

56,241

​

For the three months ended March 31, 2023, the Company recorded a provision for chargebacks, rebates (including rebates presented as rebates payable), returns and other deductions of $95.5 million, $22.2 million, $6.6 million and $6.7 million, respectively. For the three months ended March 31, 2022, the Company recorded a provision for chargebacks, rebates (including rebates presented as rebates payable), returns and other deductions of $93.8 million, $22.1 million, $12.7 million and $11.9 million, respectively.

For the nine months ended March 31, 2023, the Company recorded a provision for chargebacks, rebates (including rebates presented as rebates payable), returns and other deductions of $276.4 million, $69.5 million, $20.2 million and $20.7 million, respectively. For the nine months ended March 31, 2022, the Company recorded a provision for chargebacks, rebates (including rebates presented as rebates payable), returns and other deductions of $339.7 million, $77.4 million, $26.0 million and $38.6 million, respectively.

18

The following table identifies the activity and ending balances of each major category of revenue-related reserve for the nine months ended March 31, 2023 and 2022:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Reserve Category

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

(In thousands)

    

Chargebacks

    

Rebates

    

Returns

    

Other

    

Total

Balance at June 30, 2022

​

$

54,501

​

$

48,489

​

$

46,478

​

$

14,117

​

$

163,585

Current period provision

​

 

276,392

​

​

69,483

​

​

20,195

​

​

20,677

​

 

386,747

Credits issued during the period

​

 

(282,361)

​

​

(89,578)

​

​

(30,983)

​

​

(22,214)

​

 

(425,136)

Balance at March 31, 2023

 

$

48,532

 

$

28,394

 

$

35,690

 

$

12,580

 

$

125,196

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Reserve Category

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

(In thousands)

    

Chargebacks

    

Rebates

    

Returns

    

Other

    

Total

Balance at June 30, 2021

​

$

69,564

​

$

35,297

​

$

38,395

​

$

15,505

​

$

158,761

Current period provision

​

 

339,663

​

 

77,352

​

 

25,979

​

 

38,625

​

 

481,619

Credits issued during the period

​

 

(350,626)

​

 

(67,975)

​

 

(22,397)

​

 

(37,985)

​

 

(478,983)

Balance at March 31, 2022

 

$

58,601

 

$

44,674

 

$

41,977

 

$

16,145

 

$

161,397

​

For the three months ended March 31, 2023 and 2022, as a percentage of gross sales the provision for chargebacks was 47.1% and 43.4%, the provision for rebates was 10.9% and 10.2%, the provision for returns was 3.3% and 5.9% and the provision for other adjustments was 3.3% and 5.5%, respectively.

For the nine months ended March 31, 2023 and 2022, as a percentage of gross sales the provision for chargebacks was 45.7% and 45.9%, the provision for rebates was 11.5% and 10.5%, the provision for returns was 3.3% and 3.5% and the provision for other adjustments was 3.4% and 5.2%, respectively.

The decrease in the reserve for chargebacks from June 30, 2022 to March 31, 2023 was primarily attributable to changes in product and customer sales mix. Additionally, the reserve for rebates and returns decreased during the first six months of Fiscal 2023 due to the timing of payments. Higher than average returns in prior periods also contributed to the decrease in the reserve for returns during the period.

Note 6. Inventories

Inventories at March 31, 2023 and June 30, 2022 consisted of the following:

​

​

​

​

​

​

​

​

​

​

March 31, 

​

June 30, 

(In thousands)

    

2023

    

2022

Raw Materials

​

$

39,754

​

$

39,297

Work-in-process

​

 

11,759

​

 

9,313

Finished Goods

​

 

39,292

​

 

46,548

Total

​

$

90,805

​

$

95,158

​

During the three months ended March 31, 2023 and 2022, the Company recorded write-downs to net realizable value for excess and obsolete inventory of $0.8 million and $7.4 million, respectively. During the nine months ended March 31, 2023 and 2022, the Company recorded write-downs to net realizable value for excess and obsolete inventory of $4.1 million and $11.4 million, respectively. The write-downs for excess and obsolete inventory for the three and nine months ended March 31, 2022 was higher than the three and nine months ended March 31, 2023 primarily as a result of the discontinuance of two low-margin prescription products manufactured by KUPI in Seymour, Indiana and several products manufactured at the Silarx plant prior to the sale of the facility in Fiscal 2022.

19

Note 7. Property, Plant and Equipment, net

Property, plant and equipment, net at March 31, 2023 and June 30, 2022 consisted of the following:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

March 31, 

    

June 30, 

(In thousands)

   

Useful Lives

   

2023

   

2022

Land

 

—

​

$

—

​

$

533

Building and improvements

 

10 - 39 years

​

 

7,955

​

 

93,701

Machinery and equipment

 

5 - 10 years

​

 

54,666

​

 

158,854

Furniture and fixtures

 

5 - 7 years

​

 

1,234

​

 

3,367

Less accumulated depreciation

​

​

​

​

(54,077)

​

​

(136,433)

​

​

​

​

​

9,778

​

​

120,022

Construction in progress

 

​

​

 

2,585

​

 

13,156

Property, plant and equipment, net

​

​

​

$

12,363

​

$

133,178

​

Depreciation expense for the three months ended March 31, 2023 and 2022 was $5.8 million and $5.2 million, respectively. Depreciation expense for the nine months ended March 31, 2023 and 2022 was $15.7 million and $16.2 million, respectively.

In conjunction with the Restructuring Support Agreement, the Company, with the knowledge of its lenders, has begun to explore the sale of its Seymour, Indiana facility. The Company currently seeks to sell the facility and its contract manufacturing business to a pharmaceutical manufacturer that could benefit from the site’s exceptional history of FDA compliance, and with whom we would partner with to continue manufacturing our products at the site. The Company’s existing ANDAs and NDAs are not part of any potential sale. The Company determined that the above requires reclassification of the assets at the Seymour, Indiana facility to assets held for sale on our Consolidated Balance Sheets as of March 31, 2023. The Company evaluated the assets for impairment as the reclassification is considered a triggering event. As a result, the Company recorded an impairment charge of $72.5 million to adjust the assets to their expected fair value. For further discussion of the Chapter 11 Cases and Restructuring Support Agreement, see Note 20 “Subsequent Events.”

In the second quarter of Fiscal 2023, the Company recorded an impairment charge of $6.0 million to adjust the Torresdale facility to its approximate fair value in connection with the 2022 Restructuring Plan. See Note 4 “Restructuring Charges” for additional information on the plan.

Property, plant and equipment, net included amounts held in foreign countries in the amount of $0.7 million at March 31, 2023 and June 30, 2022.

Note 8. Fair Value Measurements

The Company’s financial instruments recorded in the Consolidated Balance Sheets include cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt obligations. The Company’s cash and cash equivalents include bank deposits and money market funds. The carrying value of certain financial instruments, primarily cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, approximate their estimated fair values based upon the short-term nature of their maturity dates.

The Company follows the authoritative guidance of ASC Topic 820, Fair Value Measurements and Disclosures. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The hierarchy is defined as follows:

Level 1 — Quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.

20

Level 2 — Directly or indirectly observable inputs, other than quoted prices, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable.

Level 3 — Unobservable inputs that are supported by little or no market activity and that are material to the fair value of the asset or liability. Financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation are examples of Level 3 assets and liabilities.

If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

Financial Instruments Disclosed, But Not Reported, at Fair Value

We estimate the fair value of the Secured Notes and the Convertible Notes using market quotations for debt that have quoted prices in active markets (Level 1). Since our Second Lien Credit Facility does not trade on a daily basis in an active market, the fair value estimate is based on market observable inputs based on borrowing rates currently available for debt with similar terms and average maturities (Level 2). The estimated fair value of the Secured Notes as of March 31, 2023 and June 30, 2022 was approximately $56 million and $140 million, respectively. The estimated fair value of the Second Lien Credit Facility as of March 31, 2023 and June 30, 2022 was approximately $30 million and $76 million, respectively. The decline in the fair value of the Secured Notes and Second Lien Credit Facility is primarily a reflection of the increased competitive pressures on the Company’s recent financial performance, which, in part, resulted in a downgrade to the Company’s credit rating. The estimated fair value of the Convertible Notes was approximately $6 million and $25 million as of March 31, 2023 and June 30, 2022, respectively. The fair value of the Convertible Notes as of March 31, 2023 was lower than the carrying value primarily due to the Company’s stock price of $1.74 at March 31, 2023 as compared to the $61.16 conversion price as well as the Company’s downgraded credit rating.

​

​

Note 9. Intangible Assets

Intangible assets, net as of March 31, 2023 and June 30, 2022 consisted of the following:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Weighted

​

Gross Carrying Amount

​

Accumulated Amortization

​

Intangible Assets, Net

​

    

Avg. Life

    

March 31, 

    

June 30, 

    

March 31, 

    

June 30, 

    

March 31, 

    

June 30, 

(In thousands)

    

(Yrs.)

    

2023

    

2022

    

2023

    

2022

    

2023

    

2022

Definite-lived:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

KUPI trade name

​

2

​

$

2,920

​

$

2,920

​

$

(2,920)

​

$

(2,920)

​

$

—

​

$

—

KUPI other intangible assets

​

15

​

​

—

​

​

19,000

​

​

—

​

​

(8,362)

​

​

—

​

​

10,638

Silarx product rights

​

15

​

​

18,531

​

​

20,000

​

​

(6,693)

​

​

(6,222)

​

​

11,838

​

​

13,778

Other product rights

​

7

​

​

17,242

​

​

16,242

​

​

(10,173)

​

​

(8,479)

​

​

7,069

​

​

7,763

Total intangible assets, net

​

​

​

$ 

38,693

​

$ 

58,162

​

$ 

(19,786)

​

$ 

(25,983)

​

$ 

18,907

​

$ 

32,179

​

In conjunction with the Restructuring Support Agreement, the Company, with the knowledge of its lenders, has begun to explore the sale of its Seymour, Indiana facility. The Company currently seeks to sell the facility and its contract manufacturing business to a pharmaceutical manufacturer that could benefit from the site’s exceptional history of FDA compliance, and with whom we would partner with to continue manufacturing our products at the site. The Company’s existing ANDAs and NDAs are not part of any potential sale. However, the KUPI other intangible assets, which consists of the Company’s contract manufacturing business associated with the Seymour, Indiana facility, is expected to be included in any potential sale of the facility. As such, the Company reclassified the KUPI other intangible assets to the assets held for sale caption in the Consolidated Balance Sheets as of March 31, 2023. For further discussion of the Chapter 11 Cases and Restructuring Support Agreement, see Note 20 “Subsequent Events.”

For the three months ended March 31, 2023 and 2022, the Company recorded amortization expense of $1.0 million and $2.6 million, respectively. For the nine months ended March 31, 2023 and 2022, the Company recorded amortization expense of $3.6 million and $10.4 million, respectively.

21

Future annual amortization expense consists of the following as of March 31, 2023:

​

​

​

​

​

(In thousands)

    

Amortization

Fiscal Year Ending June 30, 

    

Expense

2023

​

$

727

2024

​

 

2,607

2025

​

 

2,573

2026

​

 

2,406

2027

​

 

2,269

Thereafter

​

 

8,325

​

​

$

18,907

​

​

​

​

​

Note 10. Debt

The filing of the Chapter 11 Cases constituted an event of default that accelerated all of our debt obligations. As such, we have reclassified all debt obligations to debt due within a year on our Consolidated Balance Sheet as of March 31, 2023. Pursuant to Section 362 of the Bankruptcy Code, the filing of the Chapter 11 Cases automatically stayed most actions against or on behalf of the Company Parties, including actions to collect indebtedness incurred prior to the Petition Date or to exercise control over the Company Parties’ property. To facilitate the Restructuring, on May 1, 2023, the Amended ABL Credit Agreement was terminated (other than with respect to provisions regarding Letters of Credit, as defined in the Amended ABL Credit Agreement, that remain outstanding and customary obligations that expressly survived by their terms).

For information about subsequent events related to the termination of the Amended ABL Credit Agreement, the Restructuring Support Agreement, the Chapter 11 Cases and the Prepackaged Plan, see Note 20 “Subsequent Events.”

Debt, net, prior to the filing of the Chapter 11 Cases, consisted of the following:

​

​

​

​

​

​

​

​

​

​

March 31, 

​

June 30, 

(In thousands)

    

2023

    

2022

7.75% Senior Secured Notes

​

$

350,000

​

$

350,000

Unamortized discount and other debt issuance costs

​

​

(3,798)

​

​

(4,599)

7.75% Senior Secured Notes, net

​

​

346,202

​

​

345,401

Second Lien Secured Loan Facility ($190.0M Principal, $5.7M Exit Fee, and $30.2M and $22.0M accrued PIK interest at March 31, 2023 and June 30, 2022 respectively)

​

​

225,892

​

​

217,721

Unamortized discount and other debt issuance costs

​

​

(28,210)

​

​

(32,308)

Second Lien Secured Loan Facility, net

​

​

197,682

​

​

185,413

4.50% Convertible Senior Notes

​

​

86,250

​

​

86,250

Unamortized discount and other debt issuance costs

​

​

(1,743)

​

​

(2,116)

4.50% Convertible Senior Notes, net

​

​

84,507

​

​

84,134

$45.0 million Amended ABL Credit Facility

​

 

—

​

 

—

Total debt, net, due within one year

 

$

628,391

 

$

614,948

​

The weighted average interest rate for the three months ended March 31, 2023 and 2022 was 9.3% and 9.1%, respectively. The weighted average interest rate for the nine months ended March 31, 2023 and 2022 was 9.2% and 8.9%, respectively. As of March 31, 2023, the Company recorded interest payable of $16.6 million, which is included in the accrued expenses caption of the Consolidated Balance Sheets.

On April 22, 2021, the Company issued $350.0 million aggregate principal amount of the Secured Notes in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and outside the United States to persons other than U.S. persons in reliance upon Regulation S under the Securities Act. The Secured Notes bear interest semi-annually in arrears on April 15 and October 15 of each year, beginning on October 15, 2021, at a rate of 7.750% per annum in cash. The Secured Notes will mature on April 15, 2026, unless earlier redeemed or repurchased in accordance with their terms.

22

On April 5, 2021, the Company entered into an Exchange Agreement with certain participating lenders to exchange a portion of their existing Term B Loans for Second Lien Loans pursuant to a new $190.0 million Second Lien Credit Facility. On April 22, 2021, in connection with the issuance of the Secured Notes and the entrance into the Amended ABL Credit Facility, which is discussed further below, the exchange between the Company and the participating lenders was consummated. From the Closing Date until the one-year anniversary of the Closing Date, the Second Lien Loans bear 10.0% PIK interest. Thereafter, the Second Lien notes will bear 5.0% cash interest and 5.0% PIK interest until maturity, except to the extent the Company elects to pay all or portion of the PIK interest in cash. To date, the Company has not paid any PIK interest in cash. The Second Lien Loans will mature on July 21, 2026. In connection with the Second Lien Credit Facility, the Company issued to the Participating Lenders Warrants to purchase up to 2,070,000 shares of common stock of the Company at an exercise price of $27.52 per share. Refer to Note 13 “Warrants” for further information on the Warrants issued.

In connection with the Second Lien Credit Facility, the Company is required to maintain at least $5.0 million in a deposit account at all times subject to control by the Second Lien Collateral Agent, and a minimum cash balance of $15.0 million as of the last day of each month. At March 31, 2023, the Company classified the $5.0 million required deposit account balance as restricted cash, which is included in other assets caption in the Consolidated Balance Sheet. The Second Lien Credit Facility also contains an affirmative covenant requiring delivery of the Company’s year-end financial statements, accompanied by an audit opinion that is not qualified, subject to customary exceptions, as to the status of the Company as a going concern.

In addition to the Secured Notes Offering and the Second Lien Credit Facility, on April 22, 2021, the Company entered into the Amended ABL Credit Agreement, among the Company, certain of its wholly-owned domestic subsidiaries party thereto, as borrowers or as guarantors, Wells Fargo Bank, National Association, as administrative agent and as collateral agent and the other lenders party thereto, for the purpose of, among other things, increasing the aggregate amount of the revolving credit facility from $30.0 million to $45.0 million and extending the maturity thereof to the fifth anniversary of the closing date of the Secured Notes Offering (subject to a springing maturity as set forth therein).

The Amended ABL Credit Agreement provides for a revolving credit facility (the “Amended ABL Credit Facility”) that includes letter of credit and swing line sub-facilities. Borrowing availability under the Amended ABL Credit Facility is determined by a monthly borrowing base collateral calculation that is based on specified percentages of eligible accounts receivable less certain reserves and subject to certain other adjustments as set forth in the Amended ABL Credit Agreement. Availability is reduced by issuance of letters of credit as well as any borrowings. Loans outstanding under the Amended ABL Credit Agreement bear interest at a floating rate measured by reference to, at the Company’s option, either an adjusted London Inter-Bank Offered Rate (“LIBOR”) (subject to a floor of 0.75%) plus an applicable margin of 2.50% per annum, or an alternate base rate plus an applicable margin of 1.50% per annum. Unused commitments under the Amended ABL Credit Facility are subject to a per annum fee of 0.50% per annum, which fee increases to 0.75% per annum for any quarter during which the Company's average usage under the Amended ABL Credit Facility is less than $5.0 million.

23

On September 27, 2019, the Company issued $86.3 million aggregate principal amount of the Convertible Notes in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The Convertible Notes are senior unsecured obligations of the Company and bear interest at an annual rate of 4.50% payable semi-annually in arrears on April 1 and October 1 of each year, beginning on April 1, 2020. The Convertible Notes will mature on October 1, 2026, unless earlier repurchased, redeemed or converted in accordance with their terms. The Convertible Notes are convertible into shares of the Company’s common stock at a conversion rate of 16.3507 shares per $1,000 principal amount of Convertible Notes (which is equivalent to a conversion price of approximately $61.16 per share), subject to adjustments upon the occurrence of certain events (but will not be adjusted for any accrued and unpaid interest). The Company may redeem all or a part of the Convertible Notes on or after October 6, 2023 at a redemption price equal to 100% of the principal amount of the Convertible Notes redeemed, plus accrued and unpaid interest, if any, up to, but excluding, the redemption date, subject to certain conditions relating to the Company’s stock price having been met. Following certain corporate events that occur prior to the maturity date or if the Company delivers a notice of redemption, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such corporate event or notice of redemption. The indenture covering the Convertible Notes contains certain other customary terms and covenants, including that upon certain events of default occurring and continuing, either the trustee or holders of at least 25% in principal amount of the outstanding Convertible Notes may declare 100% of the principal of, and accrued and unpaid interest on, all the Convertible Notes to be due and payable. In addition, if the Company ceases to be listed or quoted on any of The NYSE, The Nasdaq Global Select Market or The Nasdaq Global Market (or any of their respective successors), holders of the outstanding Convertible Notes will have the option to require the Company to repurchase for cash all of such holder’s notes at 100% of the principal amount, plus accrued and unpaid interest. See Note 2 “The Business and Nature of Operations” for additional information regarding the out-of-compliance notices received from the NYSE.

In connection with the offering of the Convertible Notes, the Company also entered into privately negotiated “capped call” transactions with several counterparties. The capped call transaction will initially cover, subject to customary anti-dilution adjustments, the number of shares of common stock that initially underlie the Convertible Notes. The capped call transactions are expected to generally reduce the potential dilutive effect on the Company’s common stock upon any conversion of the Convertible Notes with such reduction subject to a cap.

The outstanding Secured Notes, Second Lien Credit Facility, and Amended ABL Credit Facility amounts above are guaranteed by all of Lannett’s significant wholly-owned domestic subsidiaries and are collateralized by substantially all present and future assets of the Company.

24

Note 11. Legal, Regulatory Matters and Contingencies

Federal Investigation into the Generic Pharmaceutical Industry

In November and December 2014, the Company and certain affiliated individuals and customers were served with grand jury subpoenas relating to a federal investigation of the generic pharmaceutical industry into possible violations of the Sherman Act. The subpoenas requested corporate documents of the Company relating to corporate, financial and employee information, communications or correspondence with competitors regarding the sale of generic prescription medications and the marketing, sale, or pricing of certain products, generally for the period of 2005 through the dates of the subpoenas.

The Company received a Civil Investigative Demand (“CID”) from the Department of Justice on May 14, 2018. The CID requested information from 2009-present regarding allegations that the generic pharmaceutical industry engaged in market allocation, price fixing, payment of illegal remuneration and submission of false claims. The Company has responded to the CID.

Based on internal investigations performed to date, the Company believes that it has acted in compliance with all applicable laws and regulations.

Government Pricing

On May 22, 2019, following an audit conducted by the Company, the Department of Veterans Affairs issued a Contracting Officer’s Final Decision and Demand for Payment, assessing the sum of $9.4 million for overpayments by the Veteran’s Administration (“VA”) as a result of certain commercial customer prices that were not properly disclosed to the VA for the period of January 1, 2012 through June 30, 2016. In August 2019, the Company remitted payment to the VA and was indemnified from UCB S.A. for the portion of that related to the period prior to the acquisition of KUPI (January 1, 2012 to November 24, 2015) totaling $8.1 million. The VA requested additional information for the period of July 1, 2016 through March 2018. The Company is in the process of responding to the information request.

State Attorneys General and Private Plaintiffs Antitrust and Consumer Protection Litigation

In December 2016, the Connecticut Attorney General and various other State Attorneys General filed a civil complaint alleging that six pharmaceutical companies engaged in anti-competitive behavior. The Company was not named in the action and does not compete on the products that formed the basis of the complaint. The complaint was later transferred for pretrial purposes to the United States District Court for the Eastern District of Pennsylvania as part of a multidistrict litigation captioned In re: Generic Pharmaceuticals Pricing Antitrust Litigation (the “MDL”). On October 31, 2017, the State Attorneys General filed a motion for leave to amend their complaint to add numerous additional defendants, including the Company, and claims relating to 13 additional drugs. The District Court granted that motion on June 5, 2018. The State Attorneys General filed their amended complaint on June 18, 2018. The claim relating to Lannett involves alleged price-fixing for one drug, doxycycline monohydrate, but does not involve the pricing for digoxin. The State Attorneys General also allege that all defendants were part of an overarching, industry-wide conspiracy to allocate markets and fix prices generally. On August 15, 2019, the Court denied the defendants’ joint motion to dismiss the overarching conspiracy claims but has yet to decide an individual motion filed by the Company to dismiss the overarching conspiracy claims as to it. On June 7, 2022, the Court granted a joint motion of all defendants to dismiss the federal claim of the State Attorneys General for disgorgement of defendants’ allegedly ill-gotten gains, but denied defendants’ motion to dismiss their parens patriae federal claims for injunctive relief due to lack of standing.

25

On May 10, 2019, the State Attorneys General filed a new lawsuit naming the Company and one of its employees as defendants, along with 33 other companies and individuals. The complaint again alleges an overarching conspiracy and contains claims for price-fixing and market allocation under the Sherman Act and related state laws. The complaint focuses on the conduct of another generic pharmaceutical company, and the relationships that company had with other generic companies and their employees. The specific allegations in this complaint against Lannett relate to the Company’s sales of baclofen and levothyroxine. The complaint also names another current employee as a defendant, but the allegations pertain to conduct that occurred prior to their employment by Lannett. In June 2020, the State Attorneys General filed a third overarching conspiracy complaint involving scores of different drugs used primarily to treat dermatological conditions, including alleged price-fixing by the Company for acetazolamide. Both complaints have been added to the MDL.

In 2016 and 2017, the Company and certain competitors were named as defendants in a number of lawsuits filed by private plaintiffs alleging that the Company and certain generic pharmaceutical manufacturers have conspired to fix prices of generic digoxin, levothyroxine, ursodiol and baclofen. These cases are part of a larger group of more than 100 lawsuits generally alleging that over 30 generic pharmaceutical manufacturers and distributors conspired to fix prices for multiple different generic drugs in violation of the federal Sherman Act, various state antitrust laws, and various state consumer protection statutes. The United States also has been granted leave to intervene in the cases. On April 6, 2017, these cases were added to the MDL. The various plaintiffs are grouped into three categories - Direct Purchaser Plaintiffs, End Payer Plaintiffs, and Indirect Reseller Purchasers - and filed Consolidated Amended Complaints (“CACs”) against the Company and the other defendants in August 2017.

The CACs naming the Company as a defendant involve generic digoxin, levothyroxine, ursodiol and baclofen. Pursuant to a court-ordered schedule grouping the 18 different drug cases into three separate tranches, the Company and other generic pharmaceutical manufacturer defendants in October 2017 filed joint and individual motions to dismiss the CACs involving the six drugs in the first tranche, including digoxin. In October 2018, the Court (with one exception) denied defendants’ motions to dismiss plaintiffs’ Sherman Act claims with respect to the drugs in the first tranche. In March 2019, the Company and other defendants filed answers to the Sherman Act claims. In addition, in February 2019, the Court dismissed certain of the plaintiffs’ state law claims but denied the remainder of defendants’ motions to dismiss and set a deadline of April 1, 2019 for certain plaintiffs to amend their existing complaints. Those plaintiffs amended their complaints, but further motions to dismiss the state-law claims remain pending.

Following the lead of the state Attorneys General, the Direct Purchaser Plaintiffs, End Payer Plaintiffs and Indirect Reseller Plaintiffs filed their own complaints in June 2018 alleging an overarching conspiracy relating to 14 generic drugs in the End Payer complaint and 15 generic drugs in the Indirect Reseller complaint. Although the complaints allege an overarching conspiracy with respect to all of the drugs identified, the specific allegations related to drugs the Company manufactures involve acetazolamide and doxycycline monohydrate.

In addition, between December 2019 and February 2020, the End Payer Plaintiffs, Indirect Reseller Purchasers, and Direct Purchaser Plaintiffs filed separate complaints alleging overarching, industry-wide price-fixing conspiracies modeled on the second one filed by the state Attorneys General. The new complaint involves 135 new drugs in addition to those named in previous complaints. As to the Company, the new drugs involved are pilocarpine HCL, triamterene HCTZ capsules, amantadine HCL, and oxycodone HCL. None of the defendants, including the Company, has responded yet to these new complaints.

26

Between January 2018 and December 2020, a number of opt-out parties filed individual complaints or otherwise commenced actions against the Company and dozens of other companies and individuals alleging an overarching conspiracy and individual conspiracies to fix the prices and allocate markets on scores of different drug products, including digoxin, doxycycline, levothyroxine, ursodiol and baclofen. The opt-out parties include various retailers, insurers and county governments, which have filed federal suits in Pennsylvania, New York, California, Minnesota and Texas. All of those complaints have been added to the MDL but none of the defendants, including the Company, has responded to any of the complaints. Other groups of insurers have commenced actions in Pennsylvania state court against the Company and other drug companies by filing writs of summons, which are not complaints but can serve to toll the running of statutes of limitations. Those state-court cases have not been added to the MDL, although the parties have agreed to stay those cases pending further developments in the MDL. One of the insurance state-court plaintiffs filed a motion to have its case removed from deferred status so it could be litigated simultaneously in the Philadelphia Court of Common Pleas, but the Court denied that motion on October 3, 2022, so the case currently remains in deferred status.

In June 2020, the Company and a number of other generic pharmaceutical manufacturers were named as defendants in a Statement of Claim in a proposed class proceeding in federal court in Toronto, Ontario, Canada. The case alleges a violation of Canada’s Competition Act. The allegations are similar to those in the MDL alleging an overarching, industry-wide conspiracy to allocate markets and fix the price of generic drugs. That alleged conspiracy reached Canada because these same manufacturers also allegedly sell the majority of generic drugs in Canada. The Statement of Claim alleges that the conspiracy extends to the entire generic pharmaceutical market. The specific drugs identified with respect to the Company are: acetazolamide, baclofen, digoxin, doxycycline monohydrate, levothyroxine, and ursodiol. The Company has not yet responded to the Statement of Claim.

On July 13, 2020, the District Court overseeing the MDL selected as “bellwether” cases the second overarching conspiracy case filed by the state Attorneys General in May 2019 as well as individual-conspiracy cases filed by the Direct Purchaser Plaintiffs, End Payer Plaintiffs, and Indirect Reseller Purchasers involving the drugs clobetasol, clomipramine and pravastatin. The Company is a defendant only in the overarching conspiracy case. On February 9, 2021, the District Court vacated the order selecting the bellwether cases. Thereafter, the District Court re-designated the clobetasol and clomipramine cases as individual-conspiracy bellwethers, and on May 7, 2021, selected the third complaint filed by the state Attorneys General in June 2020 as the new overarching conspiracy bellwether case. On September 9, 2021, the state Attorneys General amended their bellwether complaint. To date, none of the bellwether cases have been scheduled for trial.

The Company believes that it acted in compliance with all applicable laws and regulations. Accordingly, the Company disputes the allegations set forth in these class actions and plans to vigorously defend itself against these claims.

27

Shareholder Litigation

In November 2016, a putative class action lawsuit was filed against the Company and two of its former officers in the federal district court for the Eastern District of Pennsylvania, alleging that the Company and two of its former officers damaged the purported class by making false and misleading statements regarding the Company’s drug pricing methodologies and internal controls. In December 2017, counsel for the putative class filed a second amended complaint. The Company filed a motion to dismiss the second amended complaint in February 2018. In July 2018, the court granted the Company’s motion to dismiss the second amended complaint. In September 2018, counsel for the putative class filed a third amended complaint alleging that the Company and two of its former officers made false and misleading statements regarding the impact of competition on prices and sales of certain of the Company’s products, regarding the potential effects on the Company of regulatory investigations and antitrust litigation, and regarding the defendants’ investigation of purported anticompetitive conduct. The Company filed a motion to dismiss the third amended complaint in November 2018. In May 2019, the court denied the Company’s motion to dismiss the third amended complaint. In July 2019, the Company filed an answer to the third amended complaint. In October 2020, counsel for the putative class filed a motion for class certification. In March 2021, the Company filed a brief in opposition to the motion to certify the putative class. In August 2021, the court granted the motion to certify the proposed class, to appoint class representatives, and to appoint class counsel. In August 2021, the Company filed a petition for permission to appeal the court’s class certification order. In September 2021, counsel for the class filed a response in opposition to the Company’s petition. In November 2021, the United States Court of Appeals for the Third Circuit granted the Company’s petition for permission to appeal the class certification order. In January 2022, the Third Circuit granted the Company’s motion to stay the case pending a decision on the interlocutory appeal. The Company believes it acted in compliance with all applicable laws and continues to vigorously defend itself from these claims. The Company cannot reasonably predict the outcome of the suit at this time.

Sandoz, Inc.

On July 20, 2020, Sandoz, Inc. (“Sandoz”) filed a complaint in federal court in Philadelphia, alleging claims for tortious interference with contract, unfair competition and conversion of confidential information, arising out of Cediprof, Inc.’s (“Cediprof”) termination of Sandoz’s contract to distribute levothyroxine tablets in the United States and certain territories. Along with the complaint, Sandoz filed a motion for a temporary restraining order and preliminary injunction, seeking to enjoin the Company from commencing the distribution of levothyroxine tablets on August 3, 2020. On the same day, Sandoz filed a separate complaint and application for a temporary restraining order and preliminary injunction against Cediprof in federal court in New York, seeking to prevent Cediprof from selling its levothyroxine tablets in the United States and certain of its territories to anyone other than Sandoz. On July 27, 2020, the New York court held a hearing and denied Sandoz’s application for a temporary restraining order, ruling Sandoz had failed to establish irreparable harm. Sandoz subsequently dismissed the complaint and is proceeding against Cediprof in an Arbitration in New York, where the Company has agreed to indemnify Cediprof. On July 28, 2020, the Philadelphia court held a hearing and denied Sandoz’s application for a temporary restraining order, ruling that Sandoz had failed to establish irreparable harm and failed to establish that it is likely to succeed on the merits of its claim against Lannett. On October 5, 2020, the Company filed a motion to dismiss the complaint. On December 28, 2020, the Court granted in part and denied in part the motion, dismissing certain of the claims. The Company has filed a motion to stay the case pending the Arbitration of the Sandoz/Cediprof dispute. On January 11, 2021, the Company filed an answer and counterclaim to the complaint. Upon the conclusion of fact discovery, the Court entered an order on July 16, 2021 staying the remaining deadlines in the case pending the outcome of the Arbitration between Sandoz and Cediprof, which began on January 31, 2022. On August 5, 2022, the Arbitrator issued a final award, finding that Cediprof had breached the Sandoz contract and determining that Sandoz is entitled to lost profits, among other damages. The portion of the award subject to indemnification from the Company amounted to $10.9 million, which the Company has accrued as of June 30, 2022. The Company’s indemnification obligation will only be triggered if and when Cediprof pays the award. On November 4, 2022, Cediprof filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code. By virtue of the automatic stay arising upon the filing of the bankruptcy petition, collection efforts against Cediprof are stayed pending the resolution of the bankruptcy proceeding.

28

Ranitidine Oral Solution, USP

On June 1, 2020, a class action complaint was served upon the Company and approximately forty-five (45) other companies asserting claims for personal injury arising from the presence of NDMA in Ranitidine product, which was consolidated in a multidistrict litigation (“MDL”) pending in the United States District Court for the Southern District of Florida. Following the filing of a first amended complaint, the Company filed a motion to dismiss, which was granted and resulted in a dismissal of all claims with prejudice based on federal preemption. The Plaintiffs filed an appeal to the Eleventh Circuit Court of Appeals, which has not yet been ruled upon.

Separately, several lawsuits were filed in various state courts by state government, city government, and several private parties asserting various consumer protection and/or personal injury claims (in the case of individual plaintiffs) regarding the presence of NDMA in Ranitidine products. The Company has filed motions to dismiss in all state cases, of which some were granted, some were denied and some remain pending. The Company denies all liability in pending cases.

Other Litigation Matters

The Company is also subject to various legal proceedings arising out of the normal course of its business including, but not limited to, product liability, intellectual property, patent infringement claims and antitrust matters. It is not possible to predict the outcome of these various proceedings. An adverse determination in any of these proceedings or in any of the proceedings described above in the future could have a significant impact on the financial position, results of operations and cash flows of the Company.

Effect of Automatic Stay

Pursuant to Section 362 of the Bankruptcy Code, the filing of the Chapter 11 Cases automatically stayed most actions against or on behalf of the Company Parties. Subject to certain exceptions under the Bankruptcy Code, the filing of the Company Parties’ Chapter 11 Cases automatically stayed the continuation of most legal proceedings or the filing of other actions against or on behalf of the Company Parties or their property to recover on, collect or secure a claim arising prior to the Petition Date or to exercise control over property of the Company Parties’ bankruptcy estates, unless and until the Bankruptcy Court modifies or lifts the automatic stay as to any such claim. Notwithstanding the general application of the automatic stay described above, governmental authorities may determine to continue actions brought under their police and regulatory powers.

29

Note 12. Commitments

Leases

At March 31, 2023 and June 30, 2022, the Company had a ROU lease asset of $9.1 million and $9.6 million, respectively, and an operating lease liability of $11.2 million and $12.1 million, respectively. The current balance of the operating lease liability at March 31, 2023 was $2.1 million.

Components of lease costs are as follows:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

March 31, 

​

March 31, 

(In thousands)

​

2023

    

2022

    

2023

    

2022

Operating lease cost

​

$

456

​

$

456

​

$

1,388

​

$

1,361

Variable lease cost

​

​

61

​

 

63

​

​

140

​

 

120

Short-term lease cost (a)

​

​

95

​

 

101

​

​

323

​

 

253

Total

​

$

612

​

$

620

 

$

1,851

​

$

1,734

______________________

(a)Not recorded on the Consolidated Balance Sheet

Supplemental cash flow information and non-cash activity related to our operating leases are as follows:

​

​

​

​

​

​

​

​

​

​

Nine Months Ended

​

​

March 31, 

(In thousands)

    

2023

    

2022

Cash paid for amounts included in the measurement of lease liabilities:

​

​

​

​

​

​

Operating cash flows from operating leases

 

$

1,608

 

$

1,606

​

Weighted-average remaining lease term and discount rate for our operating leases are as follows:

​

​

​

​

​

​

​

​

​

​

Nine Months Ended

​

​

March 31, 

​

    

2023

​

2022

Weighted-average remaining lease term

​

8

years

​

9

years

Weighted-average discount rate

 

8.5

%

​

8.5

%

​

Maturities of lease liabilities by fiscal year for our operating leases are as follows:

​

​

​

​

​

(In thousands)

    

Amounts Due

2023

​

$

537

2024

​

​

2,083

2025

​

 

2,103

2026

​

 

2,124

2027

​

 

2,145

Thereafter

​

 

6,368

Total lease payments

​

 

15,360

Less: Imputed interest

​

 

4,123

Present value of lease liabilities

 

$

11,237

​

30

Other Commitments

In Fiscal 2020, the Company executed a License and Collaboration Agreement with North South Brother Pharmacy Investment Co., Ltd. and HEC Group PTY, Ltd. (collectively, “HEC”) to develop an insulin glargine product that would be biosimilar to Lantus Solostar. Under the terms of the deal, among other things, the Company shall fund up to the initial $32.0 million of the development costs and split 50/50 any development costs in excess thereof. As of March 31, 2023, the Company has incurred approximately $10.2 million of development costs towards the $32.0 million commitment made by the Company. As we have completed dosing of subjects in the clinical trial at this time, we expect development funding will be well less than $32.0 million. Lannett shall receive an exclusive license to distribute and market the product in the United States upon FDA approval under the 50/50 profit split for the first ten years following commercialization, followed by a 60/40 split in favor of HEC for the following five years.

On February 8, 2021, the Company executed a License and Collaboration Agreement and a Supply Agreement with Sunshine Lake Pharma Co., Ltd. an HEC Group company (“Sunshine”) with respect to the development of a biosimilar insulin aspart product. Under the terms of the deal, among other things, the Company shall fund up to the initial $32.0 million of the development costs, provided that if total development and other costs paid by Lannett are less than $32.0 million then the difference will be paid to Sunshine over the first year of commercialization. As of March 31, 2023, the Company has incurred approximately $2.9 million towards the $32.0 million commitment made by the Company. The parties shall negotiate the sharing of any development costs in excess of $32.0 million. Lannett shall receive an exclusive license to distribute and market the product in the United States upon FDA approval under the 50/50 profit split for the first ten years following commercialization, followed by a 60/40 split in favor of Sunshine for the following five years.

In conjunction with the HEC collaboration efforts to develop biosimilar insulin glargine and aspart, the Company also separately entered into two Customization and Supply Agreements with Ypsomed AG (“Ypsomed”) in October 2020 and July 2021 to develop, manufacture and supply an injection device to be used with both insulin products. In April 2022, the Company executed an amendment to the Customization and Supply Agreements to allow Ypsomed to expand their production capacity to meet the anticipated demand. Under the terms of the deal, the Company is required to pay 14 million Swiss Francs (“CHF”) to Ypsomed over various future milestone dates to fund the capacity expansion in exchange for a predetermined discount on future purchases of the injection device. As of March 31, 2023, the Company has paid Ypsomed 4.6 million CHF, the equivalent of approximately $4.9 million, which is recorded in the other assets caption of the Consolidated Balance Sheet. The remaining 3.4 million and 6.0 million CHF payments are to be paid in installments in calendar years 2023 and 2024, respectively.

In Fiscal 2017, the Company signed an agreement with a third-party company operating in the online pharmaceutical business, under which the Company agreed to provide up to $15.0 million in revolving loans for the purpose of expansion and other business needs. Any outstanding balance under the loan would bear interest at 2.0% and be due seven years from the date of the agreement. As of December 31, 2022, after a review of the third-party’s current financial condition as well as their projected liquidity levels, the Company determined that it is more likely than not that the third party will be unable to repay the outstanding loan. Therefore, the Company recorded a full write-off of the loan receivable of $6.8 million during the second quarter of Fiscal 2023.

​

31

Note 13. Warrants

In connection with the Second Lien Credit Facility, the Company issued to the Participating Lenders warrants to purchase up to 2,070,000 shares of common stock of the Company (the “Warrants”) at an exercise price of $27.52 per share. The Warrants were issued on April 22, 2021 with an eight-year term. The Participating Lenders received registration rights with respect to the shares of common stock of the Company to be received upon exercise of the Warrants. The Company concluded that the Warrants were indexed to its own stock and, therefore, are classified as an equity instrument. In accordance with ASC 470, Debt, the Company allocated the proceeds of the Second Lien Credit Facility issuance based on the relative fair value of the debt instrument and the Warrants separately at the time of issuance, which was determined using the Black-Scholes valuation model. The relative fair value allocated to the Warrants was $24.4 million at the issuance date.

The holders of the Warrants are entitled to receive dividends or distributions of any kind made to the common stockholders to the same extent as if the holder had exercised the Warrant into common stock. Although the Company did not issue or declare dividends during the period, the Warrants are considered participating securities under ASC 260, Earnings per share, for purposes of calculating earnings (loss) per share under the two-class method. Refer to Note 14 “Loss Per Common Share” for further details of the two-class method and the Company’s calculation of earnings (loss) per share.

In connection with the Prepackaged Plan, discussed further below, the Warrants will be cancelled. Refer to Note 20 “Subsequent Events” for additional information on the Prepackaged Plan.

Note 14. Loss Per Common Share

A reconciliation of the Company’s basic and diluted loss per common share was as follows:

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

​

March 31, 

(In thousands, except share and per share data)

    

2023

    

2022

Numerator:

​

​

​

​

​

​

Net loss

 

$

(101,470)

 

$

(34,898)

Net income allocated to participating securities for the Warrants

​

​

—

​

​

—

Interest expenses applicable to the Convertible Notes, net of tax

​

​

—

​

​

—

Amortization of debt issuance costs applicable to the Convertible Notes, net of tax

​

​

—

​

​

—

Adjusted "if-converted" net loss

 

$

(101,470)

​

$

(34,898)

​

​

​

​

​

​

​

Denominator:

​

​

​

​

​

​

Basic weighted average common shares outstanding

​

 

10,311,428

​

 

10,125,825

Effect of potentially dilutive options, restricted stock awards and performance-based shares

​

 

—

​

 

—

Effect of conversion of the Convertible Notes

​

 

—

​

​

—

Effect of participating securities for the Warrants

​

​

—

​

​

—

Diluted weighted average common shares outstanding

​

 

10,311,428

​

 

10,125,825

​

​

​

​

​

​

​

Loss per common share:

​

​

​

​

​

​

Basic

 

$

(9.84)

 

$

(3.45)

Diluted

 

$

(9.84)

 

$

(3.45)

​

32

​

​

​

​

​

​

​

​

​

Nine Months Ended

​

​

March 31, 

(In thousands, except share and per share data)

    

2023

    

2022

Numerator:

​

​

​

​

​

​

Net loss

 

$

(165,797)

​

$

(138,325)

Net income allocated to participating securities for the Warrants

​

​

—

​

​

—

Interest expenses applicable to the Convertible Notes, net of tax

​

​

—

​

​

—

Amortization of debt issuance costs applicable to the Convertible Notes, net of tax

​

​

—

​

​

—

Adjusted "if-converted" net loss

 

$

(165,797)

​

$

(138,325)

​

​

​

​

​

​

​

Denominator:

​

​

​

​

​

​

Basic weighted average common shares outstanding

​

 

10,279,085

​

 

10,065,333

Effect of potentially dilutive options, restricted stock awards and performance-based shares

​

 

—

​

 

—

Effect of conversion of the Convertible Notes

​

 

—

​

​

—

Effect of participating securities for the Warrants

​

​

—

​

​

—

Diluted weighted average common shares outstanding

​

 

10,279,085

​

 

10,065,333

​

​

​

​

​

​

​

Loss per common share:

​

​

​

​

​

​

Basic

 

$

(16.13)

​

$

(13.74)

Diluted

 

$

(16.13)

​

$

(13.74)

​

In accordance with ASC 260, Earnings per share, the Company computes earnings (loss) per share using the two-class method, which requires an allocation of earnings between the holders of common stock and the Company’s participating security holders. Basic earnings (loss) per share is calculated by dividing net income (loss) available to common stockholders, which excludes the income allocated to participating security holders, by the basic weighted average common shares outstanding. For purposes of determining diluted earnings per share, the Company further adjusts the basic earnings per share to include the effect of potentially dilutive shares outstanding, including options, restricted stock awards, performance-based shares, the Convertible Notes, and the Warrants. In this calculation, the Company reallocates net income based on the rights of each potentially dilutive share and will report the most dilutive earnings (loss) per share. Because the Warrants do not participate in losses, the Company will allocate undistributed earnings when calculating basic and diluted earnings per share in periods of net income only. The effect of the Warrants is excluded from the calculation of basic and diluted loss per share for the three and nine months ended March 31, 2023 and 2022.

​

The number of anti-dilutive shares that have been excluded in the computation of diluted earnings (loss) per share for the three months ended March 31, 2023 and 2022 were 1.8 million and 2.0 million, respectively. The number of anti-dilutive shares that have been excluded in the computation of diluted earnings (loss) per share for the nine months ended March 31, 2023 and 2022 were 1.8 million and 2.0 million, respectively. The effect of potentially dilutive shares was excluded from the calculation of diluted loss per share in the three and nine months ended March 31, 2023 and 2022 because the effect of including such securities would be anti-dilutive.

33

Note 15. Share-based Compensation

At March 31, 2023, the Company had two share-based employee compensation plans (the 2014 Long-Term Incentive Plan (“LTIP”) and the 2021 LTIP). Together these plans authorized an aggregate total of 2.0 million shares to be issued. As of March 31, 2023, the plans have a total of 393 thousand shares available for future issuances.

Historically, the Company has issued share-based compensation awards with a vesting period ranging up to 3 years and a maximum contractual term of 10 years. The Company issues new shares of stock when stock options are exercised. As of March 31, 2023, there was $3.8 million of total unrecognized compensation cost related to non-vested share-based compensation awards. That cost is expected to be recognized over a weighted average period of 1 year.

The target award value mix in Fiscal 2022 for Named Executive Officers (“NEOs”) was 50% performance shares, 30% restricted stock, and 20% provided in the form of a cash-based incentive where the value varies based on changes in our stock price over the three-year period ending June 30, 2024. In the first quarter of Fiscal 2023, the Compensation Committee approved the granting of 50% of the target long-term incentive for Fiscal 2023 (calculated based on the NEO’s Fiscal 2022 salary) in the form of a cash-based retention award, which was paid in September 2022. In the second quarter of Fiscal 2023, certain other employees were granted a cash-based incentive award, which totaled $1.3 million and was paid in October 2022. The cash-based retention award was paid as a result of the potential dilution associated with granting equity incentives; however, the awards are subject to a 36-month service-based clawback. The clawback on one-third of the retention awards will expire annually based on continued service. The Company will recognize the expense on the awards across the three-year clawback period and prepaid expense of approximately $1.4 million and $2.2 million is included in other current assets and other assets on the Consolidated Balance Sheet at March 31, 2023, respectively. The remaining 50% of the target long-term incentive for Fiscal 2023 was re-allocated to the target of each NEO’s performance-based short-term incentive plan.

Stock Options

The Company measures share-based compensation costs for options using the Black-Scholes option pricing model, which includes the use of various weighted average assumptions to estimate the fair values of stock options granted. Expected volatility is based on the historical volatility of the price of our common shares during the historical period equal to the expected term of the option. The Company uses historical information to estimate the expected term, which represents the period of time that options granted are expected to be outstanding. The risk-free rate for the period equal to the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The forfeiture rate assumption is the estimated annual rate at which unvested awards are expected to be forfeited during the vesting period. This assumption is based on our actual forfeiture rate on historical awards. Periodically, management will assess whether it is necessary to adjust the estimated rate to reflect changes in actual forfeitures or changes in expectations. Additionally, the expected dividend yield is typically equal to zero, as the Company has not historically issued a dividend.

There were no stock options granted during the nine months ended March 31, 2023 and 2022. A stock option summary as of March 31, 2023 and changes during the nine months then ended is presented below:

​

​

​

​

​

​

​

​

​

​

​

​

​

    

    

    

​

​

    

​

​

    

Weighted

​

​

​

​

Weighted-

​

​

​

​

Average

​

​

​

​

Average

​

Aggregate

​

Remaining

​

​

​

​

Exercise

​

Intrinsic

​

Contractual

(In thousands, except for weighted average price and life data)

    

Awards

    

Price

    

Value

    

Life (yrs.)

Outstanding at June 30, 2022

 

234

​

$ 

35.76

​

$

—

​

6.5

Forfeited, expired or repurchased

 

(6)

​

$ 

32.54

​

​

​

​

​

Outstanding at March 31, 2023

 

228

​

$ 

35.85

​

$

—

​

5.9

​

​

​

​

​

​

​

​

​

​

​

Vested and expected to vest at March 31, 2023

 

228

​

$ 

35.85

​

$

—

​

5.9

Exercisable at March 31, 2023

 

177

​

$ 

38.92

​

$

—

​

5.6

​

34

Restricted Stock

The Company measures restricted stock compensation costs based on the stock price at the grant date less an estimate for expected forfeitures. The annual forfeiture rate used to calculate compensation expense was 6.5% for the nine months ended March 31, 2023 and 2022.

A summary of restricted stock awards as of March 31, 2023 and changes during the nine months then ended, is presented below:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Weighted

​

​

​

​

​

​

​

Average Grant-date

​

Aggregate

(In thousands, except for weighted average price data)

    

Awards

    

Fair Value

    

Intrinsic Value

Non-vested at June 30, 2022

 

339

​

$

21.19

​

​

​

Vested

 

(139)

​

 

21.87

​

$

320

Forfeited

 

(12)

​

 

19.60

​

​

​

Non-vested at March 31, 2023

 

188

​

$

20.70

​

​

​

​

Performance-Based Shares

The Company grants performance-based awards to certain key executives. The stock-settled awards will cliff vest based on a three-year performance measurement period. Awards issued prior to July 2021 are based on relative Total Shareholder Return (“TSR”) over a three-year period, which, in accordance with ASC 718, Compensation – Stock Compensation, are considered awards tied to market conditions. Half of the performance shares granted in July 2021 will be tied to our relative TSR, consistent with awards granted in prior years, with the other half tied to a variety of strategic portfolio goals, which, in accordance with ASC 718, Compensation – Stock Compensation, are considered awards tied to performance conditions. The Company measures share-based compensation cost for TSR awards using a Monte-Carlo simulation model. Compensation cost for awards tied to strategic portfolio goals is measured using the stock price at the grant date and is recognized based on performance at target award levels. However, in accordance with ASC 718, Compensation – Stock Compensation, the Company will assess the probability that the strategic portfolio goals will be met and adjust the cumulative compensation cost recognized accordingly at each reporting period.

As of June 30, 2022, there were 262 thousand performance-based share awards outstanding, with a weighted average grant-date fair value of $30.60 per share. There were no changes to the outstanding performance-based share awards during the nine months ended March 31, 2023.

Employee Stock Purchase Plan

In February 2003, the Company’s stockholders approved an Employee Stock Purchase Plan (“2003 ESPP”), under which the Company is authorized to issue 281 thousand shares of the Company’s common stock. The 2003 ESPP was implemented on April 1, 2003 and is qualified under Section 423 of the Internal Revenue Code. In January 2022, the stockholders of the Company approved a new ESPP (“2022 ESPP” and, together with the 2003 ESPP, “ESPPs”). The Company is authorized to issue an additional 375 thousand shares of the Company’s common stock under the 2022 ESPP, which is qualified under Section 423 of the Internal Revenue Code. During the nine months ended March 31, 2023 and 2022, 62 thousand shares and 52 thousand shares were issued under the ESPPs, respectively. As of March 31, 2023, 390 thousand total cumulative shares have been issued under the ESPPs. Employees eligible to participate in the ESPP may purchase shares of the Company’s stock at 85% of the lower of the fair market value of the common stock on the first day of the calendar quarter, or the last day of the calendar quarter. Under the ESPP, employees can authorize the Company to withhold up to 10% of their compensation during any quarterly offering period, subject to certain limitations.

35

The following table presents the allocation of share-based compensation costs recognized in the Consolidated Statements of Operations by financial statement line item:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

​

March 31, 

​

March 31, 

​

(In thousands)

    

2023

    

2022

    

2023

    

2022

​

Selling, general and administrative expenses

​

$

1,367

​

$

1,501

​

$

4,203

​

$

6,313

​

Research and development expenses

​

 

15

​

 

29

​

 

71

​

 

151

​

Cost of sales

​

 

93

​

 

169

​

 

312

​

 

562

​

Total

​

$

1,475

​

$

1,699

​

$

4,586

​

$

7,026

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Tax benefit at statutory rate

​

$

332

​

$

382

​

$

1,032

​

$

1,581

​

​

​

Note 16. Employee Benefit Plan

The Company has a 401(k) defined contribution plan (the “Plan”) covering substantially all employees. Pursuant to the Plan provisions, the Company is required to make matching contributions equal to 50% of each employee’s contribution, not to exceed 4% of the employee’s compensation for the Plan year. Contributions to the Plan were $0.4 million and $0.3 million during the three months ended March 31, 2023 and 2022, respectively. Contributions to the Plan were $1.0 million and $0.8 million during the nine months ended March 31, 2023 and 2022, respectively.

​

In Fiscal 2020, the Company implemented a non-qualified deferred compensation plan for certain senior-level management and executives. The non-qualified deferred compensation plan allows certain eligible employees to defer additional pre-tax earnings for retirement, beyond the IRS limits in place under the Plan. Contributions to the non-qualified deferred compensation plan during the three and nine months ended March 31, 2023 were not material.

Note 17. Income Taxes

The federal, state and local income tax expense for the three months ended March 31, 2023 was $29 thousand compared to an income tax benefit of $1.4 million for the three months ended March 31, 2022. The effective tax rates for the three months ended March 31, 2023 and 2022 were (0.1)% and 3.8%, respectively. The effective rate for the three months ended March 31, 2023 and 2022 was significantly lower than the statutory tax rate due to the Company’s full valuation allowance position during both periods.

The federal, state and local income tax expense for the nine months ended March 31, 2023 was $95 thousand compared to an income tax benefit of $2.8 million for the nine months ended March 31, 2022. The effective tax rates for the nine months ended March 31, 2023 and 2022 were (0.1)% and 2.0%, respectively. The effective rate for the nine months ended March 31, 2023 and 2022 was significantly lower than the statutory tax rate due to the Company’s full valuation allowance position during both periods.

The Company may recognize the tax benefit from an uncertain tax position claimed on a tax return only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.

As of March 31, 2023 and June 30, 2022, the Company has total unrecognized tax benefits of $4.6 million, of which $4.5 million would impact the Company’s effective tax rate for each period, if recognized. As a result of the positions taken during the period, the Company has not recorded any material interest and penalties for the period ended March 31, 2023 in the statement of operations and no cumulative interest and penalties have been recorded either in the Company’s statement of financial position as of March 31, 2023 and June 30, 2022. The Company will recognize interest accrued on unrecognized tax benefits in interest expense and any related penalties in operating expenses.

36

The Company files income tax returns in the United States federal jurisdiction and various states. The Company’s federal tax returns for Fiscal 2014 and prior generally are no longer subject to review as such years are closed. The Company’s Fiscal 2015 through 2017 and Fiscal 2019 through 2021 federal returns are currently under examination by the Internal Revenue Service (“IRS”). As part of a lengthy process, the Company has received various Information Document Requests and Notices of Proposed Adjustment with respect to positions taken in certain income tax issues, including an accounting method change related to chargebacks and rebates that the IRS is proposing to disallow. We are in the process of assessing the impact of these notices and preparing a response to the IRS. We believe that it is more likely than not that our positions will ultimately be sustained upon further examination, and, if necessary, will contest any addition tax determined to be owed; however, an adverse outcome could have a material impact to the Company’s Consolidated Statements of Operations and financial position. In September 2022, the IRS notified the Company that a portion of its income tax receivables balance will be held until the completion of the examination of its federal tax returns. As such, the balance expected to be held by the IRS is classified as non-current income taxes receivable on the Company’s Consolidated Balance Sheet as of March 31, 2023.

Note 18. Related Party Transactions

The Company had sales of $0.3 million during each of the three months ended March 31, 2023 and 2022 to a generic distributor, Auburn Pharmaceutical Company (“Auburn”), which is a member of the Premier Buying Group. Sales to Auburn for the nine months ended March 31, 2023 and 2022 were $0.9 million and $1.0 million, respectively. Jeffrey Farber, Chair Emeritus and stockholder owning more than five percent of the Company’s stock, is the owner of Auburn. Accounts receivable includes amounts due from Auburn of $0.3 million at March 31, 2023 and June 30, 2022.

Note 19. Assets Held for Sale

State Road Facility

In September 2022, the Company signed a listing and sale agreement to engage a broker to sell its State Road facility and certain equipment at the facility. The Company adjusted the assets to fair value less costs to sell, which resulted in a $4.7 million impairment charge. As of March 31, 2023, the assets identified for sale at the State Road facility, totaling $1.3 million, were recorded in the assets held for sale caption in the Consolidated Balance Sheets.

Torresdale Facility

During the second quarter of Fiscal 2023, the Company made the decision to exit its Torresdale facility in connection with the 2022 Restructuring Plan. The Company adjusted the assets to fair value, which resulted in a $6.0 million impairment charge. In March 2023, the Company signed an exclusive sale agreement to engage a broker to sell the facility and expects the sale to be completed in calendar year 2023. As of March 31, 2023, the assets identified for sale at the Torresdale facility, totaling $1.9 million, were recorded in the assets held for sale caption in the Consolidated Balance Sheets.

37

Seymour, Indiana Facility

In conjunction with the Restructuring Support Agreement, the Company, with the knowledge of its lenders, has begun to explore the sale of its Seymour, Indiana facility. The Company currently seeks to sell the facility and its contract manufacturing business to a pharmaceutical manufacturer that could benefit from the site’s exceptional history of FDA compliance, and with whom we would partner with to continue manufacturing our products at the site. The Company’s existing ANDAs and NDAs are not part of any potential sale. However, the KUPI other intangible assets, which consists of the Company’s contract manufacturing business associated with the Seymour, Indiana facility, is expected to be included in any potential sale of the facility. The Company determined that the above requires reclassification of the assets at the Seymour, Indiana facility to assets held for sale on our Consolidated Balance Sheets as of March 31, 2023. The Company evaluated the assets for impairment as the reclassification is considered a triggering event. As a result, the Company recorded an impairment charge of $72.5 million to adjust the assets to their expected fair value. As of March 31, 2023, the property, plant and equipment at the Seymour, Indiana facility and contract manufacturing intangible assets, totaling $35.0 million, were recorded in the assets held for sale caption in the Consolidated Balance Sheets. For further discussion of the Chapter 11 Cases and Restructuring Support Agreement, see Note 20 “Subsequent Events.”

Note 20. Subsequent Events

Missed Interest Payments

Convertible Notes Interest Payment. On April 4, 2023, the Company elected to defer an interest payment on the Company’s Convertible Notes. Failure to make this interest payment within the 30-day grace period constituted an event of default under the Convertible Notes Indenture. Upon an event of default, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding Convertible Notes may declare 100% of the principal of, and accrued and unpaid interest on, all the Convertible Notes to be due and payable immediately. Acceleration of the Convertible Notes would constitute an event of default under the Secured Notes Indenture and the trustee or the holders of not less than 30.0% in aggregate principal amount of the outstanding Secured Notes may declare the principal of the Secured Notes and accrued but unpaid interest thereon to be due and payable immediately and then may exercise rights and remedies under the agreements governing the Secured Notes. Failure to pay the interest on the Convertible Notes by the end of the grace period or acceleration of the Convertible Notes constitutes an event of default under the Second Lien Credit Agreement and the administrative agent, itself or at the request of requisite lenders, may declare the Second Lien Credit Facility and interest thereon due and payable and exercise all rights and remedies under the Second Lien Credit Agreement and related agreements. Failure to pay the interest on the Convertible Notes by the end of the grace period or acceleration of the Convertible Notes also constitutes an event of default under the Amended ABL Credit Agreement and the administrative agent, itself or at the request of requisite lenders, may declare the revolving loans and interest thereon due and payable, terminate commitments and exercise all rights and remedies under the Amended ABL Credit Agreement and related agreements.

38

Secured Notes Interest Payment. On April 17, 2023, the Company elected to defer an interest payment in respect of its Secured Notes and enter a 30-day grace period. If the Company does not make this interest payment within the 30-day grace period, it will constitute an event of default under Secured Notes Indenture. Upon an event of default, the trustee or the holders of not less than 30% in aggregate principal amount of the outstanding Secured Notes may declare 100% of the principal of, and accrued and unpaid interest on, the Secured Notes to be due and payable immediately. If the Company fails to pay interest on the Secured Notes by the end of the grace period or if the Secured Notes are accelerated, it will also constitute an event of default under the Convertible Notes Indenture, and the trustee or the holders of at least 25% in aggregate principal amount of the outstanding Convertible Notes may declare 100% of the principal of, and accrued and unpaid interest on, all the Convertible Notes to be due and payable immediately. If the Company fails to pay the interest on the Secured Notes by the end of the grace period or if the Secured Notes are accelerated, it will also constitute an event of default under the Second Lien Credit Facility, and the administrative agent, itself or at the request of requisite lenders, may declare the Second Lien Credit Facility and interest thereon due and payable and exercise all rights and remedies under the Second Lien Credit Facility and related agreements. If the Company fails to pay the interest on the Secured Notes by the end of the grace period or if the trustee or holders of the Secured Notes are entitled to accelerate the Secured Notes, it will also constitute an event of default under the Company’s Amended ABL Credit Facility, and the administrative agent, itself or at the request of requisite lenders, may declare the revolving loans and interest thereon due and payable, terminate commitments and exercise all rights and remedies under the Amended ABL Credit Facility and related agreements.

Second Lien Credit Facility Interest Payment. The Company also elected to defer the interest payment due on April 24, 2023 in respect of its Second Lien Credit Agreement. The Company did not make the interest payment within the ten-business day grace period (such grace period having been extended pursuant to the Restructuring Support Agreement), which constituted an event of default under the Second Lien Credit Facility. Upon an event of default, the administrative agent, itself or at the request of requisite lenders, may declare the Second Lien Credit Facility and interest thereon due and payable and exercise all rights and remedies under the Second Lien Credit Facility and related agreements. Failure to pay the interest on the Second Lien Credit Facility by the end of the grace period also constitutes an event of default under the Secured Notes Indenture, and consequently, the trustee or the holders of not less than 30% in aggregate principal amount of the outstanding Secured Notes could declare 100% of the principal of, and accrued and unpaid interest on, the Notes to be due and payable immediately. Failure to pay the interest on the Second Lien Credit Facility by the end of the grace period also constitutes an event of default under the Convertible Notes Indenture, and consequently, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding Convertible Notes may declare 100% of the principal of, and accrued and unpaid interest on, all the Convertible Notes to be due and payable immediately. The Company’s failure to pay the interest on the Second Lien Credit Facility by the end of the grace period also constituted an event of default under the Amended ABL Credit Facility, and the administrative agent, itself or at the request of requisite lenders, may declare the revolving loans and interest thereon due and payable, terminate commitments and exercise all rights and remedies under the asset-based revolving credit agreement and related agreements.

For more information related to the effect of the automatic stay on actions to collect indebtedness incurred prior to the Petition Date or to exercise control over the Company Parties’ property, see the “Effect of the Automatic Stay” section below.

39

Delisting

On April 19, 2023, the Company received a written notice from the NYSE notifying the Company that the NYSE had commenced proceedings to delist the Company’s common stock. The NYSE reached this determination pursuant to Section 802.01(B) of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an average global market capitalization of at least $15 million over a consecutive 30 trading-day period. The NYSE suspended trading in the Company’s common stock immediately after market close on April 19, 2023, and on April 20, 2023, the Company’s common stock began trading in the over-the-counter markets under the symbol “LCIN.” After filing the Chapter 11 Cases, on May 3, 2023, our common stock began trading in the over-the-counter markets under the symbol “LCINQ.” On May 4, 2023, the NYSE filed a Form 25 with the SEC to delist our common stock from trading on the NYSE and to remove it from registration under Section 12(b) of the Exchange Act. The Delisting became effective 10 days after the filing of the Form 25. In accordance with Rule 12d2-2 of the Exchange Act, the de-registration of our common stock under Section 12(b) of the Exchange Act will become effective 90 days, or such shorter period as the SEC may determine, after the date of the Form 25 filing.

Pursuant to the Convertible Notes Indenture, the Delisting of the Company’s common stock constituted a Fundamental Change (as defined therein). Upon the occurrence of a Fundamental Change, the Company must provide all holders of Convertible Notes and the trustee a Fundamental Change Company Notice of the occurrence of the Fundamental Change and of the holder’s option to require the Company to repurchase for cash all of such holder’s notes at 100% of the principal amount, plus accrued and unpaid interest. Failure by the Company to issue a Fundamental Change Company Notice within 20 days following the Fundamental Change constitutes an event of default and, if the trustee or holders of at least 25% in aggregate principal amount of the Convertible Notes declared 100% of the principal of, and accrued and unpaid interest on, all the Notes to be due and payable immediately, the Convertible Notes would become immediately due and payable.

If holders were to exercise their option to accelerate the maturity of either of the Notes, it would also constitute an event of default under the other series of Notes, as well as the Second Lien Credit Facility and the Amended ABL Credit Agreement. For additional information related to the effect of the automatic stay on actions to collect indebtedness incurred prior to the Petition Date or to exercise control over the Company Parties’ property, see the “Effect of the Automatic Stay” section below.

Restructuring Support Agreement

On April 30, 2023, the Company Parties and the Consenting Stakeholders entered into the Restructuring Support Agreement to facilitate the Restructuring of the existing debt of, existing equity interests in and certain other obligations of the Company Parties. In connection therewith, on the Petition Date, the Company Parties commenced the Chapter 11 Cases in the Bankruptcy Court.

In accordance with the Restructuring Support Agreement, the Consenting Stakeholders agreed, among other things, to:

●support the transactions described in the Restructuring Support Agreement (the “Restructuring Transactions”) and vote and exercise any powers or rights available to it in each case in favor of any matter requiring approval to the extent necessary to implement the Restructuring Transactions;
●not object to, delay, impede or take any other action, directly or indirectly, that is reasonably likely to interfere with, delay, or impede the acceptance, implementation, or consummation of the Restructuring Transactions;
●use commercially reasonable efforts to cooperate with and assist the Company Parties in obtaining additional support for the Restructuring Transactions from the Company Parties’ other stakeholders;

40

●subject to the consent rights provided in the Restructuring Support Agreement, negotiate in good faith and use commercially reasonable efforts to execute, deliver, and implement any other necessary agreements that are consistent with the Restructuring Support Agreement to which it is to be a party in a timely manner to effectuate and consummate the Restructuring Transactions as contemplated by the Restructuring Support Agreement; and
●with respect to the Consenting Second Lien Term Lenders (as defined in the Restructuring Support Agreement) and the interest payment due on April 24, 2023 pursuant to the Second Lien Credit Agreement, extend the five-business day grace period provided in Section 8.1(c) of the Second Lien Credit Agreement to ten-business days.

In accordance with the Restructuring Supporting Agreement, the Company Parties agreed, among other things, to:

●support and take all steps reasonably necessary and desirable to consummate the Restructuring Transactions in accordance with the Restructuring Support Agreement;
●to the extent any legal or structural impediment arises that would prevent, hinder, or delay the consummation of the Restructuring Transactions contemplated by the Restructuring Support Agreement, take all steps reasonably necessary and desirable to address any such impediment;
●use commercially reasonable efforts to obtain any and all required regulatory and/or third-party approvals for the Restructuring Transactions;
●negotiate in good faith and use commercially reasonable efforts to execute and deliver any required agreements to effectuate and consummate the Restructuring Transactions as contemplated by the Restructuring Support Agreement;
●continue ordinary course practices to maintain good standing under the jurisdiction in which each Company Party and each of its subsidiaries is incorporated or organized and continue to operate the business in the ordinary course of business customary in the normal course of ordinary operations consistent with past practice taking into account the Chapter 11 Cases and Restructuring Transactions; and
●negotiate in good faith and use commercially reasonable efforts to execute and deliver any appropriate additional or alternative provisions or agreements to address any legal, financial, strategic or structural impediment that may arise that would prevent, hinder, impede, delay, or be reasonably necessary to effectuate the consummation of the Restructuring Transactions.

The Restructuring Support Agreement may be terminated upon the occurrence of certain events, including the failure to meet specified milestones related to consummation of the Prepackaged Plan. In addition, the Restructuring Support Agreement shall automatically terminate on the Effective Date of the Prepackaged Plan once all conditions precedent to the Prepackaged Plan have been satisfied.

Chapter 11 Cases, Prepackaged Plan and Disclosure Statement

As an initial step towards implementation of the Prepackaged Plan, on the Petition Date, the Company Parties filed the Chapter 11 Cases in the Bankruptcy Court. The Chapter 11 Cases are being jointly administered under the caption In re Lannett Company, Inc., et al., Case No. 23-10559 (JKS).

To ensure the Company Parties’ ability to continue operating in the ordinary course of business and minimize the effect of the Restructuring on the Company Parties’ customers and employees, the Company Parties filed motions with the Bankruptcy Court seeking a variety of “first-day” relief, including authority to pay employee wages and benefits and pay vendors and suppliers for all goods and services, each of which was approved on an interim basis by the Bankruptcy Court.

41

On May 2, 2023, the Company Parties filed the Prepackaged Plan and related Disclosure Statement. On May 3, 2023, the Company Parties also filed a proposed order approving various plan solicitation materials, including the solicitation and voting procedures, and scheduling a combined hearing for approval of the Disclosure Statement and confirmation of the Prepackaged Plan for June 8, 2023. The Court entered the scheduling order on May 4, 2023.

The Prepackaged Plan, as proposed, provides that:

●trade claims will be paid in the ordinary course of business during and after the Chapter 11 Cases;
●on the effective date of the Restructuring Transactions, Reorganized LCI will issue a single class of common equity interests to the Consenting Stakeholders pursuant to the Prepackaged Plan;
●on the effective date of the Restructuring Transactions, the Company Parties will enter into a new revolving credit facility on terms to be agreed upon;
●on the effective date of the Restructuring Transactions, Reorganized LCI will enter into a “takeback” exit financing facility in the principal amount of $60 million and such other terms as set forth in the Restructuring Support Agreement (the “Takeback Exit Facility”);
●on the effective date of the Restructuring Transactions, Reorganized LCI will distribute new warrants issued pursuant to a new warrant agreement to holders of Second Lien Term Loan Claims (as defined in the Restructuring Support Agreement);
●following the effective date of the Restructuring Transactions, Reorganized LCI will establish a customary management equity incentive plan;
●on the effective date of the Restructuring Transactions, there will be no recovery for holders of the Company’s Convertible Notes or existing equity interests; and
●the effective date of the Restructuring Transactions will be reached within 45 days of filing the Chapter 11 Cases.

The Prepackaged Plan provides that the executory contracts and unexpired leases that are not assumed or rejected as of the Effective Date (either pursuant to the Prepackaged Plan or a separate motion) will be deemed assumed pursuant to Section 365 of the Bankruptcy Code.

Effect of the Automatic Stay

Pursuant to Section 362 of the Bankruptcy Code, the filing of the Chapter 11 Cases automatically stayed most actions against or on behalf of the Company Parties, including actions to collect indebtedness incurred prior to the Petition Date or to exercise control over the Company Parties’ property. Subject to certain exceptions under the Bankruptcy Code, the filing of the Company Parties’ Chapter 11 Cases also automatically stayed the continuation of most legal proceedings or the filing of other actions against or on behalf of the Company Parties or their property to recover on, collect or secure a claim arising prior to the Petition Date or to exercise control over property of the Company Parties’ bankruptcy estates, unless and until the Bankruptcy Court modifies or lifts the automatic stay as to any such claim. Notwithstanding the general application of the automatic stay described above, governmental authorities may determine to continue actions brought under their police and regulatory powers.

42

Payoff Letter

To facilitate the Restructuring, on May 1, 2023, Amended ABL Credit Agreement was terminated (other than with respect to provisions of the Amended ABL Credit Agreement regarding Letters of Credit that remain outstanding and customary obligations that expressly survived by their terms) upon receipt by the administrative agent of a $1.95 million payment from LCI, comprising (i) a payoff amount representing principal, interest and expenses and fees of the administrative agent and the lenders and (ii) cash to collateralize the outstanding Letters of Credit to be held by the administrative agent for the benefit of the lenders with Revolving Commitments (as defined in the Amended ABL Credit Agreement). The payment made by LCI in connection with the termination of the Amended ABL Credit Agreement was pursuant to a payoff letter with the administrative agent.

CEO STI Letter Agreement

On April 30, 2023, the Company and Timothy C. Crew, the Company’s chief executive officer, entered into a letter agreement (the “CEO STI Letter Agreement”), modifying Mr. Crew’s individual payment terms under the Company’s 2023 Short-Term Incentive Plan (the “STIP”). Under the CEO STI Letter Agreement, the Company and Mr. Crew agreed to amend the STIP with respect to the provisions governing the remaining incentive amount, if any, earned by, and payable to, Mr. Crew under the terms of the STIP (determined after giving effect to the terms of the STIP in effect as of the date of the CEO STI Letter Agreement regarding continued service requirements and approval of the board of directors or compensation committee of the board of directors) for excess EBITDA and cash performance objectives in the Company’s full fiscal year ending June 30, 2023 (the “Payment”). Pursuant to the CEO STI Letter Agreement:

●50% of any Payment will be settled by the Company’s issuance to Mr. Crew on the Payment Date (as defined below) of a number of fully vested shares of New Common Stock (as defined in the Restructuring Support Agreement) equal to 0.5% of the total number of shares of New Common Stock outstanding as of the Payment Date (on a fully diluted and fully distributed basis and treating the Management Incentive Plan (as defined in the Restructuring Support Agreement) as fully allocated) (such payment, the “Stock Payment”). The Payment Date is the date that payments under the STIP for the Company’s final full fiscal year 2023 are made to other participants generally.

​

●The balance of any Payment (the “Cash Payment”) will be paid in cash as follows: (i) the Company will pay Mr. Crew on the Payment Date (the “First Installment”) an amount in cash equal to the greater of 25% of the aggregate Cash Payment and an amount sufficient to pay all federal, state and local employment and income taxes on the First Installment and the Stock Payment and (ii) one-third of the remaining amount of the Cash Payment will be paid on each of November 1, 2023, February 1, 2024, and March 14, 2024.

​

43

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Cautionary Statement About Forward-Looking Statements

This Report on Form 10-Q and certain information incorporated herein by reference contains forward-looking statements which are not historical facts made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not promises or guarantees and investors are cautioned that all forward-looking statements involve risks and uncertainties, including but not limited to: the impact of competitive products and pricing; product demand and market acceptance; new product development; acquisition-related challenges; the regulatory environment; interest rate fluctuations; reliance on key strategic alliances; availability of raw materials; fluctuations in operating results; the impact of the delisting from the New York Stock Exchange (the “NYSE”), including under our debt documents; the impact of failure to pay interest when due on our debt; our ability to successfully consummate a financial restructuring of our existing debt, existing equity interests, and certain other obligations (the “Restructuring”), and emerge from cases (the “Chapter 11 Cases”) commenced under chapter 11 of title 11 the United States Code (the “Bankruptcy Code”); our ability to improve long-term capital structure and to address our debt service obligations through the Restructuring; the potential adverse effects of the Chapter 11 Cases on our liquidity and results of operations; our ability to maintain relationships with suppliers, customers, employees and other third parties as a result of the Restructuring and the Chapter 11 Cases; the effects of the Restructuring and the Chapter 11 Cases on the Company and the interests of various constituents; our ability to obtain confirmation of the Plan under the Chapter 11 Cases and successfully consummate the Restructuring; and other risks detailed from time to time in our filings with the Securities and Exchange Commission (“SEC”). These statements are based on management’s current expectations and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements which speak only as of the date made. Lannett is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise and other events or factors, many of which are beyond our control, including those resulting from such events, or the prospect of such events, such as public health issues including health epidemics or pandemics, such as the outbreak of the novel coronavirus (“COVID-19”), whether occurring in the United States or elsewhere, which could disrupt our operations, disrupt the operations of our suppliers and business development and other strategic partners, disrupt the global financial markets or result in political or economic instability.

The following information should be read in conjunction with the consolidated financial statements and notes in Part I, Item 1 of this Quarterly Report and with Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2022. All references to “Fiscal 2023” shall mean the fiscal year ending June 30, 2023 and all references to “Fiscal 2022” shall mean the fiscal year ended June 30, 2022.

Company Overview

Lannett Company, Inc., a Delaware corporation, (“LCI,” and as it may be reorganized pursuant to the Prepackaged Plan, “Reorganized LCI”) and its subsidiaries (collectively, the “Company,” “Lannett, ” “we” or “us” and as it may be reorganized pursuant to the Prepackaged Plan, the “Reorganized Company” ) primarily develop, manufacture, package, market and distribute solid oral and extended release (tablets and capsules), topical, nasal and oral solution finished dosage forms of drugs that address a wide range of therapeutic areas. Certain of these products are manufactured by others and distributed by the Company. Additionally, the Company is pursuing partnerships, research contracts and internal expansion for the development and production of other dosage forms including: ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable and oral dosages.

The Company operates a pharmaceutical manufacturing plant in Seymour, Indiana. During Fiscal 2022, the Company completed the sale of its Silarx facility in Carmel, New York. In connection with the sale, the buyer will continue to produce certain products on behalf of the Company at the Carmel facility while the Company completes the transfer of such products to its Seymour, Indiana plant.

44

The Company’s customers include generic pharmaceutical distributors, drug wholesalers, chain drug stores, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities and health maintenance organizations.

Recent Developments

Missed Interest Payments

Convertible Notes Interest Payment

On April 4, 2023, the Company elected to defer an interest payment on the Company’s 4.50% Convertible Senior Notes (the “Convertible Notes”).

Failure to make this interest payment within the 30-day grace period constituted an event of default under the Indenture, dated as of September 27, 2019 (the “Convertible Notes Indenture”), between the Company and Wilmington Trust, National Association, as trustee. Upon an event of default, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding Convertible Notes may declare 100% of the principal of, and accrued and unpaid interest on, all the Convertible Notes to be due and payable immediately. Acceleration of the Convertible Notes would constitute an event of default under the Secured Notes Indenture (as defined below) and the trustee or the holders of not less than 30% in aggregate principal amount of the outstanding Secured Notes (as defined below) may declare the principal of the Secured Notes and accrued but unpaid interest thereon to be due and payable immediately and then may exercise rights and remedies under the agreements governing the Secured Notes. Failure to pay the interest on the Convertible Notes by the end of the grace period or acceleration of the Convertible Notes constitutes an event of default under the Second Lien Credit Agreement (as defined below) and the administrative agent, itself or at the request of requisite lenders, may declare the Second Lien Credit Facility and interest thereon due and payable and exercise all rights and remedies under the Second Lien Credit Agreement and related agreements. Failure to pay the interest on the Convertible Notes by the end of the grace period or acceleration of the Convertible Notes constitutes an event of default under the Company’s Credit and Guaranty Agreement, dated as of December 7, 2020 (as amended, the “Amended ABL Credit Agreement”), among the Company, certain of its wholly-owned domestic subsidiaries party thereto, as borrowers or as guarantors, Wells Fargo Bank, National Association, as administrative agent and as collateral agent and the other lenders party thereto, and the administrative agent, itself or at the request of requisite lenders, may declare the revolving loans and interest thereon due and payable, terminate commitments and exercise all rights and remedies under the Amended ABL Credit Agreement and related agreements.

45

Secured Notes Interest Payment

On April 17, 2023, the Company elected to defer an interest payment due on such date in respect of its 7.750% Senior Secured Notes due 2026 (the “Secured Notes” and, together with the Convertible Notes, the “Notes”) and enter a 30-day grace period.

If the Company does not make this interest payment within the 30-day grace period, it will constitute an event of default under the indenture, dated April 22, 2021, as supplemented by the first supplemental indenture, dated April 22, 2021 (the “Secured Notes Indenture”), among, the Company, the subsidiary guarantors party thereto and Wilmington Trust, National Association, as trustee and note collateral agent. Upon an event of default, the trustee or the holders of not less than 30% in aggregate principal amount of the outstanding Secured Notes may declare 100% of the principal of, and accrued and unpaid interest on, the Secured Notes to be due and payable immediately. If the Company fails to pay interest on the Secured Notes by the end of the grace period or if the Secured Notes are accelerated, it will also constitute an event of default under the Convertible Notes Indenture, and the trustee or the holders of at least 25% in aggregate principal amount of the outstanding Convertible Notes may declare 100% of the principal of, and accrued and unpaid interest on, all the Convertible Notes to be due and payable immediately. If the Company fails to pay the interest on the Secured Notes by the end of the grace period or if the Secured Notes are accelerated, it will also constitute an event of default under the Second Lien Credit Facility, and the administrative agent, itself or at the request of requisite lenders, may declare the Second Lien Credit Facility and interest thereon due and payable and exercise all rights and remedies under the Second Lien Credit Facility and related agreements. If the Company fails to pay the interest on the Secured Notes by the end of the grace period or if the trustee or holders of the Secured Notes are entitled to accelerate the Secured Notes, it will also constitute an event of default under the Company’s revolving credit facility (the “Amended ABL Credit Facility”), and the administrative agent, itself or at the request of requisite lenders, may declare the revolving loans and interest thereon due and payable, terminate commitments and exercise all rights and remedies under the Amended ABL Credit Facility and related agreements.

Second Lien Credit Facility Interest Payment

The Company also elected to defer the interest payment due on April 24, 2023 (together with the missed interest payments on the Notes, the “Missed Interest Payments”) in respect of its second lien credit and guaranty agreement, dated April 22, 2021 (the “Second Lien Credit Agreement”), by and among the Company, the other credit parties party thereto, the lenders party thereto and Alter Domus (US) LLC, as administrative agent and collateral agent, pursuant to which lenders party thereto made available to the Company a second lien term loan credit facility (the “Second Lien Credit Facility”).

The Company did not make the interest payment within the ten-business day grace period (such grace period having been extended pursuant to the Restructuring Support Agreement, as defined below), which constituted an event of default under the Second Lien Credit Facility. Upon an event of default, the administrative agent, itself or at the request of requisite lenders, may declare the Second Lien Credit Facility and interest thereon due and payable and exercise all rights and remedies under the Second Lien Credit Facility and related agreements. Failure to pay the interest on the Second Lien Credit Facility by the end of the grace period also constitutes an event of default under the Secured Notes Indenture, and consequently, the trustee or the holders of not less than 30% in aggregate principal amount of the outstanding Secured Notes could declare 100% of the principal of, and accrued and unpaid interest on, the Secured Notes to be due and payable immediately. Failure to pay the interest on the Second Lien Credit Facility by the end of the grace period also constitutes an event of default under the Convertible Notes Indenture. and consequently, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding Convertible Notes may declare 100% of the principal of, and accrued and unpaid interest on, all the Convertible Notes to be due and payable immediately. The Company’s failure to pay the interest on the Second Lien Credit Facility by the end of the grace period also constituted an event of default under the Amended ABL Credit Facility, and the administrative agent, itself or at the request of requisite lenders, may declare the revolving loans and interest thereon due and payable, terminate commitments and exercise all rights and remedies under the asset-based revolving credit agreement and related agreements.

46

For additional information related to the effect of the automatic stay on actions to collect indebtedness incurred prior to the Petition Date (as defined below) or to exercise control over the Company Parties’ property, see “Liquidity and Capital Resources – Subsequent Events Related to the Chapter 11 Cases and Other Related Matters – Effects of the Restructuring and the Chapter 11 Cases on Our Liquidity.”

Delisting

On April 19, 2023, the Company received a written notice from the NYSE notifying the Company that the NYSE had commenced proceedings to delist the Company’s common stock. The NYSE reached this determination pursuant to Section 802.01(B) of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an average global market capitalization of at least $15 million over a consecutive 30 trading-day period. The NYSE suspended trading in the Company’s common stock immediately after market close on April 19, 2023, and on April 20, 2023, the Company’s common stock began trading in the over-the-counter markets under the symbol “LCIN.” After the filing of the Chapter 11 Cases, on May 3, 2023, out common stock began trading in the over-the-counter markets under the symbol “LCINQ.” On May 4, 2023, the NYSE filed a Form 25 with the Securities and Exchange Commission (the “SEC”) to delist our common stock from trading on the NYSE and to remove it from registration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The delisting of the Company’s common stock (the “Delisting”) became effective 10 days after the filing of the Form 25. In accordance with Rule 12d2-2 of the Exchange Act, the de-registration of our common stock under Section 12(b) of the Exchange Act will become effective 90 days, or such shorter period as the SEC may determine, after the date of the Form 25 filing.

Pursuant to the Convertible Notes Indenture, the Delisting constituted a Fundamental Change (as defined therein). Upon the occurrence of a Fundamental Change, the Company must provide all holders of Convertible Notes and the trustee a notice (the “Fundamental Change Company Notice”) of the occurrence of the Fundamental Change and of the holder’s option to require the Company to repurchase for cash all of such holder’s notes at 100% of the principal amount, plus accrued and unpaid interest. Failure by the Company to issue a Fundamental Change Company Notice within 20 days following the Fundamental Change constitutes an event of default and, if the trustee or holders of at least 25% in aggregate principal amount of the Convertible Notes declared 100% of the principal of, and accrued and unpaid interest on, all the Notes to be due and payable immediately, the Convertible Notes would become immediately due and payable.

If holders were to exercise their option to accelerate the maturity of either of the Notes, it would also constitute an event of default under the other series of Notes, as well as the Second Lien Credit Facility and the Amended ABL Credit Agreement. For additional information related to the effect of the automatic stay on actions to collect indebtedness incurred prior to the Petition Date (as defined below) or to exercise control over the Company Parties’ property, see “Liquidity and Capital Resources – Subsequent Events Related to the Chapter 11 Cases and Other Related Matters – Effects of the Restructuring and the Chapter 11 Cases on Our Liquidity.”

Restructuring Support Agreement and Chapter 11 Cases

On April 30, 2023, Lannett Company, Inc., Kremers Urban Pharmaceuticals, Inc., Cody Laboratories, Inc. and Silarx Pharmaceuticals, Inc. (collectively, the “Company Parties”) and certain of the Company’s debtholders (the “Consenting Stakeholders”) entered into the restructuring support agreement (the “Restructuring Support Agreement”) to facilitate the Restructuring of the existing debt of, existing equity interests in and certain other obligations of the Company Parties. In connection therewith, on May 2, 2023 (the “Petition Date”), the Company Parties commenced the Chapter 11 Cases in the Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”). On May 2, 2023, the Company Parties filed the Joint Prepackaged Chapter 11 Plan of Reorganization of Lannett Company, Inc. and Its Debtor Affiliates (the “Prepackaged Plan”). Each Company Party will continue to operate its business as a “debtor in possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and the orders of the Bankruptcy Court. The Chapter 11 Cases are being jointly administered under the caption In re Lannett Company, Inc., et al., Case No. 23-10559 (JKS).

47

The filing of the Chapter 11 Cases constituted an event of default that accelerated all of our debt obligations under the Convertible Notes Indenture, the Secured Notes Indenture, the Second Lien Credit Agreement and the Amended ABL Credit Agreement. As such, we have reclassified all debt obligations to debt due within a year on our Consolidated Balance Sheet as of March 31, 2023. Our consolidated interim unaudited financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. For additional discussion related to the impact of the Chapter 11 Cases, see “Liquidity and Capital Resources—Subsequent Events Related to the Chapter 11 Cases and Other Related Matters.”

Going Concern

Our interim unaudited consolidated financial statements included herein have been prepared using the going concern basis of accounting, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the normal course of business. In accordance with ASC 205, Going Concern, the Company evaluated whether there are any conditions or events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q. Our ability to continue as a going concern is contingent upon, among other things, our ability to, subject to the Bankruptcy Court’s approval, implement the Prepackaged Plan, successfully emerge from the Chapter 11 Cases and establish a sustainable capital structure through the Restructuring. As a result of risks and uncertainties related to the Missed Interest Payments, the Delisting and the effects of disruption from the Chapter 11 Cases making it more difficult to maintain business, financing and operational relationships, together with the Company’s recurring losses from operations and accumulated deficit, substantial doubt exists regarding our ability to continue as a going concern. For detailed discussion about the Restructuring Support Agreement and the Prepackaged Plan, see “Liquidity and Capital Resources—Subsequent Events Related to the Chapter 11 Cases and Other Related Matters.”

Reverse Stock Split

On January 25, 2023, the stockholders of the Company and the Board of Directors approved a 1-for-4 reverse stock split (the “Reverse Stock Split”), and the Company filed an amendment to our Certificate of Incorporation to effectuate the Reverse Stock Split on February 6, 2023. In conjunction with the Reverse Stock Split, the Company has retroactively restated common stock share amounts and earnings (loss) per share for all periods presented in this Form 10-Q. The Company's authorized shares of common stock, outstanding warrants, equity-based awards and Convertible Notes were also proportionately adjusted. No fractional shares were issued in connection with the Reverse Stock Split. Following the completion of the Reverse Stock Split, Lannett’s transfer agent aggregated all fractional shares that otherwise would have been issued as a result of the Reverse Stock Split and those shares were sold into the market. Stockholders who would have otherwise held a fractional share of Lannett common stock received a cash payment from the proceeds of that sale in lieu of such fractional share. There was no change to the par value of the Company’s common stock.

48

2022 Restructuring Plan

On December 15, 2022, the Company authorized a restructuring and cost savings plan (the “2022 Restructuring Plan”) to streamline and realign our operations to ensure the continued progression of our existing pipeline and future growth. The 2022 Restructuring Plan includes operational improvements and cost efficiencies as well as engagement with more external partners and technology providers, globally, to execute on our R&D plans and operations.

The total reduction in headcount for the 2022 Restructuring Plan is expected to be approximately 60 positions and is expected to be completed by the end of Fiscal 2023. The Company estimates that it will incur approximately $3 million in severance-related costs in connection with the 2022 Restructuring Plan.

In connection with the shift in our R&D operations, the Company also anticipates exiting our State Road and Torresdale facilities in Philadelphia, Pennsylvania by the end of our current fiscal year. In the first quarter of Fiscal 2023, the Company recorded an impairment charge of $4.7 million to adjust the State Road facility and certain equipment to fair value less costs to sell and the remaining assets of $1.3 million were recorded in the assets held for sale caption in the Consolidated Balance Sheet. In the second quarter of Fiscal 2023, the Company recorded an impairment charge of $6.0 million to adjust the Torresdale facility to its approximate fair value.

Supply Chain

The COVID-19 pandemic has contributed, in part, to global supply chain disruptions, shortages, and recent inflationary pressures. While the Company is still able to receive sufficient inventory of the key materials needed across its network, the Company continues to experience pressure on its supply chain, including shipping delays, higher prices from suppliers, and reduced availability of materials, particularly excipients and packaging components. To date, the supply chain pressure has not had a material impact on the Company’s results of operations. However, the Company is regularly communicating with its suppliers, third-party partners, customers, healthcare providers and government officials in order to respond rapidly to any issues as they arise. The longer the current situation continues, it is more likely that the Company may experience some sort of material interruption to our supply chain, and such an interruption could adversely affect our business, including but not limited to, our ability to timely manufacture and distribute our products.

Climate Change

The Company believes in a more sustainable future with a reduced environmental footprint and a general view towards reducing our effect on the climate while maintaining our focus on providing affordable medicines to our customers and ultimately the patients who depend on them. The Company has begun to consider climate-related risks that are pertinent to the Company. Our aspiration is to reduce our environmental footprint. However, related efforts may result in increased costs to the Company including, but not limited to, capital investments, additional management and compliance costs, and reduced output, all of which may be material. Costs incurred by our suppliers and vendors to comply with their own sustainability commitments may also be passed through the supply chain resulting in higher operational costs to the Company. Climate change and the associated risks and regulations are expected to continue to evolve over time and could materially impact the Company’s results of operations and cash flows in any given year. The Company monitors such matters and strives to address them in a timely manner.

49

Results of Operations - Three months ended March 31, 2023 compared with the three months ended March 31, 2022

Net sales increased 3% to $80.5 million for the three months ended March 31, 2023. The table below identifies the Company’s net product sales by medical indication for the three months ended March 31, 2023 and 2022.

​

​

​

​

​

​

​

(In thousands)

​

March 31, 

Medical Indication

    

2023

    

2022

Analgesic

​

$

2,741

​

$

3,292

Anti-Psychosis

​

 

2,082

​

 

3,346

Cardiovascular

​

 

13,059

​

 

9,468

Central Nervous System

​

 

19,311

​

 

15,177

Endocrinology

​

​

8,066

​

​

6,792

Gastrointestinal

​

 

9,932

​

 

11,709

Infectious Disease

​

​

2,826

​

​

5,438

Migraine

​

 

2,768

​

 

3,507

Respiratory/Allergy/Cough/Cold

​

 

981

​

 

2,309

Other

​

 

13,342

​

 

14,700

Contract manufacturing revenue

​

 

5,399

​

 

2,619

Total net sales

​

$

80,507

​

$

78,357

The increase in net sales was driven by an increase in the selling price of products of $1.8 million and an increase in volumes of $0.4 million. The increase in the selling price of products was primarily driven by higher sales prices for certain products in the Endocrinology medical indication and Dexmethylphenidate, which is included within the Central Nervous System medical indication. The increase was partially offset by a decrease in the selling price of Posaconazole, which is included within the Infectious Disease medical indication. The increase in volumes was primarily the result of the launch of the new product Fludarabine, which is included in the Other medical indication, and an increase in volumes in our contract manufacturing business; however, the increase was offset by lower volumes within the Gastrointestinal medical indication as a result of certain product discontinuances in connection with the 2021 Restructuring Plan.

The following chart details price and volume changes by medical indication:

​

​

​

​

​

​

​

​

Sales volume

    

Sales price

 

Medical indication

    

change %

  

change %

​

Analgesic

​

10

%  

(27)

%  

Anti-Psychosis

 

(28)

%  

(10)

%

Cardiovascular

 

26

%  

12

%

Central Nervous System

 

20

%  

7

%

Endocrinology

​

—

%  

19

%

Gastrointestinal

 

(29)

%  

14

%

Infectious Disease

​

(5)

%  

(43)

%  

Migraine

 

(19)

%  

(2)

%

Respiratory/Allergy/Cough/Cold

 

(62)

%  

4

%

​

50

The Company sells its products to customers in various distribution channels. The table below presents the Company’s net sales to each distribution channel for the three months ended:

​

​

​

​

​

​

​

(In thousands)

​

March 31, 

​

March 31, 

Customer Distribution Channel

    

2023

    

2022

Wholesaler/Distributor

​

$

63,834

​

$

61,769

Retail Chain

​

 

9,845

​

 

12,361

Mail-Order Pharmacy

​

 

1,429

​

 

1,608

Contract manufacturing revenue

​

 

5,399

​

 

2,619

Total net sales

​

$

80,507

​

$

78,357

​

The overall increase in sales was primarily driven by higher sales in our contract manufacturing business. In recent years, the Company has seen increased competitive market pressure among the existing competitor base. We will continue to seek opportunities for additional launches to offset these competitive pressures.

Levothyroxine Tablets

In August 2020, the Company commenced distributing Cediprof, Inc.’s (“Cediprof”) Levothyroxine Tablets product under an interim exclusive supply and distribution agreement, which had been previously distributed by Sandoz, Inc. (“Sandoz”) under a separate distribution contract. At around the same time, Sandoz filed several complaints and motions for temporary restraining orders against the Company and Sandoz to prevent the Company from distributing Cediprof’s product. The complaints were subsequently dismissed, and the temporary restraining orders were denied. Sandoz subsequently proceeded against Cediprof in an arbitration in New York, where the Company has agreed to indemnify Cediprof. On August 5, 2022, the arbitrator issued a final award, finding that Cediprof had breached the Sandoz contract and determining that Sandoz is entitled to lost profits, among other damages. The portion of the award subject to indemnification from the Company amounted to $10.9 million, which is included in accrued expenses on the Consolidated Balance Sheets. The Company’s indemnification obligation will only be triggered if and when Cediprof pays the award. See Note 11 “Legal, Regulatory Matters and Contingencies” for additional information regarding this matter.

Cost of Sales, including amortization of intangibles. Cost of sales, including amortization of intangibles, for the third quarter of Fiscal 2023 decreased 13% to $65.3 million from $75.3 million in the same prior-year period. Product royalties expense included in cost of sales totaled $10.5 million for the third quarter of Fiscal Year 2023 and $4.6 million for the third quarter of Fiscal Year 2022. Amortization expense included in cost of sales decreased to $1.0 million in the third quarter of Fiscal 2023 compared to $2.6 million in Fiscal 2022 as a result of intangible asset impairment charges incurred during the prior fiscal year, which resulted in a lower amortizable base for certain assets. In addition, the 2021 Restructuring Plan included the discontinuance of two high volume prescription products and a lower overall headcount, which further reduced cost of sales in the third quarter of Fiscal 2023.

Gross Profit. Gross profit for the third quarter of Fiscal 2023 increased over 100% to $15.2 million or 19% of net sales from $3.1 million or 4% of net sales in the same prior-year period. The increase in gross profit percentage was primarily the result of the discontinuance of two low-margin prescription products as part of the 2021 Restructuring Plan.

Research and Development Expenses. Research and development expenses for the third quarter of Fiscal 2023 increased 22% to $7.1 million from $5.8 million for the third quarter of Fiscal 2022. The increase was primarily due to the timing of spend related to product development projects and distribution agreements.

Selling, General and Administrative Expenses. Selling, general and administrative expenses increased 16% to $20.4 million for the third quarter of Fiscal 2023 compared with $17.6 million for the third quarter of Fiscal 2022. The increase was primarily due to costs incurred related to strategic review initiatives.

51

Asset impairment charge. In conjunction with the Restructuring Support Agreement, the Company, with the knowledge of its lenders, has begun to explore the sale of its Seymour, Indiana facility. The Company currently seeks to sell the facility and its contract manufacturing business to a pharmaceutical manufacturer that could benefit from the site’s exceptional history of FDA compliance, and with whom we would partner with to continue manufacturing our products at the site. The Company’s existing ANDAs and NDAs are not part of any potential sale. However, the KUPI other intangible assets, which consists of the Company’s contract manufacturing business associated with the Seymour, Indiana facility, is expected to be included in any potential sale of the facility. The Company determined that the above requires reclassification of the assets at the Seymour, Indiana facility to assets held for sale on our Consolidated Balance Sheets as of March 31, 2023. The Company evaluated the assets for impairment as the reclassification is considered a triggering event. As a result, the Company recorded an impairment charge of $72.5 million to adjust the assets to their expected fair value.

Other Income (Expense), net. Interest expense for the three months ended March 31, 2023 totaled $15.2 million compared to $14.5 million for the three months ended March 31, 2022. The weighted average interest rate for the third quarter of Fiscal 2023 and 2022 was 9.3% and 9.1%, respectively.

Income Tax. The Company recorded income tax expense of $29 thousand in the third quarter of Fiscal 2023 as compared to an income tax benefit of $1.4 million in the third quarter of Fiscal 2022. The effective tax rate for the three months ended March 31, 2023 was (0.1)% compared to 3.8% for the three months ended March 31, 2022.

Net Loss. For the three months ended March 31, 2023, the Company reported net loss of $101.5 million, or $(9.84) per diluted share. Comparatively, net loss in the corresponding prior-year period was $34.9 million, or $(3.45) per diluted share.

52

Results of Operations - Nine months ended March 31, 2023 compared with the nine months ended March 31, 2022

Net sales decreased 11% to $236.5 million for the nine months ended March 31, 2023. The table below identifies the Company’s net product sales by medical indication for the nine months ended March 31, 2023 and 2022.

​

​

​

​

​

​

​

(In thousands)

​

March 31, 

Medical Indication

    

2023

    

2022

Analgesic

​

$

8,757

​

$

12,525

Anti-Psychosis

​

 

7,277

​

 

9,156

Cardiovascular

​

 

37,030

​

 

33,321

Central Nervous System

​

 

61,887

​

 

60,302

Endocrinology

​

 

21,209

​

 

22,934

Gastrointestinal

​

 

26,590

​

 

40,972

Infectious Disease

​

 

12,884

​

 

24,473

Migraine

​

 

9,666

​

 

12,638

Respiratory/Allergy/Cough/Cold

​

 

3,651

​

 

7,291

Other

​

 

33,056

​

 

35,327

Contract manufacturing revenue

​

 

14,473

​

 

7,451

Total net sales

​

$

236,480

​

$

266,390

​

The decrease in net sales was driven by a decrease in the selling price of products of $14.4 million and a decrease in volumes of $15.5 million. The decrease in the selling price of products was primarily driven by lower sales prices of Posaconazole, which is included within the Infectious Disease medical indication and certain products in the Endocrinology and Central Nervous System medical indications. The pressure on sales prices across our portfolio is a reflection of the competitive environment in the generic drug industry. Overall volumes, particularly volumes of Posaconazole, were also negatively impacted by the competitive environment. In addition, volumes, specifically within the Gastrointestinal medical indication, were lower as a result of certain product discontinuances in connection with the 2021 Restructuring Plan. The decrease in overall sales volumes was partially offset by an increase in volumes in our contract manufacturing business.

The following chart details price and volume changes by medical indication:

​

​

​

​

​

​

​

​

Sales volume

​

Sales price

​

Medical indication

    

change %

  

change %

​

Analgesic

 

(16)

%  

(14)

%

Anti-Psychosis

 

(16)

%  

(5)

%

Cardiovascular

 

14

%  

(3)

%

Central Nervous System

 

7

%  

(4)

%  

Endocrinology

​

8

%  

(16)

%  

Gastrointestinal

 

(42)

%  

7

%  

Infectious Disease

​

(16)

%  

(31)

%  

Migraine

​

(15)

%  

(9)

%  

Respiratory/Allergy/Cough/Cold

​

(52)

%  

2

%  

​

53

The Company sells its products to customers in various distribution channels. The table below presents the Company’s net sales to each distribution channel for the nine months ended:

​

​

​

​

​

​

​

(In thousands)

​

March 31, 

​

March 31, 

Customer Distribution Channel

    

2023

    

2022

Wholesaler/Distributor

​

$

187,276

​

$

212,295

Retail Chain

​

 

29,513

​

 

40,296

Mail-Order Pharmacy

​

 

5,218

​

 

6,348

Contract manufacturing revenue

​

 

14,473

​

 

7,451

Total net sales

​

$

236,480

​

$

266,390

The overall decrease in sales was primarily driven by lower sales of certain key products due to new competitors entering the market and the discontinuance of two low-margin prescription products as part of the 2021 Restructuring Plan. The Company has also seen increased competitive market pressure among the existing competitor base in recent years, which has resulted in an overall decrease in sales to the distribution channels above. We will continue to seek opportunities for additional launches and contract manufacturing business to offset these competitive pressures.

Cost of Sales, including amortization of intangibles. Cost of sales, including amortization of intangibles, for the first nine months of Fiscal 2023 decreased 19% to $194.4 million from $241.1 million in the same prior-year period. Product royalties expense included in cost of sales totaled $28.8 million for the first three months of Fiscal Year 2023 and $27.2 million for the first three months of Fiscal Year 2022. Amortization expense included in cost of sales decreased to $3.6 million for the first nine months of Fiscal 2023 compared to $10.4 million for the first nine months Fiscal 2022 as a result of intangible asset impairment charges incurred during the prior fiscal year, which resulted in a lower amortizable base for certain assets. The Company has experienced increased competitive market pressure in recent years, which has resulted in overall decrease in sales volumes and, therefore, lower cost of sales in the current period. In addition, the 2021 Restructuring Plan included the discontinuance of two high volume prescription products and a lower overall headcount, which further reduced cost of sales in the second quarter of Fiscal 2023.

Gross Profit. Gross profit for the first nine months of Fiscal 2023 increased 66% to $42.1 million or 18% of net sales. In comparison, gross profit for the first nine months of Fiscal 2022 was $25.3 million or 10% of net sales.

Research and Development Expenses. Research and development expenses for the first nine months of Fiscal 2023 increased 18% to $19.2 million from $16.3 million in Fiscal 2022. The increase was primarily due to the timing of spend related to product development projects and distribution agreements.

Selling, General and Administrative Expenses. Selling, general and administrative expenses were $55.5 million for the first nine months of Fiscal 2023 compared with $55.3 million in Fiscal 2022.

Asset impairment charges. In conjunction with the Restructuring Support Agreement, the Company, with the knowledge of its lenders, has begun to explore the sale of its Seymour, Indiana facility. The Company currently seeks to sell the facility and its contract manufacturing business to a pharmaceutical manufacturer that could benefit from the site’s exceptional history of FDA compliance, and with whom we would partner with to continue manufacturing our products at the site. The Company’s existing ANDAs and NDAs are not part of any potential sale. However, the KUPI other intangible assets, which consists of the Company’s contract manufacturing business associated with the Seymour, Indiana facility, is expected to be included in any potential sale of the facility. The Company determined that the above requires reclassification of the assets at the Seymour, Indiana facility to assets held for sale on our Consolidated Balance Sheets as of March 31, 2023. The Company evaluated the assets for impairment as the reclassification is considered a triggering event. As a result, the Company recorded an impairment charge of $72.5 million to adjust the assets to their expected fair value.

In December 2022, the Company announced the 2022 Restructuring Plan, which includes a plan to exit and sell its Torresdale facility. The Company adjusted the assets to approximate fair value, which resulted in a $6.0 million impairment charge.

54

In September 2022, the Company signed a listing and sale agreement to engage a broker to sell its State Road facility and certain equipment at the facility. The Company adjusted the assets to fair value less costs to sell, which resulted in a $4.7 million impairment charge.

Gain on sale of intangible assets. In connection with the sale of the Company’s Carmel, NY facility in Fiscal 2022, Chartwell had the option to purchase certain ANDAs from the Company. In the first quarter of Fiscal 2023, Chartwell exercised this option and purchased additional ANDAs under a separate agreement, which resulted in an aggregate gain totaling $3.1 million.

Other Income (Expense), net. Interest expense for the nine months ended March 31, 2023 totaled $45.4 million compared to $43.2 million for the nine months ended March 31, 2022. The weighted average interest rate for the first nine months of Fiscal 2023 and 2022 was 9.2% and 8.9%, respectively.

In Fiscal 2017, the Company signed an agreement with a third-party company operating in the online pharmaceutical business, under which the Company agreed to provide up to $15.0 million in revolving loans for the purpose of expansion and other business needs. Any outstanding balance under the loan would bear interest at 2.0% and be due seven years from the date of the agreement. As of December 31, 2022, after a review of the third-party’s current financial condition as well as their projected liquidity levels, the Company determined that it is more likely than not that the third party will be unable to repay the outstanding loan. Therefore, the Company recorded a full write-off of the loan receivable of $6.8 million during the second quarter of Fiscal 2023.

Income Tax. The Company recorded income tax expense of $95 thousand in the first nine months of Fiscal 2023 as compared to an income tax benefit of $2.8 million in the first nine months of Fiscal 2022. The effective tax rate for the nine months ended March 31, 2023 was (0.1)% compared to 2.0% for the nine months ended March 31, 2022.

Net Loss. For the nine months ended March 31, 2023, the Company reported net loss of $165.8 million, or $(16.13) per diluted share. Comparatively, net loss in the corresponding prior-year period was $138.3 million, or $(13.74) per diluted share.

Liquidity and Capital Resources

Cash Flow

The Company has historically financed its operations with cash flow generated from operations. However, more recently, the Company has experienced and continues to expect cash flow pressures related to the competitive environment within the industry. Management has maintained discipline spending and has implemented various working capital improvements and cost-cutting initiatives, namely the 2022 Restructuring Plan and the Prepackaged Plan, to offset some of these pressures. At March 31, 2023, (negative) working capital was $(471.4) million as compared to $185.2 million at June 30, 2022, a decrease of $656.6 million primarily due to the acceleration of our debt obligations. For more information on the terms of the Restructuring Support Agreement, the Chapter 11 Cases and the effects of both on the Company’s liquidity, refer to the “Subsequent Events Related to the Chapter 11 Cases and Other Related Matters” section below.

Net cash used in operating activities of $38.4 million for the nine months ended March 31, 2023 reflected net loss of $165.8 million, adjustments for non-cash items of $128.8 million, as well as cash used by changes in operating assets and liabilities of $1.4 million. In comparison, net cash provided by operating activities of $11.9 million for the nine months ended March 31, 2022 reflected net loss of $138.3 million, adjustments for non-cash items of $114.5 million, as well as cash provided by changes in operating assets and liabilities of $35.7 million.

Significant changes in operating assets and liabilities from June 30, 2022 to March 31, 2023 were comprised of:

●A decrease in income taxes receivable totaling $18.9 million primarily due to income tax refunds received during the second quarter of Fiscal 2023.

55

●An increase in accounts receivable of $11.9 million mainly due to the timing of customer receipts. The Company’s days sales outstanding (“DSO”) at March 31, 2023, based on gross sales for the nine months ended March 31, 2023 and gross accounts receivable at March 31, 2023, was 82 days. The level of DSO at March 31, 2023 was comparable to the Company’s expectation that DSO will be in the 70 to 85-day range based on customer payment terms.
●An increase in accrued expense of $11.1 million primarily attributable to the interest related to the 7.750% Senior Secured Notes.
●A decrease in accounts payable of $8.7 million mainly due to the timing of vendor invoices and payments.
●A decrease in rebates payable of $8.1 million primarily as a result of timing of commercial and government rebate payments
●An increase in other assets of $6.2 million primarily due to the retention bonuses for Named Executive Officers (“NEOs”) and certain other employees paid in September and October 2022, which will be recognized on the Consolidated Statement of Operations over a three-year clawback period.

Significant changes in operating assets and liabilities from June 30, 2021 to March 31, 2022 were comprised of:

●A decrease in accounts receivable of $34.9 million mainly due to lower gross sales in the three months ended March 31, 2022 compared to the three months ended June 30, 2021. The Company’s days sales outstanding (“DSO”) at March 31, 2022, based on gross sales for the nine months ended March 31, 2022 and gross accounts receivable at March 31, 2022, was 75 days. The level of DSO at March 31, 2022 was comparable to the Company’s expectation that DSO will be in the 70 to 85-day range based on customer payment terms.
●A decrease in royalties payable of $7.6 million mainly due lower sales of distributed products, particularly Posaconazole and Levothyroxine Tablets and Capsules.

Net cash used in investing activities of $2.9 million for the nine months ended March 31, 2023 was mainly the result of purchases of property, plant and equipment of $6.6 million and purchases of intangible assets of $1.0 million partially offset by proceeds from the sale of assets of $4.7 million. Net cash provided by investing activities of $1.5 million for the nine months ended March 31, 2022 was mainly the result of proceeds from the sale of the Silarx facility in Carmel, NY and the Cody API real estate of $12.2 million partially offset by purchases of property, plant and equipment of $9.3 million and purchases of intangible assets of $1.5 million.

Net cash used in financing activities was not material for the nine months ended March 31, 2023. Net cash used in financing activities of $0.5 million for the nine months ended March 31, 2022 was due to purchases of treasury stock totaling $0.8 million, partially offset by proceeds from issuance of stock pursuant to stock compensation plans of $0.3 million.

56

Credit Facility and Other Indebtedness

The Company has previously entered into and may enter future agreements with various government agencies and financial institutions to provide additional cash to help finance the Company’s acquisitions, various capital investments and potential strategic opportunities. These borrowing arrangements as of March 31, 2023 are as follows:

7.750% Senior Secured Notes due 2026

On April 22, 2021, the Company issued $350.0 million aggregate principal amount of the Secured Notes in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and outside the United States to persons other than U.S. persons in reliance upon Regulation S under the Securities Act. The Secured Notes bear interest semi-annually in arrears on April 15 and October 15 of each year, beginning on October 15, 2021, at a rate of 7.750% per annum in cash. The Secured Notes will mature on April 15, 2026, unless earlier redeemed or repurchased in accordance with their terms.

Second Lien Secured Loan Facility

On April 5, 2021, the Company entered into an Exchange Agreement with certain participating lenders to exchange a portion of their existing Term B Loans for Second Lien Loans pursuant to a new $190.0 million Second Lien Credit Facility. On April 22, 2021, in connection with the issuance of the Secured Notes and the entrance into the Amended ABL Credit Facility, which is discussed further below, the exchange between the Company and the participating lenders was consummated. From the Closing Date until the one-year anniversary of the Closing Date, the Second Lien Loans bear 10.0% PIK interest. Thereafter, the Second Lien notes will bear 5.0% cash interest and 5.0% PIK interest until maturity, except to the extent the Company elects to pay all or portion of the PIK interest in cash. To date, the Company has not paid any PIK interest in cash. The Second Lien Loans will mature on July 21, 2026. In connection with the Second Lien Credit Facility, the Company issued to the Participating Lenders warrants to purchase up to 2,070,000 shares of common stock of the Company (“Warrants”) at an exercise price of $27.52 per share. The Warrants were issued on April 22, 2021 with an eight-year term. The Participating Lenders received registration rights with respect to the shares of common stock of the Company to be received upon exercise of the Warrants. The holders of the Warrants are entitled to receive dividends or distributions of any kind made to the common stockholders to the same extent as if the holder had exercised the Warrant into common stock. The Warrants are considered participating securities under ASC 260, Earnings per share.

In connection with the Second Lien Credit Facility, the Company is required to maintain at least $5.0 million in a deposit account at all times subject to control by the Second Lien Collateral Agent, and a minimum cash balance of $15.0 million as of the last day of each month. At March 31, 2023, the Company classified the $5.0 million required deposit account balance as restricted cash, which is included in other assets caption in the Consolidated Balance Sheet.

Amended ABL Credit Facility

On December 7, 2020, the Company entered into a credit and guaranty agreement, which provided for an asset-based revolving credit facility (the “ABL Credit Facility”) of up to $30.0 million, subject to borrowing base availability, and included letter of credit and swing line sub-facilities. On April 22, 2021, the Company entered into the “Amended ABL Credit Agreement, among the Company, certain of its wholly-owned domestic subsidiaries party thereto, as borrowers or as guarantors, Wells Fargo Bank, National Association, as administrative agent and as collateral agent, and the other lenders party thereto, for the purpose of, among other things, increasing the aggregate amount of the revolving credit facility from $30.0 million to $45.0 million and extending the maturity thereof to the fifth anniversary of the closing date of the Secured Notes Offering (subject to a springing maturity as set forth therein).

57

The Amended ABL Credit Agreement provides for the Amended ABL Credit Facility that includes letter of credit and swing line sub-facilities. Borrowing availability under the Amended ABL Credit Facility is determined by a monthly borrowing base collateral calculation that is based on specified percentages of eligible accounts receivable less certain reserves and subject to certain other adjustments as set forth in the Amended ABL Credit Agreement. Availability is reduced by issuance of letters of credit as well as any borrowings. Loans outstanding under the Amended ABL Credit Agreement bear interest at a floating rate measured by reference to, at the Company’s option, either an adjusted London Inter-Bank Offered Rate (“LIBOR”) (subject to a floor of 0.75%) plus an applicable margin of 2.50% per annum, or an alternate base rate plus an applicable margin of 1.50% per annum. Unused commitments under the Amended ABL Credit Facility are subject to a fee of 0.50% per annum, which fee increases to 0.75% per annum for any quarter during which the Company’s average usage under the Amended ABL Credit Facility is less than $5.0 million.

4.50% Convertible Senior Notes due 2026

On September 27, 2019, the Company issued $86.3 million aggregate principal amount of the Convertible Notes in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The Convertible Notes are senior unsecured obligations of the Company and bear interest at an annual rate of 4.50% payable semi-annually in arrears on April 1 and October 1 of each year, beginning on April 1, 2020. The Convertible Notes will mature on October 1, 2026, unless earlier repurchased, redeemed or converted in accordance with their terms. The Convertible Notes are convertible into shares of the Company’s common stock at a conversion rate of 16.3507 shares per $1,000 principal amount of Convertible Notes (which is equivalent to a conversion price of approximately $61.16 per share), subject to adjustments upon the occurrence of certain events (but will not be adjusted for any accrued and unpaid interest). The Company may redeem all or a part of the Convertible Notes on or after October 6, 2023 at a redemption price equal to 100% of the principal amount of the Convertible Notes redeemed, plus accrued and unpaid interest, if any, up to, but excluding, the redemption date, subject to certain conditions relating to the Company’s stock price having been met. Following certain corporate events that occur prior to the maturity date or if the Company delivers a notice of redemption, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such corporate event or notice of redemption. The indenture covering the Convertible Notes contains certain other customary terms and covenants, including that upon certain events of default occurring and continuing, either the trustee or holders of at least 25% in principal amount of the outstanding Convertible Notes may declare 100% of the principal of, and accrued and unpaid interest on, all the Convertible Notes to be due and payable.

In addition, if the Company ceases to be listed or quoted on any of the NYSE, The Nasdaq Global Select Market or The Nasdaq Global Market (or any of their respective successors), holders of the outstanding Convertible Notes will have the option to require the Company to repurchase for cash all of such holder’s notes at 100% of the principal amount, plus accrued and unpaid interest. On April 19, 2023, the Company received a written notice from the NYSE notifying the Company that the NYSE had commenced proceedings to delist the Company’s common stock. Pursuant to the Convertible Notes Indenture, the Delisting constituted a Fundamental Change (as defined therein). Upon the occurrence of a Fundamental Change, the Company must provide all holders of Convertible Notes and the trustee a Fundamental Change Company Notice of the occurrence of the Fundamental Change and of the holder’s option to require the Company to repurchase for cash all of such holder’s notes at 100% of the principal amount, plus accrued and unpaid interest. Failure by the Company to issue a Fundamental Change Company Notice within 20 days following the fundamental change constitutes an event of default and, if the trustee or holders of at least 25% in aggregate principal amount of the Convertible Notes declared 100% of the principal of, and accrued and unpaid interest on, all the Convertible Notes to be due and payable immediately, the Convertible Notes would become immediately due and payable.

In connection with the offering of the Convertible Notes, the Company also entered into privately negotiated “capped call” transactions with several counterparties. The capped call transaction will initially cover, subject to customary anti-dilution adjustments, the number of shares of common stock that initially underlie the Convertible Notes. The capped call transactions are expected to generally reduce the potential dilutive effect on the Company’s common stock upon any conversion of the Convertible Notes with such reduction subject to a cap.

58

Subsequent Events Related to the Chapter 11 Cases and Other Related Matters

Restructuring Support Agreement

On April 30, 2023, the Company Parties and the Consenting Stakeholders entered into the Restructuring Support Agreement to facilitate the Restructuring of the existing debt of, existing equity interests in and certain other obligations of the Company Parties. In connection therewith, on the Petition Date, the Company Parties commenced the Chapter 11 Cases in the Bankruptcy Court.

In accordance with the Restructuring Support Agreement, the Consenting Stakeholders agreed, among other things, to:

●support the transactions described in the Restructuring Support Agreement (the “Restructuring Transactions”) and vote and exercise any powers or rights available to it in each case in favor of any matter requiring approval to the extent necessary to implement the Restructuring Transactions;
●not object to, delay, impede or take any other action, directly or indirectly, that is reasonably likely to interfere with, delay, or impede the acceptance, implementation, or consummation of the Restructuring Transactions;
●use commercially reasonable efforts to cooperate with and assist the Company Parties in obtaining additional support for the Restructuring Transactions from the Company Parties’ other stakeholders;
●subject to the consent rights provided in the Restructuring Support Agreement, negotiate in good faith and use commercially reasonable efforts to execute, deliver, and implement any other necessary agreements that are consistent with the Restructuring Support Agreement to which it is to be a party in a timely manner to effectuate and consummate the Restructuring Transactions as contemplated by the Restructuring Support Agreement; and
●with respect to the Consenting Second Lien Term Lenders (as defined in the Restructuring Support Agreement) and the interest payment due on April 24, 2023 pursuant to the Second Lien Credit Agreement, extend the five-business day grace period provided in Section 8.1(c) of the Second Lien Credit Agreement to ten-business days.

In accordance with the Restructuring Supporting Agreement, the Company Parties agreed, among other things, to:

●support and take all steps reasonably necessary and desirable to consummate the Restructuring Transactions in accordance with the Restructuring Support Agreement;
●to the extent any legal or structural impediment arises that would prevent, hinder, or delay the consummation of the Restructuring Transactions contemplated by the Restructuring Support Agreement, take all steps reasonably necessary and desirable to address any such impediment;
●use commercially reasonable efforts to obtain any and all required regulatory and/or third-party approvals for the Restructuring Transactions;
●negotiate in good faith and use commercially reasonable efforts to execute and deliver any required agreements to effectuate and consummate the Restructuring Transactions as contemplated by the Restructuring Support Agreement;
●continue ordinary course practices to maintain good standing under the jurisdiction in which each Company Party and each of its subsidiaries is incorporated or organized and continue to operate the business in the ordinary course of business customary in the normal course of ordinary operations consistent with past practice taking into account the Chapter 11 Cases and Restructuring Transactions; and

59

●negotiate in good faith and use commercially reasonable efforts to execute and deliver any appropriate additional or alternative provisions or agreements to address any legal, financial, strategic or structural impediment that may arise that would prevent, hinder, impede, delay, or be reasonably necessary to effectuate the consummation of the Restructuring Transactions.

The Restructuring Support Agreement may be terminated upon the occurrence of certain events, including the failure to meet specified milestones related to consummation of the Prepackaged Plan. In addition, the Restructuring Support Agreement shall automatically terminate on the Effective Date of the Prepackaged Plan once all conditions precedent to the Prepackaged Plan have been satisfied.

Chapter 11 Cases, Prepackaged Plan and Disclosure Statement

As an initial step towards implementation of the Prepackaged Plan, on the Petition Date, the Company Parties filed the Chapter 11 Cases in the Bankruptcy Court. The Chapter 11 Cases are being jointly administered under the caption In re Lannett Company, Inc., et al., Case No. 23-10559 (JKS).

To ensure the Company Parties’ ability to continue operating in the ordinary course of business and minimize the effect of the Restructuring on the Company Parties’ customers and employees, the Company Parties filed motions with the Bankruptcy Court seeking a variety of “first-day” relief, including authority to pay employee wages and benefits, and pay vendors and suppliers for all goods and services, each of which was approved on an interim basis by the Bankruptcy Court.

On May 2, 2023, the Company Parties filed the Prepackaged Plan and related Disclosure Statement. On May 3, 2023, the Company Parties also filed a proposed order approving various plan solicitation materials, including the solicitation and voting procedures, and scheduling a combined hearing for approval of the Disclosure Statement and confirmation of the Prepackaged Plan for June 8, 2023. The Court entered the scheduling order on May 4, 2023.

The Prepackaged Plan, as proposed, provides that:

●trade claims will be paid in the ordinary course of business during and after the Chapter 11 Cases;
●on the effective date of the Restructuring Transactions, Reorganized LCI will issue a single class of common equity interests to the Consenting Stakeholders pursuant to the Prepackaged Plan;
●on the effective date of the Restructuring Transactions, the Company Parties will enter into a new revolving credit facility on terms to be agreed;
●on the effective date of the Restructuring Transactions, Reorganized LCI will enter into a “takeback” exit financing facility in the principal amount of $60 million and such other terms as set forth in the Restructuring Support Agreement (the “Takeback Exit Facility”);
●on the effective date of the Restructuring Transactions, Reorganized LCI will distribute new warrants issued pursuant to a new warrant agreement to holders of Second Lien Term Loan Claims (as defined in the Restructuring Support Agreement);
●following the effective date of the Restructuring Transactions, Reorganized LCI will establish a customary management equity incentive plan;
●on the effective date of the Restructuring Transactions, there will be no recovery for holders of the Company’s convertible notes or existing equity interests; and
●the effective date of the Restructuring Transactions will be reached within 45 days of filing the Chapter 11 Cases.

60

Executory Contracts

The Prepackaged Plan provides that the executory contracts and unexpired leases that are not assumed or rejected as of the Effective Date (either pursuant to the Prepackaged Plan or a separate motion) will be deemed assumed pursuant to Section 365 of the Bankruptcy Code.

Effects of the Restructuring and the Chapter 11 Cases on Our Liquidity

The filing of the Chapter 11 Cases constituted an event of default that accelerated all of our debt obligations under the Convertible Notes Indenture, the Secured Notes Indenture, the Second Lien Credit Agreement and the Amended ABL Credit Agreement. However, pursuant to the Bankruptcy Code, the filing of the Chapter 11 Cases automatically stayed most actions against the Company Parties, including most actions to collect indebtedness incurred prior to the Petition Date or to exercise control over the Company Parties’ property. Accordingly, although the filing of the Chapter 11 Cases triggered events of default under the Company’s existing debt obligations, creditors are stayed from taking action as a result of these defaults. Additionally, under Section 502(b)(2) of the Bankruptcy Code, the Company is no longer required to pay interest on its indentures and credit facilities accruing on or after the Petition Date.

Additionally, in connection with the Chapter 11 Cases, the Company has incurred, and expects to continue to incur, significant professional fees and other costs in connection with the Chapter 11 Cases. There can be no assurance that the Company’s current liquidity is sufficient to allow it to satisfy its obligations related to the Chapter 11 Cases or to pursue confirmation of the Prepackaged Plan.

Other Liquidity Matters

Along with executing on our existing pipeline products, we are continuously evaluating the potential for product and company acquisitions as a part of our future growth strategy. In conjunction with a potential acquisition, the Company may utilize current resources or seek additional sources of capital to finance any such acquisition, which could have an impact on future liquidity. The continued competitive pressures on our current portfolio may impact the ultimate success of existing pipeline projects, which may result in the Company exploring alternative opportunities for capital to support the launch of products in the future.

We may also from time to time depending on market conditions and prices, contractual restrictions, our financial liquidity and other factors, seek to prepay outstanding debt or repurchase our outstanding debt through open market purchases, privately negotiated purchases, or otherwise. The amounts involved in any such transactions, individually or in the aggregate, may be material and may be funded from available cash or from additional borrowings.

The Company files income tax returns in the United States federal jurisdiction and its Fiscal 2015 through 2017, 2019, 2020 and 2021 federal returns are currently under examination by the Internal Revenue Service (“IRS”). As part of a lengthy process, the Company has received various Information Document Requests and Notices of Proposed Adjustment with respect to positions taken in certain income tax issues, including an accounting method change related to chargebacks and rebates that the IRS is proposing to disallow. We are in the process of assessing the impact of these notices and preparing a response to the IRS. We believe that it is more likely than not that our positions will ultimately be sustained upon further examination, and, if necessary, will contest any additional tax determined to be owed; however, an adverse outcome could have a material impact to the Company’s Consolidated Statements of Operations and financial position.

61

Research and Development Arrangements

In the normal course of business, the Company has entered into certain research and development and other arrangements. As part of these arrangements, the Company has agreed to certain contingent payments, which generally become due and payable only upon the achievement of certain developmental, regulatory, commercial and/or other milestones. In addition, under certain arrangements, we may be required to make royalty payments based on a percentage of future sales, or other metric, for products currently in development in the event that the Company begins to market and sell the product. Due to the inherent uncertainty related to these developmental, regulatory, commercial and/or other milestones, it is unclear if the Company will ever be required to make such payments.

Critical Accounting Policies

The preparation of our Consolidated Financial Statements in accordance with accounting principles generally accepted in the United States and the rules and regulations of the U.S. Securities & Exchange Commission requires the use of estimates and assumptions. A listing of the Company’s significant accounting policies is detailed in Note 3 “Summary of Significant Accounting Policies.” A subsection of these accounting policies has been identified by management as “Critical Accounting Policies and Estimates.” Critical accounting policies and estimates are those which require management to make estimates using assumptions that were uncertain at the time the estimates were made and for which the use of different assumptions, which reasonably could have been used, could have a material impact on the financial condition or results of operations.

Management has identified the following as “Critical Accounting Policies and Estimates”: Revenue Recognition, Inventories, Income Taxes, and Valuation of Long-Lived Assets, including Intangible Assets. Refer to the Company’s Form 10-K for the fiscal year ended June 30, 2022 for a description of our Critical Accounting Policies.

​

62

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company has historically invested in equity securities, U.S. government agency securities and corporate bonds, which are exposed to market and interest rate fluctuations. The market value, interest and dividends earned on these investments may vary based on fluctuations in interest rate and market conditions.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Form 10-Q, management performed, with the participation of our Chief Executive Officer and Chief Financial Officer, an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosures.

Based upon the evaluation, the Chief Executive Officer and Chief Financial Officer concluded that Lannett’s disclosure controls and procedures were effective as of the end of the period covered by this report.

Change in Internal Control Over Financial Reporting

There has been no change in Lannett’s internal control over financial reporting during the nine months ended March 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

​

63

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Information pertaining to legal proceedings can be found in Note 11 “Legal, Regulatory Matters and Contingencies” of the Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q and is incorporated by reference herein.

Effect of Automatic Stay upon filing under Chapter 11 of the Bankruptcy Code

Pursuant to Section 362 of the Bankruptcy Code, the filing of the Chapter 11 Cases automatically stayed most actions against or on behalf of the Company Parties. Subject to certain exceptions under the Bankruptcy Code, the filing of the Company Parties’ Chapter 11 Cases automatically stayed the continuation of most legal proceedings or the filing of other actions against or on behalf of the Company Parties or their property to recover on, collect or secure a claim arising prior to the Petition Date or to exercise control over property of the Company Parties’ bankruptcy estates, unless and until the Bankruptcy Court modifies or lifts the automatic stay as to any such claim. Notwithstanding the general application of the automatic stay described above, governmental authorities may determine to continue actions brought under their police and regulatory powers.

ITEM 1A. RISK FACTORS

Lannett Company, Inc’s Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (the “2022 Annual Report”) includes a detailed description of its risk factors. The following information updates, and should be read in conjunction with, the information disclosed in Part I, Item 1A, “Risk Factors,” contained in the 2022 Annual Report. Except as described below, the Company’s risk factors as of the date of this Quarterly Report on Form 10-Q have not changed materially from those described in Part I, Item 1A, “Risk Factors” of the 2022 Annual Report.

Risks Related to the Restructuring, Prepackaged Plan and Chapter 11 Cases

We may not be able to obtain confirmation of a Chapter 11 plan of reorganization.

To emerge successfully from Bankruptcy Court protection as a viable entity, we must meet certain statutory requirements with respect to adequacy of disclosure with respect to a Chapter 11 plan of reorganization, solicit and obtain the requisite acceptances of such a reorganization plan and fulfill other statutory conditions for confirmation of such a plan. Although we have distributed to our creditors a Disclosure Statement with respect to the Prepackaged Plan and our solicitation of the Prepackaged Plan has begun, certain parties in interest may file objections to the Plan in an effort to persuade the Bankruptcy Court that we have not satisfied the confirmation requirements under section 1129 of the Bankruptcy Code. The precise requirements and evidentiary showing for confirming a plan, notwithstanding its rejection by one or more impaired classes of claims or equity interests, depends upon a number of factors including, without limitation, the status and seniority of the claims or equity interests in the rejecting class.

We have requested that a confirmation hearing on the Prepackaged Plan to be held in June, but it is possible that hearing could be delayed. It is also possible that the Bankruptcy Court will not confirm the Prepackaged Plan. If the Prepackaged Plan is not confirmed by the Bankruptcy Court, it is unclear whether we would be able to reorganize our business and what, if anything, holders of claims against us would ultimately receive with respect to their claims.

64

There is no assurance that we will be able to successfully complete the Restructuring contemplated in the Prepackaged Plan or realize all or any of the expected benefits from the Restructuring, creating substantial doubt about our ability to continue as a going concern.

Our ability to continue as a going concern is contingent upon, among other things, our ability to, subject to the Bankruptcy Court’s approval, implement the Prepackaged Plan, successfully emerge from the Chapter 11 Cases and establish a sustainable capital structure through the Restructuring. Our ability to consummate the Restructuring is subject to risks and uncertainties many of which are beyond our control. These factors, together with the Company’s recurring losses from operations and accumulated deficit, create substantial doubt about our ability to continue as a going concern. There can be no assurance that we will be able to successfully consummate the Restructuring on the terms set forth in the Prepackaged Plan, or at all, or realize all or any of the expected benefits from the Restructuring. See Note 20 “Subsequent Events” of the notes to consolidated financial statements contained herein for more information on the Restructuring, the Prepackaged Plan and the Chapter 11 Cases.

We have sought the protection of the Bankruptcy Court, which subjects us to the risks and uncertainties associated with bankruptcy and may harm our business.

We have sought the protection of the Bankruptcy Court and as a result our operations and ability to develop and execute our business plan, and our ability to continue as a going concern, are subject to the risks and uncertainties associated with bankruptcy. As such, seeking Bankruptcy Court protection could have a material adverse effect on our business, financial condition, results of operations and liquidity. Our senior management has been required to spend a significant amount of time and effort attending to the Restructuring instead of focusing exclusively on our business operations. Bankruptcy Court protection also might make it more difficult to retain management and other employees necessary to the success and growth of our business.

Other significant risks include the following:

●our ability to consummate the Prepackaged Plan;
●the high costs of bankruptcy and related fees;
●the imposition of restrictions or obligations on the Company by regulators related to the bankruptcy and emergence from Chapter 11;
●our ability to obtain sufficient financing to allow us to emerge from bankruptcy and execute our business plan post-emergence;
●our ability to maintain our relationships with our suppliers, service providers, customers, employees, and other third parties;
●our ability to maintain contracts that are critical to our operations; and
●the actions and decisions of our debtholders and other third parties who have interests in our Chapter 11 Cases that may be inconsistent with our plans.

Delays in the Chapter 11 Cases could increase the risks of our being unable to reorganize our business and emerge from bankruptcy and increase our costs associated with the bankruptcy process.

65

If the Restructuring Support Agreement is terminated, our ability to confirm and consummate the Prepackaged Plan may be materially and adversely affected.

On April 30, 2023, the Company Parties and the Consenting Stakeholders entered into the Restructuring Support Agreement. The Restructuring Support Agreement contains a number of termination events, some of which would permit the Consenting Stakeholders the right to terminate such Restructuring Support Agreement, which could adversely affect our ability to consummate the Prepackaged Plan. Such termination events include, for example: the breach in any material respect by any of the Company Parties of the representations, warranties and covenants set forth therein; the issuance by any governmental authority of any order that would be expected to prevent the consummation of the Restructuring Transactions (as defined in the Restructuring Support Agreement); an order or motion seeking the entry of an order converting one or more of the Chapter 11 Cases to a case under chapter 7 of the Bankruptcy Code; or the failure to meet any of the Milestones (as defined in the Restructuring Support Agreement). If the Restructuring Support Agreement is terminated, we may be unable to consummate the Prepackaged Plan, and there can be no assurance that we would be able to enter into a new plan or that any new plan would be as favorable to holders of claims as the Prepackaged Plan. In addition, any Chapter 11 Cases may become protracted, which could significantly and detrimentally impact our relationships with our partners, suppliers, service providers, customers, employees, and other third parties.

The consummation of the transactions contemplated by the Prepackaged Plan may not occur.

We will not complete the transactions contemplated by the Prepackaged Plan unless and until all conditions precedent to the consummation of the Prepackaged Plan are satisfied or waived. Those conditions include:

●the Restructuring Support Agreement having not been terminated and remaining in full force and effect;
●the Bankruptcy Court entering the Cash Collateral Orders, and the Final Cash Collateral Order (each as defined in the Prepackaged Plan) shall be in full force and effect;
●the entry by the Bankruptcy Court of the order confirming the Prepackaged Plan pursuant to Bankruptcy Code section 1129 (such order, the “Confirmation Order”), with such Confirmation Order being a final order and in full force and effect;
●the issuance of the New Common Stock;
●the issuance of the New Warrants in accordance with the New Warrant Agreement (as defined in the Prepackaged Plan)
●the due execution and delivery of the Takeback Exit Documents (as defined in the Plan) by all of the entities that are parties thereto, the satisfaction or waiver of all conditions precedent (other than any conditions related to the occurrence of the Effective Date) to the effectiveness of the Takeback Exit Facility and the closing of the Takeback Exit Facility;
●the due execution and delivery of all agreements, documents, and instruments in connection with the New RCF by all of the entities that are parties thereto, the satisfaction or waiver of all conditions precedent (other than any conditions related to the Effective Date) and the closing of the New RCF; and
●the receipt of all authorizations, consents, regulatory approvals, rulings, or documents that are necessary to implement and effectuate the Prepackaged Plan and the Restructuring Transactions.

Some of these conditions are not under our control. There can be no assurance that any or all of the conditions precedent will be satisfied or waived or that these transactions will be completed as currently contemplated or at all. Even if these transactions are completed, they may not be completed on the anticipated schedule or terms. If these transactions are not completed on the anticipated schedule or terms, we may incur significant additional costs and expenses.

66

The agreements governing our current indebtedness, and the terms of future indebtedness including the exit facilities and takeback debt, contain or will contain various covenants that impose restrictions on us and certain of our subsidiaries that may reduce our operating and financial flexibility and we may not be able to satisfy our obligations under these or other, future debt arrangements.

The generic pharmaceutical industry is highly competitive. The terms of our various financing agreements contain, and we expect that the terms of our exit financing and takeback debt will contain, covenants that, among other things, limit our ability and the ability of certain of our subsidiaries to:

●incur additional debt and issue preferred stock;
●incur or create liens;
●redeem and/or prepay certain debt;
●pay dividends on our stock or repurchase stock;
●make certain investments;
●engage in specified sales of assets;
●enter into transactions with affiliates; and
●engage in consolidation, mergers and acquisitions.

In addition, the exit facilities will require us to comply with specified financial ratios. Any future indebtedness may also require us to comply with similar or other covenants.

These restrictions on our ability to operate our business could seriously harm our business by, among other things, limiting our ability to take advantage of financings, mergers, acquisitions and other corporate opportunities. Various risks, uncertainties and events beyond our control could affect our ability to comply with these covenants. Failure to comply with any of the covenants in our existing or future financing agreements could result in a default under those agreements and under other agreements containing cross-default provisions. A default would permit lenders to accelerate the maturity for the debt under these agreements and to foreclose upon any collateral securing the debt. Under these circumstances, we might not have sufficient funds or other resources to satisfy all of our obligations, including our obligations under the notes. In addition, the limitations imposed by financing agreements on our ability to incur additional debt and to take other actions might significantly impair our ability to obtain other financing. This could have serious consequences to our financial condition and results of operations and could cause us to become bankrupt or insolvent.

In addition, rating agencies have lowered, and may lower in the future, our debt ratings, if in the rating agencies’ judgment such action is appropriate. The lowering of a rating would likely increase our future borrowing costs and reduce our access to capital. Our negotiations with vendors, customers and business partners can be negatively impacted if they deem us a credit risk as a result of our credit rating.

67

We expect to be subject to claims that will not be discharged in the Chapter 11 Cases.

The Bankruptcy Code provides that the effectiveness of a plan of reorganization discharges a debtor from substantially all debts arising prior to petition date, other than as provided in the Prepackaged Plan or the Confirmation Order. The Prepackaged Plan provides that holders of General Unsecured Claims (as defined in the Prepackaged Plan), including, but not limited to, litigation claims against us and/or our subsidiaries, will have their claims “ride through” the bankruptcy, meaning such claims will be satisfied in the ordinary course of business.

In particular, the Prepackaged Plan currently provides that except to the extent less favorable treatment is agreed to by the Company Parties or the Reorganized Debtors (as defined in the Prepackaged Plan), as applicable, and a holder of an Allowed General Unsecured Claim (as defined in the Prepackaged Plan), each Allowed General Unsecured Claim shall, at the option of the applicable Company Party, be either (i) Reinstated (as defined in the Prepackaged Plan) or (ii) paid in full in Cash (as defined in the Prepackaged Plan) on the later of (x) the Effective Date (as defined in the Prepackaged Plan) and (y) the date on which such payment would otherwise be due in the ordinary course of business in accordance with the terms and conditions of the particular transaction giving rise to such Allowed General Unsecured Claim.

To the extent such claims could have been asserted prior to bankruptcy or arose during the bankruptcy, such claims can be asserted after we emerge from bankruptcy. The outcome and timing of potential matters is uncertain, and it is possible material costs, penalties, fines, sanctions, or injunctive relief could result from such a matter. As a result, an adverse ruling with respect to potential matters could have a material impact on our financial condition, results of operations, liquidity, and cash flows.

The negotiations regarding the Restructuring have consumed and will continue to consume a substantial portion of the time and attention of our management, which may have an adverse effect on our business and results of operations, and we may face increased levels of employee attrition.

Our management has spent, and continues to be required to spend, a significant amount of time and effort focusing on the Restructuring. This diversion of attention may have a material adverse effect on the conduct of our business, and, as a result, on our financial condition and results of operations, particularly if the Restructuring and the Chapter 11 Cases are protracted. During the pendency of the Restructuring, our employees will face considerable distraction and uncertainty and we may experience increased levels of employee attrition. A loss of key personnel or material erosion of employee morale could have a materially adverse effect on our ability to meet customer expectations, thereby adversely affecting our business and results of operations. The failure to retain or attract members of our management team and other key personnel could impair our ability to execute our strategy and implement operational initiatives, thereby having a material adverse effect on our financial condition and results of operations. Likewise, we could experience losses of customers or business partners who may be concerned about our ongoing long-term viability.

In certain instances, the Chapter 11 Cases may be converted to a case under Chapter 7 of the Bankruptcy Code.

Following commencement of the Chapter 11 Cases, upon a showing of cause, the Bankruptcy Court may convert such Chapter 11 Cases to cases under chapter 7 of the Bankruptcy Code (“Chapter 7”). In such event, a Chapter 7 trustee would be appointed or elected to liquidate our assets for distribution in accordance with the priorities established by the Bankruptcy Code. We believe that liquidation under Chapter 7 would result in significantly smaller distributions being made to our creditors than those provided for in a Prepackaged Plan because of (i) the likelihood that the assets would have to be sold or otherwise disposed of in a distressed fashion over a short period of time rather than a controlled manner and as a going concern, (ii) additional administrative expenses involved in the appointment of a Chapter 7 trustee, and (iii) additional expenses and claims, some of which would be entitled to priority, that would be generated during the liquidation and from the rejection of leases and other executory contracts in connection with a cessation of operations.

68

As a result of the Chapter 11 Cases, our historical financial information may not be indicative of our future financial performance, which may be volatile.

During the Chapter 11 Cases, we expect our financial results to be volatile as restructuring activities and expenses, contract terminations and rejections, and claims assessments significantly impact our consolidated financial statements. As a result, our historical financial performance is likely not indicative of our financial performance after the date of the filing of the Chapter 11 Cases.

Upon emergence from bankruptcy, the composition of the Reorganized Company’s board of directors will, and the Reorganized Company’s management team may, change significantly.

Under the Prepackaged Plan, the composition of the Reorganized Company’s board of directors will change significantly upon emergence. Pursuant to the Prepackaged Plan, the board of directors of Reorganized LCI will be composed of five directors, one of whom will be Reorganized LCI’s chief executive officer and four of whom will be determined by the Consenting Stakeholders in consultation with Reorganized LCI’s chief executive officer. Any new directors are likely to have different backgrounds, experiences and perspectives from those individuals who currently serve on our board of directors. While we expect to engage in an orderly transition process as we integrate newly appointed board members, our board of directors following emergence from bankruptcy may have different views on strategic initiatives and a range of issues that will determine the future of the Company. As a result, the future strategy and plans of the Company may differ materially from those of the past.

In addition, the composition of our management team may change significantly. Qualified individuals are in high demand and we may incur significant costs to attract them. In addition, the loss of any of our senior management or other key employees or changes in the composition of our management team could materially and adversely affect our ability to execute their strategy and implement operational initiatives and have a material and adverse effect on our financial condition, liquidity and results of operations.

It is highly likely that the shares of our existing common stock will be canceled in upon emergence from the Chapter 11 Cases and holders of existing common stock receive no recovery under the Prepackaged Plan.

If the restructuring contemplated by the Prepackaged Plan is consummated, all existing equity interests of LCI, including common stock and any outstanding warrants or options, will be extinguished without any recovery. Additionally, the Prepackaged Plan may not be confirmed by the Bankruptcy Court, in which case, the recoveries of existing securityholder may be subject to change. As such, trading prices for any of the Company’s securities may not bear any substantive relationship to the outcome for security holders in the Chapter 11 Cases.

Additionally, on April 19, 2023, the Company received a written notice from the NYSE notifying the Company that the NYSE had commenced proceedings to delist the Company’s common stock. The NYSE suspended trading in the Company’s common stock immediately after market close on April 19, 2023, and on April 20, 2023, the Company’s common stock began trading in the over-the-counter markets under the symbol “LCIN” and on May 3, 2023, our common stock began trading in the over-the-counter markets under the symbol “LCINQ.” The over-the-counter markets are significantly more limited than the NYSE, and quotation on the over-the-counter markets may result in a less liquid market available for existing and potential securityholders to trade the common stock and could further depress the trading price of the common stock. We can provide no assurance that the common stock will continue to trade on the over-the-counter markets, whether broker-dealers will continue to provide public quotes of the common stock or whether the trading volume of the common stock will be sufficient to provide for an efficient trading market.

​

69

ITEM 6. EXHIBITS

(a)A list of the exhibits required by Item 601 of Regulation S-K to be filed as a part of this Form 10-Q is shown on the Exhibit Index filed herewith.

Exhibit Index

10.104

​

​

Incorporated by reference to Exhibit 10.1 on Form 8-K dated May 1, 2023

​

​

10.105

​

​

Incorporated by reference to Exhibit 10.2 on Form 8-K dated May 1, 2023

​

​

​

​

​

3.9

​

Updated and Amended Certificate of Incorporation

​

Filed Herewith

​

​

​

​

​

31.1

​

Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

​

Filed Herewith

​

​

​

​

​

31.2

​

Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

​

Filed Herewith

​

​

​

​

​

32**

​

Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2022

​

Furnished Herewith

​

​

​

​

​

99.1

​

Disclosure Statement for the Joint Prepackaged Chapter 11 Plan of Reorganization of Lannett Company, Inc. and its Debtor Affiliates

​

Incorporated by reference to Exhibit 99.1 on Form 8-K dated May 2, 2023

​

​

​

​

​

101.INS

​

XBRL Instance Document – the instance document does not appear within the Interactive Data File because its XRBL tags are embedded within the Inline XRBL Document

​

Filed Herewith

​

​

​

​

​

101.SCH

​

XBRL Taxonomy Extension Schema Document

​

Filed Herewith

​

​

​

​

​

101.CAL

​

XBRL Taxonomy Extension Calculation Linkbase Document

​

Filed Herewith

​

​

​

​

​

101.DEF

​

XBRL Taxonomy Extension Definition Linkbase Document

​

Filed Herewith

​

​

​

​

​

101.LAB

​

XBRL Taxonomy Extension Label Linkbase Document

​

Filed Herewith

​

​

​

​

​

101.PRE

​

XBRL Taxonomy Extension Presentation Linkbase Document

​

Filed Herewith

​

​

​

​

​

104

​

Cover Page Interactive Data File – The cover page interactive data file does not appear in the Interactive Data File because its XRBL tags are embedded within the Inline XRBL document

​

Filed Herewith

** Furnished Herewith

70

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​

​

​

LANNETT COMPANY, INC.

​

​

​

Dated: May 15, 2023

By:

/s/ Timothy Crew

​

​

Timothy Crew

​

​

Chief Executive Officer

​

​

​

​

​

​

Dated: May 15, 2023

By:

/s/ John Kozlowski

​

​

John Kozlowski

​

​

Vice President of Finance, Chief Financial Officer and Principal Accounting Officer

​

​

​

​

​

​

​

​

71

Lannett (NYSE:LCI)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Lannett Charts.
Lannett (NYSE:LCI)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Lannett Charts.